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Summary 
Three major challenges in the field of breast cancer have been identified as research priorities 
for this study. The first is the need to combine genetic testing of high-risk patients with familial 
breast cancer with pharmacogenetics to reduce recurrence risk in cancer survivors due to drug 
failure as a consequence of anti-cancer treatment that does not match the patient’s genotype. 
The second is the delineation of key pathways through which genes implicated in breast cancer 
and associated co-morbidities can serve as nutritional and drug targets across diagnostic 
boundaries. The third is the discovery of genetic alterations underlying familial breast cancer not 
attributed to mutations in the two major tumour suppressor genes, BRCA1 and BRCA2. 
 
The study population consisted of 164 breast cancer patients (60 Coloured/Mixed Ancestry and 
104 Caucasian), of whom 88 patients were selected from a total of 813 individuals who provided 
informed consent for inclusion of their data in a genomics database resource generated at the 
interface between the laboratory and routine clinical practice. In addition, DNA samples of 101 
cancer-free individuals above the age of 65 years were available for clinical validation of 
potentially causative variants in an extended female control group. 
 
In the first phase of this study, real-time polymerase chain reaction (PCR) TaqMan© technology 
was used to confirm the potential value of adding pharmacogenetic testing (CYP2D6 allele 4) to 
standard immunohistochemistry (IHC)-based breast tumour subtyping complemented by BRCA 
mutation screening and/or microarray gene profiling in eligible patients. In phase two of the 
study, common genetic risk factors for cardiovascular disease (CVD) were shown to be 
significantly associated with earlier age (10 years on average) of breast cancer onset/diagnosis 
(APOE E4 allele p=0.003; 95% CI: 4-15) and body mass index (BMI) (MTHFR 1298 A>C; 
p=0.01; 95% CI: 3-14) in patients stratified according to estrogen receptor (ER) status, after 
adjustment for potential confounders. Age at diagnosis/onset of breast cancer was significantly 
lower in patients with ER-negative versus ER-positive tumours, after adjustment for ethnicity 
(p=0.022), while BMI was significantly higher in patiens with ER-positive compared to ER-
negative tumours after adjustment for age, ethnicity, and family history of cancer (p=0.035). 
These findings contributed to the development of an exome pre-screening algorithm (EPA) used 
in part 3 of this study to select three genetically uncharacterized breast cancer patients for 
whole exome sequencing (WES) performed in comparison with three ethnically concordant 
cancer-free controls. WES followed by variant calling using both the standard human genome 
reference sequence (hg19) and an ethnically concordant major allele reference genome 
(MARS) revealed a more than 20% discrepancy in the number of gene variants identified in the 
same samples. After exclusion of a large number of false-positives caused by minor alleles in 
Stellenbosch University  https://scholar.sun.ac.za
  iii 
hg19, two rare missense mutations (<1%) were identified in a family with ER-positive breast 
cancer: RAD50 R385C and MUC1 Q67E. Three different bioinformatics tools were used to 
predict functionality and both mutations were confirmed by Sanger sequencing and/or real-time 
PCR in the Pathology Research Facility (PRF) laboratory. Neither the RAD50 nor the MUC1 
missense mutation were identified in the exomes of an unrelated breast cancer patient with 
triple-negative breast cancer or three population-matched control individuals.    
 
This study led to the development of a pathology-supported genetic testing framework for WES 
beyond the limitations of single-gene BRCA mutation screening in South African breast cancer 
patients. Our findings support previous WES results indicating that the majority of genetically 
uncharacterised familial breast cancer may be caused by a combination of low-moderate 
penetrance mutations exerting their effect in a high-risk environment reflected by high BMI. 
WES enables identification of genetic risk factors of relevance to both cancer development and 
tailored therapeutic intervention in a single genetic test.  
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Opsomming 
Drie belangrike uitdagings in die veld van borskanker-navorsing is geïdentifiseer as die fokus vir 
navorsing in hierdie studie.  Die eerste is die nodigheid om genetiese toetsing van hoë-risiko 
pasiënte met familiële borskanker te kombineer met farmakogenetika, om die risiko van 
siekteherhaling in borskanker oorlewendes as gevolg van mislukking van kankerbehandeling 
wat nie in ooreenstemming is met die pasiënt se genotipe nie, te voorkom. Die tweede is die 
afbakening van sleutel paaie waardeur gene wat betrek word by borskanker en verwante ko-
morbiditeite, voedings- en medikasie behandelingsteikens oor diagnostiese grense heen kan 
voorsien. Die derde is die ontdekking van genetiese veranderinge onderliggend aan familiële 
borskanker wat nie verklaar kan word deur mutasies in die twee belangrikste kanker-
onderdrukker gene, BRCA1 en BRCA2 nie. 
Die studiepopulasie het bestaan uit 164 borskankerpasiënte (60 Kleurling/Gemengde Afkoms 
en 104 Koukasiers), van wie 88 geselekteer is uit 'n totaal van 813 individue wat ingeligte 
toestemming verleen het vir insluiting van hulle data in ‘n genomiese databasishulpbron, wat 
ontwikkel is op die interfase van die laboratorium en roetine kliniese praktyk. DNA van ‘n 
verdere 101 kankervrye individue bokant die ouderdom van 65 jaar was beskikbaar vir kliniese 
validasie van potensieel kanker-verwante variante in ‘n uitgebreide vroulike kontrole groep. 
In die eerste fase van die studie is reël-tyd polimerase ketting reaksie (PKR) TaqMan© 
tegnologie gebruik om die potensiële waarde te bepaal om farmakogenetiese toetsing (CYP2D6 
alleel 4) by te voeg tot standaard immunohistochemie (IHC)-gebasseerde borstumour 
subtipering wat gekomplementeer is deur BRCA mutasie sifting en/of  mikroarray-geen 
profilering in toepaslike pasiënte. In fase twee van die studie is algemene genetiese 
risikofaktore vir kardiovaskulêre siekte (KVS) aangetoon om betekenisvol geassosieerd te wees 
met vroeër ouderdom (10 jaar gemiddeld) van borskanker aanvang/diagnose (APOE E4 alleel, 
p=0.003; 95% CI: 4-15) en liggaamsmassa indeks (BMI) (MTHFR 1298 A>C; p=0.01; 95% CI: 
3-14) in pasiënte wat gestratifiseer is volgens estrogeen reseptor (ER) status, na aanpassing vir 
potensiële strengelveranderlikes. Ouderdom by diagnose/aanvang van borskanker was 
betekenisvol laer in ER-negatiewe as ER-positiewe pasiënte na statistiese aanpassing vir 
etnisiteit (p=0.022), terwyl BMI beduidend hoër was in ER-positiewe as ER-negatiewe 
borskanker pasiënte na aanpassing vir ouderdom, etnisiteit en familiegeskiedenis van kanker 
(p=0.035). Hierdie bevindinge het bygedra tot die ontwikkeling van ‘n eksoom pre-siftings 
algoritme (EPA) wat gebruik is in deel 3 van hierdie studie om drie geneties 
ongekarakteriseerde borskanker pasiente vir WES te selekteer. Die resultate is vergelyk met die 
bevindings in drie kankervrye kontroles uit dieselfde populasiegroep. WES, gevolg deur variant 
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roeping met beide die standaard mensgenoom verwysingsvolgorde (hg19) en ‘n etnies 
verenigbare major alleel verwysings genoom (MARS) het meer as 20% teenstrydigheid getoon 
in die aantal geen variante wat geïdentifiseer is in dieselfde DNS monsters. Nadat ‘n groot 
aantal vals-positiewe resultate uitgesluit is wat deur minor allele in hg19 veroorsaak is, is twee 
raar missens mutasies (<1%) geïdentiseer in ‘n familie met ER-positiewe borskanker: RAD50 
R385C en MUC1 Q67E. Drie verskillende bioinformatika programme is gebruik om 
funksionaliteit te voorspel en albei mutasies is bevestig deur Sanger volgorderbepaling en/of 
RT-PKR. Nie een van die twee missens mutasies in die RAD50 of MUC1 gene is gevind in die 
eksome van ‘n onverwante borskanker pasiënt met trippel-negatiewe borskanker of in die 
eksome van die drie kontrole indiwidue van dieselfde populasiegroep nie. 
Hierdie studie het gelei tot die ontwikkeling van 'n raamwerk vir WES wat n verbetering is op die 
beperkings van enkelgeen BRCA-toetsing van Suid-Afrikaanse borskankerpasiënte. Ons 
bevindinge ondersteun vorige WES-resultate wat aangedui het dat die meeste geneties-
ongekarakteriseerde familiere borskankers waarskynlik veroorsaak word deur 'n kombinasie van 
lae tot matige penetrasie-mutasies wat tot uitdrukking kom in 'n hoë-risiko omgewing soos 
gereflekteer word deur hoë BMI. WES maak dit moontlik om genetiese risikofaktore te 
identifiseer wat relevant is tot beide kankerontwikkeling en geteikende terapeutiese intervensie 
met dieselfde genetiese toets. 
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Molecular pathology plays an increasingly important role in cancer prevention, diagnosis and 
treatment. The significant impact of breast cancer on the health economy sparked extensive 
research in South Africa (Grant et al. 2013; Grant et al. 2014) and elsewhere into the molecular 
pathways underlying distinct tumour subtypes that differ in their response to treatment. In South 
Africa breast cancer is the most common neoplasm among Asian and Caucasian women, and 
the second most common cancer among women of African descent and the Coloured 
population of Mixed Ancestry (Vorobiof et al. 2001). Inter-ethnic variability in breast cancer risk 
is explained by a combination of genetic and environmental risk factors that contribute to cancer 
development and tumour gene expression. 
Over the last decade a new era of personalized medicine was introduced with the promise that 
pharmacogenomics will deliver the right treatment at the right time in patients with cancer and 
associated diseases (Evans and Relling 2004). As is evidenced by the exponential growth in 
applied pharmacogenetics literature over the past 10 years (Figure 1.1), pharmacogenetics has 
become one of the leading and potentially most actionable areas of the personalized medicine 
paradigm (Frueh et al. 2008; Lesko and Zineh 2010; Zineh and Pacanowsi 2011).  
 
 
 
 
 
 
 
 
Figure 1.1. Number of Pubmed citations (http://www.ncbi.nlm.nih.gov/pubmed) by date using 
the keywords “clinical pharmacogenetics”, “pharmacogenomics” or “pharmacogenetics”. 
Reproduced with permission from Scott (2011). 
 
The extent to which breast cancer gene 1 and breast cancer gene 2 (BRCA1 and BRCA2) 
mutations, non-deterministic genetic risk modifiers and relevant lifestyle factors influence 
individual predisposition towards the development of breast cancer in a subtype-specific 
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manner, represents an important avenue for ongoing research endeavors. Most studies to date 
have failed to demonstrate a significant overall survival difference between sporadic and familial 
breast cancer caused by mutations in the BRCA1 and BRCA2 genes (Bordeleau et al. 2010). 
This finding confirms the importance of genetic risk modifiers and lifestyle factors as 
determinants of adverse clinical outcome across breast cancer subtypes, including BRCA-
positive patients (King et al. 2003). Newman et al. (2008) furthermore provided compelling 
evidence that treatment failure due to impaired drug metabolism caused by reduced 
Cytochrome P450 family 2 subfamily D polypeptide (CYP2D6) enzyme function, may increase 
the risk of recurrence in patients with BRCA mutations or other forms of familial breast cancer.  
The above findings are of particular relevance in South Africa due to a founder effect found to 
be responsible for a relatively high frequency of specific BRCA1/2 mutations in high-risk families 
with multiple affected members (Reeves et al. 2004; Agenbag 2005; van der Merwe et al. 
2012b; van der Merwe and van Rensburg 2009). This prompted an investigation into the 
potential significance of combining diagnostic BRCA1/2 and predictive CYP2D6 
pharmacogenetic testing in South African breast cancer patients, as reported in Phase 1 of this 
study (van der Merwe et al. 2012a). CYP2D6 metabolises more than 25% of all commonly 
prescribed drugs and may therefore provide a treatment target across diagnostic boundaries. 
This is of particular relevance in patients with breast cancer and associated co-morbidities such 
as depression and cardiovascular disease (CVD) due to the high frequency of therapeutic 
failure reported with use of antidepressants (as substrates or inhibitors of CYP2D6 enzymatic 
activity), cholesterol-lowering statins, beta-blockers, and tamoxifen (Frudakis et al. 2007; 
Newman et al. 2008; Nagele et al. 2011; Suppli et al. 2011). Tamoxifen has been associated 
with the development of deep vein thrombosis (DVT) and various cognitive effects (Paganini-Hill 
et al. 2000; Eberling et al. 2004; Decensi et al. 2005). Although the evidence regarding 
association of tamoxifen with depression is inconsistent, mood changes are frequently reported 
with the use of this hormonal anti-cancer treatment (Thompson et al. 1999; Patten and Barbui 
2004).  
Previous studies have shown that the risk for developing CVD may exceed the risk of breast 
cancer recurrence in survivors (Patten et al. 2012). Obesity which represents a major metabolic 
risk factor for CVD is reciprocally associated with depression (Faith et al. 2002; de Wit et al. 
2009) and increases the risk of various cancers, including postmenopausal breast cancer, 
colorectal and prostate cancer (Louie et al. 2013). Li et al. (2009) found a 40-50% elevation in 
risk associated with obesity, which is consistent with the results from women enrolled in the 
National Surgical Adjuvant Breast and Bowel B-14 randomized trial of adjuvant tamoxifen 
performed in patients with node-negative estrogen receptor (ER)-positive tumours (Dignam et 
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al. 2003).  Breast cancer survivors in the highest quartile for body mass index (BMI) had at least 
50% increased risk of a second primary breast cancer compared to women in the lowest BMI 
quartile (Trentham-Dietz et al. 2007). The negative effect of obesity and lack of exercise also 
applies to familial breast cancer caused by mutations in the BRCA1 and 2 genes (King et al. 
2003). Swisher et al. (2015) confirmed the benefits of exercise and a healthy diet to improve the 
quality of life in survivors of triple-negative breast cancer, the tumour subtype most frequently 
associated with mutations in the BRCA1 gene. 
Obesity represents an important target for lifestyle intervention and application of 
pharmacogenetics related to the use of anti-inflammatory drugs has been shown to reduce the 
risk of cancer (Ford et al. 2015). It has been estimated that 15-20% of all cancer deaths may be 
attributable to obesity (Calle et al. 2003; Chang et al. 2013). Since tumour growth is regulated 
by interactions between cancer cells and their tissue microenvironment, dysfunctional fat tissue 
and altered signaling pathways were identified as important mechanisms whereby obesity could 
lead to cancer development. Duval and Tweedie (2000) showed that post-menopausal obese 
women possessed a three-fold increase in the risk of breast cancer compared to their non-
obese control counterparts. Furthermore, Laumann et al. (2008) has shown that a higher BMI is 
associated with worse response to neoadjuvant chemotherapy and worse overall survival. 
Genes involved in the folate-homocysteine pathway have been identified as important 
therapeutic targets in relation to both gene-diet and gene-diet interaction, due to the known 
deleterious effects of obesity, excessive alcohol intake and smoking on DNA methylation which 
is implicated in the development of breast cancer and associated comorbidities. Decreased 
genomic DNA methylation may occur as a consequence of reduced enzyme activity caused by 
low folate status and polymorphic variation in at least 30 genes involved in the folate 
metabolism pathway (Friso et al. 2002; Wettergren et al. 2010). These include the most 
extensively studied methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR) 
and methionine synthase reductase (MTRR) genes.  The enzymes encoded by the 
aforementioned genes are important in the one-carbon transfer processes known to be 
essential for optimal DNA synthesis, methylation and repair. The methylation pathway therefore 
presents an important target for possible prevention of cumulative effects that could impact on 
the development of comorbidities or disease relapse in breast cancer patients (Peerbooms et al. 
2011; Cohen et al. 2012). We have previously studied the clinical relevance of the MTHFR 677 
C>T mutation in South African individuals participating in a chronic disease screening program 
and could confirm the association between low dietary folate intake, obesity and depression 
(Delport et al. 2014). 
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The development of new ways to use current genomic knowledge for the benefit of patients 
remains a challenge in the field of breast cancer. Albeit significant advances over recent years, 
screening for causative mutations underlying familial breast cancer not attributed to defects in 
the BRCA1 and BRCA2 genes revealed many variants of uncertain clinical significance (VUS). 
This presents a dilemma not only in treatment decision-making, but also in relation to genetic 
counselling of patients and their at-risk family members. Mutations in the BRCA1 and BRCA2 
genes account for less than 50% of familial breast cancer (Wooster et al. 2003), which suggest 
that other genes, individually or in combination, confer the residual risk seen in heritable 
cancers. Our understanding of the germline contribution to gene expression levels in tumours 
have improved significantly with the use of next generation sequencing (NGS). This technology 
enabled the identification of rare gene variants with high impact as well as low-moderate-
penetrance mutations, which could collectively account for disease risk and treatment failure in 
genetically uncharacterized patients. Sequencing of the entire BRCA1 and 2 genes in South 
African patients is usually only performed after exclusion of founder mutations causing protein 
truncating mutations (Reeves et al. 2004; Agenbag 2005; van der Merwe et al. 2012b; van der 
Merwe and van Rensburg 2009). Although detection of causative missense mutations in the 
BRCA1/2 genes are uncommon, BRCA1 R1699Q (c.5096G>A, p.Arg1699Gln) classified as an 
intermediate-risk allele (Spurdle et al. 2012) has recently been reported in a South African 
family with breast cancer (unpublished data). It is therefore important not to disregard missense 
mutations in the BRCA1/2 or other cancer-related genes without further studies to determine 
possible clinical relevance.  
The vast amounts of information that have been generated with the advent of NGS currently 
exceed the rate at which large amounts of data are validated in a diagnostic setting. Given the 
slow pace of validation studies, translation of genomic discoveries into practical benefits may be 
one of the most difficult challenges to meet at present. A genomics database resource for 
determination of the clinical relevance of new genomic information is therefore required for on-
going assessment and monitoring of treatment outcomes.  
Early detection of relatively frequent (>1%) functional polymorphisms with low penetrance as 
putative actionable treatment targets may facilitate prevention of cumulative risk across the 
disease spectrum. Single nucleotide polymorphisms (SNPs) in genes encoding drug-
metabolizing enzymes and those dependent on vitamin co-factors for optimal function may 
explain inter-individual variation in treatment response, drug toxicity and/or recurrence risk in 
both familial and sporadic breast cancer. Recognition of the significant impact of multi-functional 
SNPs found to be of clinical relevance in cancer and related comorbidities support the 
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development of a pharmacogenomics assay that could serve as a prescreen step for whole 
exome sequencing (WES) or targeted NGS.  
 
1.1. Research focus 
The current investigation is based on the hypothesis that integration of genetic information with 
clinical and environmental factors (e.g. medication, lifestyle) may allow the development of a 
novel pathology-supported pharmacogenomics assay for improved clinical management of 
breast cancer and associated comorbidities. Although genetic as well as modifiable 
environmental risk factors including obesity, alcohol consumption and smoking were shown to 
have a significant effect on the recurrence rate of breast cancer (Li et al. 2009), their role in ER-
positive versus ER-negative breast cancer patients remains to be elucidated in the South 
African context. 
Although the focus of personalized genomic medicine is on disease management, the potential 
for cancer prevention calls for a wider clinical application in primary healthcare. Technological 
advances derived from whole genome sequencing (WGS) and genome wide association studies 
(GWAS) provides the capacity to integrate clinical and genotypic information for assessment of 
generalized health risks and promotion of wellness  (Patel et al. 2013). Current health promotion 
strategies incorporate lifestyle factors and clinical indicators such as BMI into screening 
programs, but are largely insufficient to evaluate the role of medication side effects and drug 
failure in the development of comorbidities and recurrence risk among cancer survivors. The 
potential value of combining all these factors with genomic information using a comprehensive 
pathology-supported genetic testing (PSGT) strategy developed in South Africa over recent 
years (Kotze et al. 2015) has not previously been explored in breast cancer patients.  
The assessment of non-deterministic risk modifiers incorporated into a multi-gene assay that 
also takes BRCA mutation status into account may be ideally suited to determine eligibility for 
WES using the PSGT approach. Towards this goal, three challenges were identified and 
addressed in this study. Firstly, the need to combine diagnostic BRCA mutation detection with 
pharmacogenetic testing to reduce recurrence risk in familial breast cancer due to inappropriate 
treatment. Secondly, the delineation of pathways through which genes implicated in both breast 
cancer and related co-morbidities may be targeted for individualized nutritional and drug 
treatment across diagnostic boundaries. Thirdly, the discovery of genetic alterations underlying 
familial breast cancer not attributed to mutations in BRCA1 and BRCA2 and determination of 
clinical relevance. While NGS provides a way to cover all three areas of risk in one test, new 
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ways to interpret the vast amount of new genomic knowledge derived from WES is required for 
clinical application to the benefit of each individual patient.  
Current research initiatives acknowledge the need for defining selection criteria to identify 
genetic subgroups of patients where the potential benefits of genetic testing would outweigh the 
risk of unnecessary testing (Fostira et al. 2012). Identification of disease subtypes with a genetic 
component allows for classification of patients into different treatment groups based on disease 
mechanism and not only symptoms (Phipps et al. 2011; Phipps et al. 2012). Development of a 
genetic testing strategy whereby pathology and genetic tests are assessed together in a 
multiplex assay may overcome the limitations of individual health disciplines, especially if 
combined with bioinformatics tools to apply WES in genetically uncharacterized patients with 
familial breast cancer. To bridge the gap between the generation of massive amounts of 
genomic information towards achievement of a high degree of concordance between genotype 
and phenotype, the generation of a database resource for validation of new genomic 
applications was a priority. 
The aim of this study was to provide a method to facilitate the prevention of cumulative risk for 
comorbidities such as vascular disease and depression in breast cancer patients through the 
development of a comprehensive PSGT service informed by molecular tumour subtyping. 
Results from histopathological assessment and genetic testing were assessed as part of a 
multidisciplinary approach to chronic disease screening used to identify patients eligible for 
extended genomic analysis including microarray-based gene expression profiling (Grant et al. 
2013; Grant et al. 2014) and NGS (this study). The etiology, epidemiology, pathology and 
treatment of breast cancer, as well as the different categories of risk in relation to testing (e.g. 
diagnostic, predictive/pharmacogenetics), exome sequencing, and counselling aspects related 
to the genomics era are reviewed in chapter 2. The aims of the study are motivated by the 
identification of gaps in current knowledge (chapter 3) related to three challenges addressed in 
three phases of the current investigation:  
In Phase I of the study, we determined the appropriateness of adding CYP2D6 
pharmacogenetic testing to the breast cancer genetic screening options already available in 
South Africa, which includes BRCA mutation screening and transcriptional profiling to assess 
ER, PR and HER2 status.  
In Phase II, high BMI and other CVD risk factors were assessed in breast cancer patients, 
stratified according to ER status, to facilitate the development of an exome pre-screening 
algorithm (EPA).  
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In Phase III, the newly developed EPA was used to select three breast cancer patients (from 
two unrelated families) for whole exome sequencing (WES) in comparison with three cancer-
free controls. Discordance reported between different variant calling pipelines prompted 
comparison between the standard human reference genome (hg19) and a synthetic major allele 
reference sequence (MARS).  
A description of the study population and methodology employed is documented in chapter 4 
while the findings obtained in relation to the Phase 1-3 analyses are presented separately in the 
results and discussion sections (Chapter 5). This is followed by a general conclusion based on 
the new knowledge and the database resource generated as a result of this investigation 
(Chapter 6). The references used (Chapter 7) is followed by additional results pertaining to each 
of the study phases and concluded with a list of congress presentations and publications in an 
appendix chapter (8).  
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LITERATURE REVIEW 
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2.1. Breast cancer evolution 
Breast carcinoma is a form of genetic disease that originates from breast tissue. Records and 
illustrations of breast cancer date back to ancient times, approximately 3000- 2500 B.C., with 
The Edwin Smith Surgical Papyrus providing accurate accounts of the disease (Breasted 1984). 
In 400 B.C., Hippocrates described the progressive stages of breast cancer and developed the 
humoral theory which ascribed the imbalance of liquids in the body as a cause of disease, 
representing early hypotheses on the etiology of cancer. He believed that an imbalance of the 4 
bodily fluids (blood, phlegm, yellow bile and black bile), particularly an excess of black bile 
underlie carcinogenesis (Homer 1966). In the 1st century A.D., Leonides of Alexandria described 
his approach of incision and cautery (Ariel 1987), which involved leaving a wide margin of 
excision and only removing relatively small tumours, introducing the principles of modern-day 
surgical practice (Lewison 1953). Galen in 200 A.D. on the other hand contended that breast 
cancer was a systemic disease and attributed it to the accumulation of black bile in the blood 
(De Moulin 1983). The aforementioned physicians proposed that menopause was somehow 
linked to cancer, indirectly associating the disease with old age.   
 
2.2. Etiology of breast cancer 
Carcinogenesis is a multi-step process, the etiology of which includes both environmental 
factors such as tobacco smoke, chemicals, radiation, and infectious agents and internal factors 
including hormones, immune conditions, and genetic variations. These factors may act in 
concert to initiate or promote the development of neoplasms resulting from dysfunction of 
regulation of cell growth due to the accumulation of genetic alterations (Garcia et al. 2007; 
Stratton et al. 2009). Malignant transformation involves a progressive process starting with 
atypical hyperplasia followed by carcinoma in situ and eventually evolution from pre-invasive to 
invasive breast cancer. Benign lesions differ from malignant tumours in terms of cellular growth 
rate (relatively slow growth) and morphology (tumour cells resemble in appearance that of 
normal cells) and are not life-threatening. Pre-cancerous lesions including atypical hyperplasia 
and carcinoma in situ do not invade the surrounding fatty breast tissue or spread to lymph 
nodes or distant sites. Malignancy on the other hand is characterized by dissemination of 
tumour cells beyond the original tumour to other parts of the body (American Cancer Society 
2009). The spread of these unregulated cells (metastasis) may be fatal if growth is not 
controlled or ceased.   
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2.3. Histopathological classification of breast cancer 
Breast cancer includes a collection of different diseases or subtypes characterized by different 
biological and pathological features, clinical presentation, response to treatment, clinical 
behavior, and outcome (Rivenbark et al. 2013; Dieci et al. 2014).  Heterogeneity is observed on 
different levels ranging from the classic histopathological characterization to the more modern 
molecular classification. Using TNM (tumour size, nodal spread, metastases) staging, the 
disease can be broadly categorized into in situ carcinoma and invasive (infiltrating) carcinoma. 
Breast carcinoma in situ is further sub-classified as either ductal or lobular whereby growth 
patterns and cytological features form the basis to distinguish between the two types (Malhotra 
et al. 2010). Invasive ductal carcinoma (IDC) that develops in the milk ducts of the breast is the 
most common type of breast cancer, comprising approximately 65-85% of all breast cancers 
(Figure 2.1).   
 
 
 
 
 
 
 
 
 
Figure 2.1. Figure depicting invasive ductal and invasive lobular carcinoma 
(http://www.drugs.com/health-guide/breast-cancer.html).  
 
Less commonly diagnosed is invasive lobular breast carcinoma (ILBC) that develops in the 
breast milk-producing lobules or glands and comprise about 10-15% of all cases of advanced 
breast cancer (Leong and Zhuang 2011; Onitilo et al. 2009). Other malignancies of the breast 
include nipple cancer and relatively rare undifferentiated neoplasms (American Cancer Society 
2015). Ductal and lobular carcinoma in situ (DCIS and LCIS) are considered precursors or 
predisposing determinants of risk for subsequent invasive disease. In 2003, the overall 5-year 
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survival rate for both IDC and ILC was approximately 85% (Arpino et al. 2004). DCIS in itself is 
harmless, although if untreated approximately 60% of these low-grade lesions will become 
invasive over the course of 40 years follow-up (Evans et al. 2004). Table 2.1 provides a 
summary of the various types of breast cancer, their anatomical sites of origin and prevalence. 
 
Table 2.1. Classification and prevalence of the different types of breast cancers. 
Breast cancer type Anatomical site Prevalence 
Ductal Carcinoma Milk ducts 73% 
Invasive ductal carcinoma (IDC) Cancer originates in milk ducts 
but invades breast tissue 
65-85% 
Ductal carcinoma in situ (DCIS) Grows only on the lining of milk 
ducts 
15% 
Lobular Carcinoma Lobes or lobules of the breast 12% 
Invasive lobular carcinoma (ILC) Cancer originates in lobules 
but invades breast tissue 
10-15% 
Lobular carcinoma in situ (LCI) Grows only in the lobes and 
terminal ducts of the breast 
Unknown 
Other  
(nipple, mucinous, medullary, 
tubular, adenoid cystic, 
angiosarcoma, phyllodes, 
papillary, metaplastic, lymphoma) 
Various sites including 
connective tissue and lymph 
nodes 
~10% 
 
 
2.4. Disease Prevalence 
Cancer is the leading cause of death in first world countries and the second leading cause of 
death in developing countries (World Health Organization 2008). Breast cancer is the most 
common non-cutaneous neoplasm in females, with more than 1 million women diagnosed 
worldwide and about 400 000 women killed each year (Kamangar et al. 2006). In 2012, 1.7 
million women received a diagnosis of breast cancer. Since 2008 mortality has increased by 
14% while estimates of breast cancer incidence have increased by more than 20% worldwide 
(International Agency for Research on Cancer 2013). In South Africa more than 6 000 women 
are diagnosed with breast cancer annually and approximately 40% of them are predicted to die 
from the disease (http://www.cansa.org.za). Breast cancer is second only to lung cancer as the 
most common cause of cancer mortality (Ferlay et al. 2013). The disease is ~100 times more 
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common in women than it is in men, however, males tend to have poorer outcomes due to delay 
in diagnosis. Although incidence rates have risen approximately 30% in westernized countries 
over the preceding 30 years, mortality rate reductions have been attributed to earlier detection 
of the disease through mammography and screening programs as well as improved treatment 
strategies. In contrast, incidence rates have been rising in many developing countries including 
Asian and African countries (Ngoma 2006). 
According to the American Cancer Society (2015), an estimated 231,840 new cases of invasive 
breast cancer are expected to be diagnosed among women in the United States during 2015, 
with approximately 2,350 men affected. Among Caucasian women, the breast cancer incidence 
rate decreased by nearly 7% from 2002 to 2003. This decline has been attributed to reductions 
in the use of hormone replacement therapy (HRT), subsequent to reports that stated that use of 
combined estrogen plus progestin therapy was associated with an increased risk of breast 
cancer (Gann and Morrow 2003), venous thrombosis (Cushman et al. 2004), coronary heart 
disease (Manson et al. 2003), dementia and mild cognitive impairment (Shumaker et al. 2003). 
In contrast, HRT use has been associated with reduction of the risk of osteoporosis (Stevenson 
2006; Marjoribanks et al. 2012) and more controversially an increased risk of CVD (Hickey et al. 
2012; Schierbeck et al. 2012). Incidence rates which were stable in Caucasian women, 
marginally increased in black women (0.3% per year) between 2007 and 2011. 
Due to these alarming figures and the heterogeneity of the South African population, a need 
exists for the identification of subgroups of the population that may be at increased risk of breast 
cancer development or recurrence due to genetic susceptibility, environmental exposures or 
treatment failure. 
 
2.5. Risk factors  
The primary breast cancer risk factors that have been identified are a genetic predisposition, 
age, gender, lack of childbearing or breastfeeding, and higher hormone levels (Giordano et al. 
2004; Collaborative Group on Hormonal Factors in Breast Cancer 2002, Yager and Davidson 
2006). Reproductive risk factors include a long menstrual history, use of oral contraceptive pills, 
and older age at first child birth (>30 years) (Warwick et al. 2003). Together, the increased 
breast cancer risk conferred by the aforementioned factors may reflect cumulative estrogen 
effects on breast tissue.  
 
Substantial clinical and epidemiological evidence have linked cumulative and sustained 
exposure to estrogens with increased risk of developing breast cancer. The most established 
risk factors for breast cancer are thought to influence risk through increasing concentrations of 
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endogenous estrogens (Pike et al. 1998). Moreover, the most widely acknowledged mechanism 
of estrogen carcinogenicity is binding to its specific nuclear receptor alpha, thereby exerting a 
potent stimulus on breast cells to proliferate. Studies that isolated the estrogen receptor (ER) 
protein to correlate ovarian function with estrogen production, mutually led to the identification of 
a strong association between estrogen dose/length of exposure and increased breast cancer 
risk (Cauley et al. 1999; Kabuto et al. 2000). Estrogens are considered to play a major role in 
promoting the proliferation of both the normal and the neoplastic breast epithelium. Several 
mechanisms are postulated to be involved in their carcinogenic effects: stimulation of cellular 
proliferation through their receptor-mediated hormonal activity, direct genotoxic effects by 
increasing mutation rates (oxidative DNA damage that cause DNA breaks) and induction of 
aneuploidy (Russo et al. 2006; Giam and Rancati 2015).  
 
Moreover, a family history of breast cancer and certain breast stages giving rise to abnormal 
cells confers increased risk for breast cancer. A woman's risk is significantly increased if a 1st or 
2nd degree family member has had early-onset breast cancer (<40 years) (American Cancer 
Society 2015). Ethnicity also plays a role in the development of breast cancer as risk differs 
across ethnic groups (Levy-Lahad et al. 1997; Reeves et al. 2004; Agenbag 2005, van der 
Merwe and van Rensburg 2009, van der Merwe et al. 2012b).  
Non-modifiable factors associated with increased breast cancer risk include high breast tissue 
density (the ratio of glandular tissue to fatty tissue, measured on a mammogram) (Whitehead et 
al. 1985), high bone mineral density (Qu et al. 2013), type 2 diabetes (Boyle et al. 2012), high-
dose radiation to the chest as a result of medical procedures and benign breast conditions such 
as biopsy-confirmed atypical hyperplasia, DCIS and LCIS (American Cancer Society 2015).  
In addition, the use of post-menopausal HRT (Ross et al. 2000), lack of physical activity, 
obesity, smoking and consumption of one or more alcoholic beverages per day have been 
associated with increased breast cancer risk (Room et al. 2005; American Cancer Society 
2015). In 2010, a study conducted on 72 000 women by the National Cancer Institute (NCI) 
found that compared to women who maintained their weight, 20-year old women who 
progressively gained weight as they aged doubled their risk of developing breast cancer after 
menopause. In addition, overweight (BMI ≥ 25) or obesity (BMI ≥ 30) adversely affects survival 
in postmenopausal patients (Chlebowski et al. 2011). Overweight and obesity are responsible 
for 6.9% of cancers, which is nearly double the proportion caused by infectious agents 
estimated as 3.7%.  Li et al. (2009) demonstrated a 7.2-fold elevated risk of contralateral breast 
cancer in women who smoked and consumed 7 or more alcoholic beverages per week. 
Between 4-5% of breast cancer cases are primarily caused by alcohol consumption 
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(Longnecker 1994; Parkin et al. 2011). Smoking and alcohol consumption were not associated 
with increased risk of triple negative breast cancer (TNBC), but were modestly associated with 
increased risk of ER-positive breast cancer (Kabat et al. 2011). A pooled analysis of >300 000 
women and 4 335 cases suggested that consumption of 2-5 alcoholic beverages per day 
increases the risk of breast cancer by roughly 40% (Smith-Warner et al. 1998). The underlying 
mechanisms through which alcohol is thought to increase the risk for breast cancer include an 
influence on circulating estrogen levels (Purohit 1998), enhanced permeability of chemical 
carcinogens, immune function, metabolism of alcohol to acetaldehyde (a known carcinogen) 
(Feron et al. 1991) and decreased absorption of essential nutrients such as dietary folate 
(Thomas 1995). Diet is of particular relevance to this study which focuses on gene-diet 
interaction (nutrigenetics) that may modify the risks associated with breast cancer. The 
Mediterranean diet has been linked to a reduction in the risk of breast cancer (Toledo et al. 
2015). 
Breast feeding, reduced alcohol consumption, moderate or vigorous physical activity and 
maintaining a healthy body weight have been associated with lower risk of breast cancer 
(American Cancer Society 2015).  
 
2.6. Breast cancer screening and prognosis 
Early detection remains the primary defense available to patients in preventing the development 
of breast cancer. Despite advances in imaging technology, discrepancies regarding 
recommended schedules have complicated the process of screening. Careful consideration 
therefore needs to be given to the benefits and harms of the screening intervention, along with 
the costs involved. 
Breast cancer screening refers to the evaluation of healthy women (showing no signs or 
symptoms of the disease) for breast cancer in an attempt to achieve an earlier diagnosis. As 
early detection improves clinical outcome, a number of screening tests including clinical and 
self-breast examinations, mammography, ultrasound, magnetic resonance imaging and genetic 
screening have been employed (Khatcheressian et al. 2006; Dey 2014). In a clinical setting, the 
diagnostic procedure is initiated with a clinical breast examination, mammography, and fine 
needle aspiration (FNA) or core/excisional biopsy, where a portion of the tumour or the entire 
lump is removed for tissue or cellular analysis.  
Clinical breast examinations (CBE) every 3 years as well as frequent self-examinations have 
been recommended for women younger than 40 years (at average risk for breast cancer). For 
women over the age of 40 years however, annual CBEs have been suggested. In terms of 
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imaging, the most widely recommended screening approach in the United States for this group 
has been annual mammography. Mammography is a special type of low-dose x-ray imaging 
used to create detailed images of the breast. This screening method is currently the best 
available population-based method to detect breast cancer at an early stage, when treatment is 
most effective (Saarenmaa et al. 1999). The two types of mammography examinations include 
screening mammography, which is performed in asymptomatic women and diagnostic 
mammography, which is performed in symptomatic women when a breast lump, nipple 
discharge or abnormality is found during self-examination or screening mammography. 
Although mammography remains the most cost-effective approach for breast cancer screening, 
its sensitivity ranges between 69% and 90% (Rankin 2000) which slightly improves when 
combined with CBE.   
Ultrasonography is generally used to assist the clinical examination of a suspicious lesion 
detected on mammography or physical examination. This technique is however limited by a 
number of factors including failure to detect micro-calcifications and poor specificity (33%) (Kuhl 
et al. 2000). Magnetic resonance imaging (MRI) has been explored as a modality for detecting 
breast cancer in women at high risk and in younger women. A combination of MRI techniques 
has been found to be highly sensitive to malignant changes in the breast when combined with 
mammography and CBE (~99%). The 10-fold higher cost and substantially poorer specificity 
(26%) compared to mammography resulted in limited use MRI screening as a general screening 
tool (Obdeijn et al. 2010). MRI screening has however been recommended in a subset of high-
risk patients including those with BRCA mutations and a positive family history of cancer (Kriege 
et al. 2004; Warner et al. 2004). 
Prognosis is an estimated prediction of outcome and the probability of progression-free survival 
(PFS) or disease-free survival (DFS) (American Cancer Society 2015). Survival is often 
calculated as an average number of months (or years) that 50% of patients survive, or 
alternatively, the percentage of patients that are alive after 1, 5, 15 and 20 years. Patients with 
good prognoses are typically offered less invasive treatments such as hormone therapy or 
lumpectomy and radiation, while patients with poor prognoses are offered more aggressive 
treatments, such as mastectomy and chemotherapy (Horwich et al. 1994). Prognostic factors 
include age of the patient, staging and disease recurrence. Stage is the most important 
prognostic factor as it takes into consideration tumour size, local involvement, lymph node 
status and the presence of metastatic disease (Table 2.2, summarized from Garcia et al. 2007 
and http://www.breastcancer.org/symptoms/diagnosis/staging).  
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Table 2.2. Stages of Breast Cancer 
Stage  Definition 
Stage 0 
Cancer cells remain inside the breast duct, without invasion into normal adjacent breast 
tissue. 
Stage 1 Size of 2 cm or less and is confined to the breast (lymph nodes are clear). 
Stage 2A 
No tumour can be found in the breast, but cancer cells are found in the axillary lymph 
nodes (the lymph nodes under the arm). 
The tumour measures 2 cm or smaller and has spread to the axillary lymph nodes. 
The tumour is larger than 2 cm but no larger than 5 cm and has not spread to the axillary 
lymph nodes. 
Stage 2B 
The tumour is larger than 2 cm but no larger than 5 cm and has spread to the axillary 
lymph nodes. 
The tumour is larger than 5cm but has not spread to the axillary lymph nodes. 
Stage 3A 
No tumour is found in the breast; cancer is found in axillary lymph nodes that are sticking 
together or to other structures, or cancer may be found in lymph nodes near the breast 
bone. 
The tumour is any size; cancer has spread to the axillary lymph nodes, which are sticking 
together or to other structures, or cancer may be found in lymph nodes near the breast 
bone. 
Stage 3B 
The tumour may be any size and has spread to the chest wall and/or skin of the breast 
and,  
May have spread to axillary lymph nodes that are clumped together or sticking to other 
structures or cancer may have spread to lymph nodes near the breastbone. 
Inflammatory breast cancer is considered at least stage 3B. 
Stage 3C 
There may either be no sign of cancer in the breast or a tumour may be any size and 
may have disseminated to the chest wall and/or the skin of the breast as well as the 
lymph nodes (above or below the collarbone an axillary nodes near breast bone 
Stage 4 The cancer has metastasized to other parts of the body. 
 
A higher stage at diagnosis is typically associated with a worse prognosis. The greater the 
resemblance to normal cells, the slower the growth of the tumour cell and the better the 
prognosis. Grade on the other hand is a measure of the degree of differentiation of tumour cells. 
Cells that are not well differentiated will appear immature, divide more rapidly, and exhibit 
tendencies toward metastases. Well differentiated cells are assigned a grade of 1, moderate 
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grade 2, and poor or undifferentiated cells are allocated a higher grade of 3 or 4 (depending 
upon the scale employed). Early-onset disease tend to have a poorer prognosis due to a 
probable familial component linked to a more aggressive disease subtype such as estrogen 
receptor (ER), progesterone receptor (PR)-negative and human epidermal growth factor 
receptor-2 (HER2)–negative breast cancer (Fredholm et al. 2009; Partridge et al. 2010; 
Freedman and Partridge 2013). 
 
2.7. Molecular profiling and Intrinsic disease subtypes 
Molecular profiling of breast tumours, based upon variations in gene expression, has been used 
to characterize breast cancers beyond the conventional evaluation of grade, histology, and 
immunohistochemical (IHC) analysis of hormone receptors and HER2 overexpression. Breast 
cancer is among the earliest and most intensely studied diseases using DNA microarray 
platforms for gene expression profiling. This molecular profiling has enriched our understanding 
of disease heterogeneity and yielded valuable prognostic and predictive information. Four 
different gene lists including a varying number of genes have been used for molecular subtype 
identification and classification of breast cancer (Perou et al. 2000; Mackay et al. 2011). The 
resulting molecular classification has highlighted the existence of four major subtypes that 
overlap with different clinico-pathological classification systems (Su et al. 2011; Al-Ejeh et al. 
2011).   
The routine assessment of hormone receptor status is considered the standard of care in all 
newly diagnosed breast cancer patients. IHC and in-situ hybridization (ISH) techniques are used 
to determine ER, PR and HER2 receptor expression in early-stage breast cancer to prioritize 
the need for targeted treatment interventions. Variability in results reported has highlighted 
IHC/ISH testing limitations resulting from the lack of assay standardization, inter-observer 
variability in interpretation, as well as discrepancies between guidelines used to define cut-off 
limits for ER and HER2-positivitiy (Thomson et al. 2001; Regitnig et al. 2002). The development 
of RNA-based gene expression profiling techniques using microarray analysis and reverse 
transcription polymerase chain reaction (PCR) resulted from efforts to increase the prognostic 
and predictive value of the aforementioned conventional, routine tests. Grant et al. (2015) 
determined HER2 status across three assay platforms in an attempt to address the clinical 
dilemma presented by equivocal and contradictory results frequently obtained in patients with 
early-stage breast cancer.  These authors demonstrated 100% concordance of HER2 status 
following IHC/FISH reflex testing of the identified discordant cases using microarrays 
(TargetPrint), thereby improving quality assurance and consequently the level of confidence on 
which treatment decisions were based. 
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Gene expression profiling technologies have allowed for the description of distinct breast cancer 
subtypes based on intrinsic molecular profiles (Perou et al. 2000; Prat and Perou 2011). It has 
been demonstrated that ER status is the main discriminator of molecular signatures which 
supports the long-standing hypothesis that ER-positive and ER-negative breast cancers are 
different diseases (Gruvberger et al. 2001). The different subtypes among ER-positive and ER-
negative tumours have various implications for prognosis and treatment (Perou et al. 2000; 
Sotiriou et al. 2003). These observations suggest that gene expression profiling has the 
potential to change current breast cancer management, as evidenced with the use of the 70-
gene MammaPrint profile (Agendia, Inc., Irvine, CA) in the South African population (Grant et al. 
2013). MammaPrint uses a microarray platform for classification of early-stage breast cancer 
into low- or high-risk groups for chemotherapy selection. This test also enables sub-
classification of tumour tissue into luminal A, luminal B, HER2-positive and basal-like subtypes 
(BluePrint), based on the ~25 000 genes in the human genome evaluated during development 
of the MammaPrint test (Tian et al. 2010). 
At least four distinct breast cancer subtypes identified have recently been extended to about 10 
subtypes with the use of next generation sequencing (NGS) (Curtis et al. 2012). Surrogate 
definitions of the intrinsic subtypes include two main subtypes of ER-negative tumours: basal-
like and HER2-enriched, and three subtypes of ER-positive tumours: luminal A and luminal B 
(HER2-positive) and luminal B (HER2-negative).  
 
2.7.1. Luminal A and B subtypes 
Luminal cancers derive their name from similarity to genes expressed by normal breast luminal 
epithelial cells. They typically express luminal cytokeratins 8 and 18 and are the most common 
subtypes that make up the majority of ER-positive breast cancer. They are characterized by the 
expression of ER, PR, and other genes associated with ER activation.  
Luminal A tumours make up ~40% of all breast cancers and are associated with the most 
favourable outcomes compared to other subtypes. They usually have high expression of ER-
related genes, low expression of the HER2 cluster of genes, and low expression of proliferation-
related genes. Luminal B tumours on the other hand are less common (~20%) and are 
subdivided into those expressing HER2 and those who lack HER2 expression. They exhibit 
relatively lower (than luminal A) expression of ER-related genes, variable expression of the 
HER2 cluster, and higher expression of the proliferation-related genes (Yersal and Barutca 
2014; Ades et al. 2014).  
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Cell proliferation markers used to distinguish between luminal A and luminal B tumours (HER2-
negative) present substantial challenges in the clinical setting. In cases where reliable marker 
indexes are not available, alternative measures of proliferation such as a histological grade are 
used in distinguishing between luminal A and B subtypes. More recently, microarray-based 
molecular profiling using the 80-gene BluePrint has been shown to accurately discriminate 
between the luminal A and B subtypes (Glück et al. 2013; Whitworth et al. 2014), the latter 
being characterized by increased tumour proliferation, higher recurrence rates, poorer overall 
prognosis (Correa Geyer and Reis-Filho 2009; Wirapati et al. 2008) and are compatible with a 
high-risk 70-gene prognostic profile (Leo et al. 2012; Grant et al. 2013). BluePrint molecular 
subtyping determines the mRNA levels of 80 genes that discriminate between the three breast 
cancer subtypes based on functional molecular pathways: Luminal, HER2, and Basal. 
MammaPrint substratifies Luminal into Luminal A (MammaPrint Low Risk) and Luminal B 
(MammaPrint High Risk). The BluePrint reclassified 22% of breast tumours, reassigning more 
responsive patients to the HER2 and Basal categories while reassigning less responsive 
patients to the Luminal category. Based on these findings, Whitworth et al. (2014) suggested 
that compared with IHC/FISH, BluePrint more accurately identified patients likely to respond (or 
not respond) to neoadjuvant chemotherapy. 
 
2.7.2. HER2-enriched subtype 
The HER2-enriched subtype (previously the ER-/HER2+ subtype) makes up about 10-15% of 
breast cancers and is characterized by high expression of HER2 and proliferation gene clusters, 
and low expression of the luminal cluster. For this reason, these tumours are typically negative 
for ER and PR, and positive for HER2. This subtype comprises only ~50% of clinically HER2-
positive breast cancer (Eroles et al. 2012). The other approximate 50% display high expression 
of both the HER2 and luminal gene clusters and fall within the luminal B subtype. HER2-positive 
tumours are associated with increased cell proliferation, angiogenesis, tumour invasiveness, 
and a high nuclear grade (Chikarmane et al. 2015) and prior to HER2-targeted therapy, this 
subtype carried a very poor prognosis (Slamon et al. 2001; Cadoo et al. 2013).  
The most appropriate management plan for a patient diagnosed with cancer may be informed 
by an assessment of the components of the patient’s germline genome and their genome.  In 
addition to the use of RNA/protein expression to distinguish between different breast cancer 
subtypes, single nucleotide polymorphisms (SNPs) have been investigated for their role in 
defining these subtypes. O’Brien et al. (2013) demonstrated that low-penetrance genetic risk 
factors for breast cancer vary by subtype and further clarified the role of several key 
susceptibility genes. The discovery of the involvement of SNPs in the determination of disease 
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subtype led to the development of high-density SNP arrays. Hansen et al. (2015) sought to 
determine whether examination of HER2 copy number using high-density SNP arrays can 
provide additional diagnostic power to assess HER2 gene status. They concluded that 
determination of HER2 copy number variations by SNP array-based genomic segmentation 
analysis provides additional diagnostic sensitivity and accuracy, thereby providing an effective 
supplement to IHC/FISH HER2 analysis so that more women may be elected for targeted 
treatment with HER2 inhibitors. SNP pharmacogenetic analysis to determine the need for 
trastuzumab treatment of HER2-positive patients may however on its own be insufficient to 
replace gene expression analysis and IHC. The knowledge and new insights gained through 
SNP analysis may furthermore identify targets for intervention prior to the development of 
cancer, serving as a tool for prevention which is the direction and ultimate goal of genetic 
testing. In line with the findings of Hansen et al. (2015), Kotze et al. (2015) suggested a 
comprehensive approach that combines tumour pathology, genetic and relevant biochemisty for 
the classification of patients into different treatment groups.  
Variations in the HER2 gene have been identified that modify the protein sequence of the 
HER2-neu protein, but how these polymorphisms affect prognosis and response to HER2 
targeted therapy is unknown. Su et al. (2015) genotyped 3 SNPs in the HER2 gene in 303 
breast cancer patients to study their association with HER2 protein expression in breast cancer. 
Two SNPs (rs1058808 and rs2517956) were significantly associated with HER2 protein 
expression (p=0.007 and p=0.008, respectively), but not with other parameters such as clinical 
stage, tumour size, histological grade, lymph node metastasis, ER, PR, Ki67 and P53 status 
(p>0.05). SNPs in the recently discovered metastasis-associated in colon cancer-1 (MACC1) as 
well as in the Insulin-like growth factor 1 (IGF-1) and Vascular endothelial growth factor A 
(VEGFA) genes have been associated with the poor clinical outcome of HER2-positive breast 
cancer (Maae et al. 2012; Muendlein et al. 2013; Muendlein et al. 2014). In a case-control study, 
Stanton et al. (2015) studied 11 SNPs in relation to trastuzumab cardiotoxicity in 140 breast 
cancer patients. The HER2 Pro 1170 Ala SNP was significantly associated with trastuzumab 
cardiac toxicity (p=0.04) after adjusting for relevant confounders. This SNP may therefore 
identify a subset of breast cancer patients who are at increased risk of trastuzumab therapy 
cardiotoxicity and may be useful in conjunction with other biomarkers for stratifying patients into 
different risk categories for optimal clinical management.  
 
2.7.3. Basal-like subtype 
The basal-like subtype, named after its similarity in expression to that of the basal epithelial 
cells, makes up about 15-20% of breast cancers. It is characterized by low expression of the 
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luminal and HER2 gene clusters and is typically ER, PR, and HER2-negative, which has led to 
the term "triple-negative". While most triple-negative breast cancers (TNBCs) are basal-like, and 
most basal-like tumours are triple-negative, there is about 30% discordance between these two 
classifications (Bertucci et al. 2008). These tumours have high expression of the proliferation 
cluster of genes with exceptionally high mitotic rates, are virtually always high grade and are 
characterized by widespread genomic instability (even early in the disease) (Livasy et al. 2006; 
Fulford et al. 2006; Turner et al. 2007). Furthermore, they display high expression of the 
epidermal growth factor receptor, as well as a unique cluster of genes called the basal cluster, 
which include basal epithelial cytokeratins 5, 14, and 17. The basal-like subtype is strongly 
associated with BRCA1 mutation-positive cancers of which over 80% fall into this subtype. In 
addition, population-based studies suggest that this subtype is overrepresented in early-onset 
cases and in women of African-American descent (Carey et al. 2006; Morris et al. 2007; Bauer 
et al. 2007). Basal-like breast cancers are associated with poor prognosis and the worst survival 
rates compared to the luminal A and luminal B subtypes (Foulkes et al. 2003). Commercially 
available NGS tests (e.g. OncoDEEP, Belgium) may be particularly useful in triple-negative 
breast cancer or metastatic cancer (e.g. breast, colon, lung, ovarian, etc.) to determine 
functional pathways for the application of personalized medicine. Personalized medicine 
approaches use targeted therapies in subgroups of patients considered to derive the most 
benefit based on their genetic background. 
The findings of Rummel et al. (2013) supported that of Fostira et al. (2012) who recommended 
that patients with early-onset TNBC should be considered eligible for BRCA1 mutation testing 
even in the absence of a family history of cancer. Fostira et al. (2012) demonstrated that 23% of 
BRCA1 mutation carriers had no reported family history of breast or related cancers, which 
implies that 23% of BRCA-mutation positive patients would have been missed had they not 
been tested on account of the absence of a positive family history.  
Knowledge of the extent to which BRCA founder mutations, modifier genes and lifestyle risk 
factors relevant to the South African population correlate with hormone receptor status 
represents an important research question to ultimately guide treatment decisions. An increased 
risk of TNBC was observed among females with a first-degree family history of breast cancer 
(Phipps et al. 2011). While women with basal-like/triple-negative disease experience high short-
term mortality (O’Brien et al. 2010, Perez et al. 2011), the development and FDA approval of 
targeted anti-HER2 therapy has improved survival rates for women with HER2-positive disease.  
A frequently occurring phenomenon seen in breast cancer is altered tumour receptor status 
throughout disease progression - possibly influenced by adjuvant therapies - which significantly 
influences patient survival. Women with ER-positive primary tumours that switched to ER-
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negative tumours had a 48% increased risk of mortality (95% CI, 1.08 to 2.05) compared with 
women with stable ER-positive tumours (Lindström et al. 2012). Accurate documentation of 
ethnicity, family history, mutation status, HR status and other relevant clinical information 
therefore becomes increasingly important for present and future classification of patients into 
different treatment groups.  
 
2.8. Breast cancer treatment strategies 
Breast cancer is treated by surgery, radiation, hormone therapy, chemotherapy and 
immunotherapy. The presence of estrogen and progesterone receptors on tumour cells is 
important in terms of guiding treatment. Two-thirds of invasive breast cancers are ER and PR-
positive (Nicholson et al. 2003; Gonzales-Anguloetal et al. 2007) and require the hormones 
estrogen and progesterone to proliferate. A greater incidence of ER-positive tumours has been 
reported among postmenopausal women. Naturally, breast cancer patients who test negative 
for ER and PR will not respond to hormone therapy, bestowing their chances of survival on 
remaining treatment options (mainly chemotherapy), as well as disease morphology (Garcia et 
al 2007). 
  
2.8.1. Surgery 
The radical mastectomy, designed by William Stewart Halsted in 1889, was coined the Halsted 
radical mastectomy. About 90% of women in the United States of America (USA) who were 
treated for breast cancer underwent Halsted radical mastectomies from 1894 to about 1979. 
Although this procedure reduced the recurrence rate from 51-82% to 6% (Yang et al. 2005), it 
was a disfiguring surgery which increased morbidity to a great extent. Its consequences ranged 
from universal lymphedema (condition in which excess lymph fluid collects in tissues, causing 
swelling) to severely restricted arm movement, resulting in eventual chronic pain (Zurrida et al. 
2011). Within that period, women who were diagnosed with breast carcinoma immediately 
underwent radical mastectomies in the belief that it was unequivocally necessary in order to 
prevent metastasis.  
Currently, the various types of breast cancer surgery include: 
1. Lumpectomy (breast-conserving surgery) that involves removal of the tumour and some 
unaffected tissue around it. The lymph nodes may also be removed by making a second 
incision under the armpit.  
2. Partial/segmental mastectomy or quadrantectomy involving the removal of the 
cancerous area as well as the surrounding area of healthy tissue, more so than with a 
lumpectomy. This is usually followed by administration of radiation. 
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3. Simple or total mastectomy where the entire breast is removed, yet sparing the lymph 
nodes. Simple mastectomy is most frequently performed for prevention of new cancer 
development or when current cancer is in its early stages as in the case of in situ, micro-
invasive, and stage IA breast cancers. With a double mastectomy however, both breasts 
are removed as a pre-emptive strategy to prevent development of cancer in the other 
breast in high-risk cases. 
4. Radical mastectomy involves removal of the entire breast and nipple, lymph nodes in the 
armpit, and chest muscles under the breast. This procedure is currently rarely performed 
as a modified radical mastectomy is as effective and less disfiguring (The 1979 National 
institute for health consensus statement concluded that survival for modified radical 
mastectomy was equivalent to radical mastectomy). 
5. Modified radical mastectomy whereby the entire breast along with the nipple is removed. 
Some lymph nodes in the armpits are removed, however the chest muscles are not 
removed. 
 
2.8.2. Radiation therapy 
Radiation therapy involves treatment with high-energy rays or particles purposed to destroy 
cancer cells. It may be administered externally (external beam radiation) or internally 
(brachytherapy) subsequent to breast-conserving surgery to reduce the risk of recurrence in the 
breast or lymph nodes (Vinh-Hung and Verschraegen 2004), or after mastectomy in patients 
with tumours >5 cm or metastasis to the lymph nodes and/or other areas of the body (Fisher et 
al. 1985; Fisher et al. 1989).  A functional polymorphism in the Apurinic endonuclease 1 
(APEX1) gene (rs1130409) involved in the base excision repair pathway has been associated 
with higher sensitivity to ionizing radiation and increased risk of treatment-related pneumonitis 
(Yin et al. 2011). The same variant has been shown to modulate prognosis of advanced non-
small cell lung cancer in patients following platinum-based chemotherapy (Zhao et al. 2013).  
 
2.8.3. Hormone treatment 
The female sex hormones estrogen and progesterone are naturally produced by the ovaries and 
promotes the growth and survival of normal as well as cancerous breast epithelial cells by 
binding to and subsequently activating the ER. Estrogen-dependent processes that are 
important in the development and progression of the majority of breast cancers may be 
disturbed by the following 3  ways: 1) interference with the binding of estrogen to the ER and/or 
to the promoter elements of the genes it regulates by selective estrogen receptor modulators 
(SERMs) such as raloxifene and tamoxifen; 2) reduction or inhibition of ER expression by 
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fulvestrant, a selective ER down-regulator which acts by limiting ER availability for estrogen 
binding, and 3) reduction of the amount of estrogen produced via ovarian removal in 
premenopausal women and use of aromatase inhibitors/ inactivators (AIs) in postmenopausal 
women.  
 
2.8.3.1. Aromatase inhibitor treatment 
Aromatase inhibitors and inactivators act by hindering the body's ability to produce estrogen 
from androgens through the suppression of aromatase enzyme activity. While ovarian 
aromatase is responsible for the majority of circulating estrogen in premenopausal women, 
aromatase in fat and muscle may be responsible for much of the circulating estrogen in 
postmenopausal women. In tissues that are highly sensitive to estrogen including the breast, 
vagina, uterus, heart and blood vessels, bone and the brain, aromatase provides local estrogen 
in an autocrine manner. Consequently, breast aromatase activity is frequently increased in 
breast cancer (Simpson et al. 2001). 
Three generations of AIs have been developed to date with each successive generation having 
a higher specificity for the aromatase enzyme, greater suppression of aromatase activity and 
fewer adverse events, and (Dowsett 1990; MacNeill et al. 1992; van der Wall et al. 1993; 
Dowsett et al. 1995; Geisler et al. 1996; Geisler et al. 1998). The use of first- and second-
generation AIs was limited by side effects such as dizziness, fatigue, nausea and vomiting, 
rash, ataxia as well as by a lack of enzyme selectivity. Third-generation AIs are superior 
compared to their predecessors as they are associated with greater suppression of aromatase 
activity and fewer adverse events. The two classes of third-generation AIs include non-steroidal 
AIs (anastrozole and letrozole) which reversibly bind to the aromatase enzyme and steroidal AIs 
such as exemestane which irreversibly binds to aromatase. They are therefore currently the 
preferred treatment for ER-positive and/or PR-positive breast cancer in postmenopausal women 
in the early and metastatic setting (Winer et al. 2004). Adverse events include hot flushes, 
fatigue, vaginal dryness, loss of libido, joint stiffness, arthralgias and loss of bone mineral 
density with subsequent increased risk of fracture (Winer 2004). In premenopausal women, AIs 
have a limited ability to reduce circulating estrogen and are generally not prescribed in this 
subgroup of breast cancer patients without concomitant drugs that suppress the rise in 
gonadotrophins and subsequent increase in hormone levels (Winer 2005). 
 
2.8.3.2. Tamoxifen treatment 
Tamoxifen is a selective estrogen receptor modulator (SERM) that has been used for more than 
three decades as an endocrine treatment for HR-positive breast cancer, with indications in the 
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preventative, adjuvant and metastatic settings (Bernard et al. 2006). As an adjuvant therapy in 
early breast cancer it improves overall survival, and its widespread use is thought to have made 
a significant contribution to the reduction in breast cancer mortality (Ring et al. 2004). Used 
widely in the treatment of advanced breast cancer, it remains the standard adjuvant therapy for 
pre-menopausal women and a valid treatment option, alongside AIs for post-menopausal 
women (Newman et al 2008; Ferraldeschi et al. 2010).  
Tamoxifen is a non-steroidal agent with potent anti-estrogenic properties which competes with 
estrogen for binding sites in breast and other tissues. It competitively binds to estrogen 
receptors on tumours and other tissue targets, thereby producing a nuclear complex that 
reduces DNA synthesis and inhibits the effects of estrogen (Ring et al. 2004; Ferraldeschi et al. 
2010). It causes (pre)cancerous cells to remain in the G0 and G1 (quiescent) phases of the cell 
cycle, preventing cells from dividing rather than causing cell death. Its mechanism of action is 
therefore cytostatic as opposed to cytocidal (Lippman et al. 1999). 
Tamoxifen is metabolised in the liver by the cytochrome P450 isoforms CYP2D6 and CYP3A4 
into active metabolites such as 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen 
(endoxifen), which have 30-100 times greater affinity to the estrogen receptor than tamoxifen 
itself (Figure 2.2). Since endoxifen is 30-100 fold more efficient as an estrogen antagonist than 
tamoxifen (Jordan et al. 1977), its plasma concentration is crucial in determining the efficacy the 
drug. Concentrations of active metabolites are affected by factors such as environmental drug-
induced (eg. antidepressants) and genetic factors including CYP2D6.  
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Figure 2.2. Tamoxifen metabolism in the liver (reproduced with permission from PharmKB, 
https://www.pharmgkb.org/pathway/PA145011119). 
 
Although tamoxifen has several beneficial effects, approximately 30% of all patients treated with 
this drug do not experience the full medical benefit due to the co-administration of other drugs or 
genetic mutations in the gene encoding the enzyme that bio-transforms it into its active 
metabolite (Ferraldeschi and Newman 2010). This leads to significant inter-individual variability 
in drug metabolism and differences in drug response, making the beneficial and adverse effects 
of tamoxifen virtually unpredictable for individual patients before the availability of genetic 
testing (Bernard et al. 2006). 
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Tamoxifen binds to the ER which in turn interacts with DNA. The tamoxifen/ER complex recruits 
other proteins known as co-repressors to inhibit estrogen-mediated gene activation. Some of 
these proteins include the nuclear receptor co-repressor (NCoR) and the silencing mediator for 
retinoid and thyroid receptor (SMRT) (Shang et al. 2000; Ring et al. 2004). The effectiveness of 
tamoxifen can be influenced by various elements including growth factors. High levels of growth 
factor proteins including ErbB2/HER2 have been shown to occur in tamoxifen-resistant cancers 
(Jansen et al. 2005). Tamoxifen seems to require protein PAX2 for its full anti-cancer effect 
since the tamoxifen/ER complex is able in the presence of high PAX2 expression to suppress 
the expression of the proliferative HER2 protein (Hurtado et al. 2008). In contrast, when AIB-1 
expression is higher than PAX2, the tamoxifen/ER complex up-regulates the expression of 
HER2, resulting in stimulation of breast cancer proliferation.  
Tamoxifen through its antagonistic effect on the ER has been shown to reduce the risk of bone 
loss in postmenopausal women in addition to exerting favourable effects on osteoporosis 
prevention in postmenopausal women (Nakamura et al. 2007). In contrast, tamoxifen appears to 
be associated with bone loss in pre-menopausal women, particularly those who continue to 
menstruate after adjuvant chemotherapy (Vehmanenet et al. 2006). The dual role of tamoxifen 
is evidenced by its antagonistic effects in breast tissue as well as its partial agonistic effect on 
the endometrium. The rationale for using tamoxifen for a limited period of 5 years is therefore 
based on the substantial increased risk for endometrial cancer (Grilli et al. 2006). 
A significant number of tamoxifen-treated breast cancer patients experienced a reduction of 
libido (Cella et al. 2006). Although tamoxifen treatment in post-menopausal women was 
associated with beneficial effects on serum lipid profiles (de Medina et al. 2004), long-term data 
from clinical trials have failed to demonstrate a cardio-protective effect (Esteva and Hortobagyi 
2006). In women with variation in the apolipoprotein E (ApoE) gene, tamoxifen can however 
cause a rapid increase in triglyceride concentration in the blood (Liberopoulos et al. 2002). 
Tamoxifen use has also been associated with increased risk of thromboembolic events (TEs) in 
women at high risk for the disease due to variation in genes involved in haemostasis including 
factor V leiden (FVL) (Garber et al. 2010), prothrombin (FII) and MTHFR (Elhassan and Abdalla 
2015). The risk of thromboembolism with tamoxifen use is also increased during and 
immediately after major surgery or periods of immobility (Decensi et al. 2005). Tamoxifen is also 
a contributory cause of fatty liver, otherwise known as hepatosteatosis (Osman et al. 2007). 
Tamoxifen-treated breast cancer patients showed evidence of reduced cognition (Paganini-Hill 
et al. 2000) and semantic memory scores (Eberling et al. 2004), which may be exacerbated in 
carriers of the MTHFR 677 C>T and ApoE E4 mutations (Lengacher et al. 2015). A study by 
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Bender et al. (2001) demonstrated that memory impairment in patients treated with tamoxifen 
was less severe compared with those treated with the AI Anastrozole.  
Tamoxifen has been described as a chemo-preventative agent, as it decreased the incidence of 
invasive and non-invasive breast cancer. Studies involving more than 50 000 tamoxifen-treated 
women have produced prevention or risk reduction results in the range of 43% to 49% in three 
distinct invasive breast cancer risk settings of 1) healthy high-risk women, 2) patients with early-
stage breast cancer (reduction of contralateral breast cancer risk), and 3) patients with DCIS 
(Fisher et al. 1998; Fisher et al. 2005). These preventive effects of tamoxifen highlight the 
remarkable consistency of this treatment agent in settings of high breast cancer risk (Lippman et 
al. 1999). According to the Early Breast Cancer Trialists’ Collaborative Group (2005), allocation 
to about 5 years of adjuvant tamoxifen treatment (for ER-positive disease only) reduced the 
annual breast cancer death rate by 31%, regardless of the use of chemotherapy, age (<50, 50-
69, ≥70 years), PR status or other tumour characteristics. They contended that 5 years of 
tamoxifen treatment is significantly more effective than just 1-2 years of the treatment (p<0.001 
for recurrence, p=0.01 for breast cancer mortality). It has also been suggested that tamoxifen 
may reduce breast cancer risk through mechanisms other than receptor-mediated estrogen 
inhibition (Ring and Dowsett 2004). 
The lack of hormone receptor positivity in BRCA1 tumours suggests that treatment with 
tamoxifen, or other hormonal therapy, may be less effective in these patients. BRCA1 tumours 
are mostly ER and PR-negative while BRCA2 tumours are more commonly positive for both 
receptors (Karp et al. 1997; Lomen et al. 1998). TNBCs are common among patients with 
BRCA1 mutations (Lakhani et al. 2005). The finding that TNBC is most common among 
premenopausal women, especially those of African descent (Lund et al. 2009; Morris et al. 
2007), emphasizes the importance of the development of novel chemotherapeutic drugs such 
as poly ADP ribose polymerase (PARP) inhibitors that target BRCA-deficient breast cancer. 
 
2.8.4. Chemotherapy 
Chemotherapy predominantly used for stage 2-4 breast cancers is particularly beneficial in ER-
negative disease (Hortobagyi 1998; Miller and Sledge 1999). The chemotherapy agents are 
often administered in combinations for periods of 3 to 6 months. Chemotherapy agents work by 
destroying fast-growing and/or fast-replicating cancer cells, mainly by causing DNA damage and 
interference of DNA replication. These agents may however also damage normal cells, which 
may cause severe side effects including cardiac toxicity (Bird and Swain 2008), contralateral 
and secondary non-breast cancer (Schaapveld et al. 2008; Beadle et al. 2009), sexual and 
reproductive effects (Partridge et al. 2008), neurotoxicity and cognitive impairment (Brezden et 
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al. 2000; Bender et al. 2001; Ahles et al. 2002; Falleti et al. 2005; Vardy 2009) and anxiety and 
depression (Silva et al. 2010; Hack et al. 2012). The most commonly used neoadjuvant 
chemotherapy regimens contain an anthracycline (adriamycin or epirubicin) (AC) in combination 
or sequentially administered with taxanes (paclitaxel or docetaxel) (CAT).  Anthracyclines can 
be combined with cyclophosphamide and fluoropyrimidine. Another common combination 
treatment includes cyclophosphamide, methotrexate (MTX) and 5-fluorouracil (5FU) (CMF).  
The folate pathway is an important target for both cancer prevention and treatment. The anti-
cancer activities of CMF used as the cornerstone chemotherapeutic agents for treatment of 
metastatic disease are exerted through inhibition of this pathway (Shrubsole et al. 2005). It is 
therefore noteworthy that a number of studies have associated the 677 C>T mutation in the 
MTHFR gene with increased clinical response to 5FU, but an increased toxicity to MTX (Yood et 
al. 2012; Chiusolo et al. 2002; Toffoli et al. 2003; Cohen et al. 2003). Concomitant folate 
supplementation is generally recommended during treatment with MTX to reduce toxicity of 
MTX. While high folate intake was associated with a decreased risk of postmenopausal breast 
cancer in some studies (Ericson et al 2007; Lajous et al. 2006), others could not confirm this 
association (Feigelson et al. 2003; Rohan et al. 2000). Conflicting results may be attributed to 
the dual role of folate in cancer development: folic acid supplementation may provide protection 
early in carcinogenesis, yet may promote carcinogenesis if administered later and at very high 
intakes (Ulrich 2006; Kim 2006). This may pose a clinical dilemma in patients with two copies of 
the MTHFR T-allele, who have an increased requirement for folate above the daily 
recommended dose (RDA) (Moriyama et al. 2002). Since folic acid (synthetic folate) is more 
bioavailable than folate obtained from natural sources, single-nutrient high-dose 
supplementation is not recommended for cancer patients (Ulrich 2007). Synthetic folic acid 
requires several reduction reactions to produce the active molecule used in one carbon 
metabolism and therefore sufficient intake as part of a healthy diet should be encouraged or 
supplementation with an active form of folate recommended. Early detection of MTHFR 677 TT 
homozygotes as a high-risk genetic subgroup with increased requirements of folate and other 
vitamin co-factors is essential to optimize the enzymatic functional balance between DNA 
synthesis, repair and methylation processes (Friso et al. 2002; Peerbooms et al. 2011; Cohen et 
al. 2012). 
 
2.8.4.1. Platinum-based chemotherapy 
The platinum salts (cisplatin, carboplatin, and oxaliplatin) exert their anti-cancer activity by 
directly binding to DNA, causing the formation of DNA-platinum adducts and subsequently intra- 
and inter-strand DNA crosslinks. These DNA crosslinks ultimately impede replication and 
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transcription, leading to single and double-strand DNA breaks with resultant cytotoxicity (Noll et 
al. 2006).  
Cisplatin (cis- diamminedichloroplatinum), also known as Peyrone’s chloride, is one of the most 
widely used chemotherapeutic drugs. It was approved in 1978 as the first drug in its class, and 
early on was demonstrated to be active in the first-line treatment of advanced breast cancer 
(Sledge et al. 1998). Over time and with the availability of better-tolerated therapeutics, 
platinums fell out of favor in the treatment of advanced breast cancer. While cisplatin has a 
strong anti-cancer activity, it also exerts negative side effects including toxicity to the kidneys 
and nervous system (Kelland 2007). Carboplatin is a bidentate carboxylate ligand approved by 
the FDA in 1989 for the treatment of ovarian, head and neck, and lung tumours (Dasari and 
Tchounwou 2014). The DNA adducts formed by this molecule are the same ones introduced by 
cisplatin and thrombocytopenia is its main negative side effect.  
The last platinum drug approved by FDA in 2002 is oxaliplatin. With a slightly different 
mechanism of action than the aforementioned platinums, oxaliplatin is effective in the treatment 
of carboplatin and cisplatin-resistant tumours (Raymond et al. 2002) and in combination with 5-
fluorouracil (5-FU), is successfully used to treat colorectal cancer (Kelland 2007). 
The more recently developed phenanthriplatin is one of the most promising drugs as this 
compound kills cancer cells more efficiently than cisplatin and oxaliplatin and appears to be 
immune to acquired resistance mechanisms (Park et al. 2012). 
 
2.8.4.2. PARP inhibitors  
Poly (ADP-ribose) polymerase (PARP) inhibitors represent a new and promising class of 
chemotherapeutic drugs aimed at disrupting PARP function in homologous recombination-
defective cancers (O'Shaughnessy et al. 2009). PARP is a family of proteins with enzymatic 
properties, scaffolding properties, and recruiting ability for other necessary DNA repair proteins. 
PARP1 and PARP 2 are the best known of these proteins, with PARP1 being the most 
expressed member of the family and playing a critical role in base excision repair (BER) 
(Rouleau et al. 2010). PARP1 inhibition was found to be effective in the treatment of BRCA1 
and BRCA2-positive cancers. Its effectiveness is based on the ability to induce single-strand 
breaks which leads to stalling of replication forks as well as the formation of double-strand 
breaks that cannot be repaired in the absence of functional BRCA1 and/or BRCA2 proteins. 
This results in high levels of genomic instability and ultimately cell death. Olaparib was the first 
PARP1 inhibitor to be approved by the US food and drug administration (FDA) for the treatment 
of ovarian cancers with BRCA mutations. Currently, other PARP1 inhibitors including niraparib, 
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iniparib, veliparib, rucaparib and BMN-673 are being assessed in clinical trials, alone or in 
combination with chemotherapy or radiotherapy, for several sporadic tumours (Tangutoori et al. 
2015). 
 
2.8.5. HER2 Immunotherapy 
In addition to the assessment of HER2 oncogene amplification and/or overexpression as a 
prognostic marker, testing is used to determine eligibility for HER2-targeted therapies including 
trastuzumab, lapatinib and pertuzumab used in clinical practice. Trastuzumab has been shown 
to reduce recurrence risk by up to 50% when combined with chemotherapy (Piccart-Gebhart et 
al. 2005; Romond et al. 2005). Despite its great potential for risk reduction, indications for 
trastuzumab treatment in relation to tumour size and nodal involvement are controversial 
(National Comprehensive Cancer Network practice guidelines 2009, Park et al. 2010). A tumour 
size of <1 cm is considered small enough to obviate the need for chemotherapy (Grant et al. 
2014). In addition, quantitative scoring of the HER2 gene copy number rather than HER2:-
CEP17 ratio to define HER2 positivity is supported by Hanna et al. (2014). A HER2 gene copy 
number of <2.2 is considered ineffective for classification as HER2-positive. 
 
Trastuzumab is a humanized recombinant monoclonal antibody directed specifically against 
HER2 receptor. It is currently used as part of the neoadjuvant treatment regimen in patients with 
HER2-positive breast cancer (Kaufmann et al. 2007). Trastuzumab is the first developed agent 
targeting the HER2 pathway and its binding to the extracellular domain of HER2 receptor leads 
to inhibition of tumour cell growth. Mechanisms of anti-tumour action include antibody-
dependent cell-mediated cytotoxicity, inhibition of cleavage of the extracellular domain of the 
HER2 receptor, inhibition of ligand-independent HER2 receptor dimerization, inhibition of 
downstream signaling pathways and angiogenesis, induction of cell-cycle arrest and apoptosis, 
and interference with DNA repair (Molina et al. 2001; Baselga et al. 2001; Spetor et al. 2009). 
 
Lapatinib is a small, orally active molecule which reversibly inhibits HER-1 and HER2 tyrosine 
kinase. This inhibition leads to blockage of the MAPK and PI3/Akt signaling pathways, resulting 
in growth arrest and/or apoptosis (Xia et al. 2002). Some data indicate that lapatinib can also 
block HER2-HER3-mediated cell growth (Amin et al. 2010; Ghosh et al. 2011). Being a small 
molecule that can penetrate the blood-brain barrier, it has also been studied in the treatment 
and prevention of brain metastases (Saleem et al. 2015; Tomasello et al. 2010).  
 
Pertuzumab is the humanized monoclonal antibody that binds to dimerization domain II of HER2 
receptor, which is necessary for HER2 activation and cell signaling. Clinically, the most 
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important action of pertuzumab is inhibition of HER2-HER3 dimerization. Pertuzumab affects 
important signaling pathways that mediate cell proliferation and synergistically with trastuzumab 
inhibits breast tumour cell survival (Graus-Porta et al. 1997; Citri et al. 2003; Baselga and Swain 
2009).  
 
2.8.6.  mTOR inhibitors  
Aberrations in the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of 
rapamycin (PI3K-AKT-mTOR) pathway are frequently observed in breast cancer. This pathway 
plays an important role in the regulation of cell proliferation, metabolism, motility, angiogenesis, 
and survival. Pathway hyperactivation has been linked to cancer pathogenesis, progression, 
and treatment resistance (Shaw et al. 2006). Cancer cells develop resistance to various 
therapies through activation of the PI3K-AKT-mTOR pathway, hence the addition of mTOR 
inhibitors to endocrine therapy, chemotherapy, and anti-HER2 therapy to enhance efficacy 
and/or delay treatment resistance have been considered. Dysregulation resulting in 
hyperactivation of the mTOR pathway has been associated with a poor outcome in breast 
cancer (Jerusalem et al. 2014).  
 
2.9. Genetic contribution to breast cancer development and recurrence 
The impact of inherited genetic variations associated with adverse clinical outcomes in breast 
cancer can be divided into distinct categories of risk based on their penetrance and prevalence 
in the general population (Coate et al. 2010) (Tables 2.3 to 2.5). Highly penetrant mutations of 
low prevalence mainly in the BRCA1 and BRCA2 tumour suppressor genes are responsible for 
early-onset familial breast cancer in 5-10% of all affected patients across ethnic groups. A study 
in non-BRCA families identified mutations in several well-known, high and moderate 
susceptibility genes including ataxia telangiectasia mutated (ATM) (~5%), the double strand 
break repair protein (RAD50) (~3%), checkpoint kinase 2 (CHEK2) (~ 2%), partner and localizer 
of BRCA2 (PALB2) (~1%), meiotic recombination 11, homologue A (MRE11A) (~1%) and tumor 
protein p53 (TP53) (~1%) (Aloraifi et al. 2015). Novel pathogenic variants in 30 other genes 
could collectively explain the missing heritability in up to 35% of BRCA-negative patients.  
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Table 2.3. High penetrance breast cancer predisposing genes  
Gene name Protein function Reference 
High penetrance genes 
CDH1 
Cadherin-1 (CDH1) is a tumour suppressor 
gene and is important in cell–cell adhesion in 
epithelial tissue.  Germline mutations in CDH1 
predispose to diffuse gastric cancer and early 
onset breast cancer, specifically associated 
with lobular carcinoma.  
Dossus and Benusiglio 2015; 
Nelen et al. 1996; Berx et al. 
1995; Lalloo and Evans 
2012; http://www.uniprot.org/ 
MLH1 
MLH1 is a component of the post-replicative 
DNA mismatch repair system. It is also 
implicated in DNA damage signaling which 
induces cell-cycle arrest and may lead to 
apoptosis in case of major DNA damages. 
Bianchi et al. 2011; Hamann 
2000; http://www.uniprot.org/ 
MSH2 
MSH2 is a component of the post-replicative 
DNA mismatch repair system. It forms two 
different heterodimers which binds to DNA 
mismatches thereby initiating DNA repair. 
Westenend et al. 2005; 
Hamann 2000; 
http://www.uniprot.org/ 
PTEN 
PTEN facilitates regulating of cell growth. A 
mutated PTEN gene causes Cowden 
syndrome, a rare disorder in which people 
have higher risks of both benign and 
cancerous breast tumours, as well as growths 
in the digestive tract, thyroid, uterus, and 
ovaries.  
Hamann 2000; Nelen et a. 
1996; Berx et al. 1995; Lalloo 
and Evans 2012; 
http://www.uniprot.org/ 
STK11 
STK11 plays a role in the suppression of 
cellular proliferation and apoptosis. Gene 
mutations confer a risk of various cancers 
including female breast cancer. 
Hamann 2000; Manolio et al. 
2009; Hemminki et al. 1998; 
http://www.uniprot.org/ 
 TP53 
TP53 regulates the expression of target 
genes, thereby inducing cell cycle arrest, 
apoptosis, senescence, DNA repair, or 
changes in metabolism. Mutations in this gene 
are associated with a variety of human 
cancers including hereditary cancers. 
Hamann 2000; Dossus and 
Benusiglio 2015; Manolio et 
al. 2009; Hemminki et al. 
1998; http://www.uniprot.org/ 
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Table 2.4. Moderate penetrance breast cancer predisposing genes  
Gene name Protein function Reference 
Moderate penetrance genes 
ATM 
ATM helps repair damaged DNA and has 
been linked to an increased rate of breast 
cancer in some families as inheriting one 
defective copy of the gene prevents adequate 
repair of damaged DNA.  
Hollestelle et al. 2010; 
Broeks et al. 2000; Swift et 
al. 1987; 
http://www.uniprot.org/ 
BARD1 
BARD1 coordinates a range of cellular 
pathways including DNA damage repair, 
ubiquitination and transcriptional regulation to 
maintain genomic stability. It plays a central 
role in cell cycle control in response to DNA 
damage. 
Seal et al. 2006; Ripperger et 
al. 2008; 
http://www.uniprot.org/ 
BRIP1 
BRIP1 is required for the maintenance of 
chromosomal stability. It is also involved in the 
repair of DNA double-strand breaks by 
homologous recombination in a manner that 
depends on its association with BRCA1. 
Seal et al. 2006; Hollestelle 
et al. 2010; 
http://www.uniprot.org/ 
CHEK2 
CHEK2 is a cell-cycle checkpoint regulator 
and putative tumour suppressor.  When 
activated, the encoded protein stabilizes the 
p53 ptotein, leading to cell cycle arrest. It also 
interacts with and phosphorylates BRCA1, 
allowing it to restore survival after DNA 
damage. Gene mutations confer risk for 
sarcomas, breast and brain cancers. 
Hollestelle et al. 2010; Kainu 
et al. 2000; Meijers-Heijboer 
et al. 2002; 
http://www.uniprot.org/ 
MRE11 
MRE11 is involved in DNA double-strand 
break repair and possess single-strand 
endonuclease activity and double-strand-
specific 3'-5' exonuclease activity. It is also 
involved in meiotic double-strand break 
processing. 
Shibata et al. 2014; Bartkova 
et al. 2008; 
http://www.uniprot.org/ 
MUC1 
MUC1 is an oncoprotein that is aberrantly 
overexpressed in breast cancer cells and 
associates with HER2 at the surface of breast 
Siroy et al. 2013; Raina et al. 
2014; http://www.uniprot.org/ 
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cancer cells. 
NBS1 
NBS1 is a member of the MRE11/RAD50 
double-strand break repair complex. It is 
involved in DNA double-strand break repair 
and DNA damage-induced checkpoint 
activation. 
Bogdanova et al. 2008; Nseir 
et al. 2005; Hollestelle et al. 
2010; http://www.uniprot.org/ 
PALB2 
PALB2 interacts with BRCA2 and allows it to 
connect with BRCA1, forming the BRCA 
complex. Mutations in this gene disrupt DNA 
repair pathways 
Tischkowitz et al. 2010; 
Hollestelle et al. 2010; 
Rahman et al. 2007; 
http://www.uniprot.org/ 
RAD50 
RAD50 is essential for double-stranded DNA 
break repair interacting with BRCA1, NBN and 
MRE11. An abnormal RAD50 gene has been 
linked to a higher risk of breast cancer in some 
families as cells cannot sufficiently repair 
damaged DNA.  
Shibata et al. 2014; Damiola 
et al. 2014; 
http://www.uniprot.org/ 
RAD51 
RAD51 participates in homologous 
recombination and double-strand break repair 
processes. It binds to both single and double-
stranded DNA and forms part of a PALB2-
scaffolded homologous recombination 
complex containing BRCA2 and RAD51C. It 
also plays a role in regulating mitochondrial 
DNA copy number under conditions of 
oxidative stress in the presence of RAD51C 
and XRCC3. 
Park et al. 2008; Sigurdsson 
et al. 2002; Sage et al. 2010; 
Pellegrini et al. 2002;  
http://www.uniprot.org/ 
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Table 2.5. Low penetrance breast cancer predisposing genes  
Gene name Protein function Reference 
Low penetrance genes 
APEX1 
APEX1 is a multifunctional protein that plays a 
central role in the cellular response to 
oxidative stress. The two major activities of 
APEX1 is DNA repair and redox regulation of 
transcriptional factors. 
Hsu et al. 2014; Hinz et al. 
2014; Chohan et al. 2015; 
http://www.uniprot.org/ 
CASP8 
Most upstream protease of the activation 
cascade of caspases are responsible for the 
TNFRSF6/FAS mediated and TNFRSF1A 
induced cell death. 
http://www.uniprot.org/ 
FGFR2 
FGFR2 is a tyrosine-protein kinase that acts 
as cell-surface receptor and plays an essential 
role in the regulation of embryonic 
development, cell proliferation, differentiation, 
migration and apoptosis. 
Fletcher et al. 2013; Robbez-
Masson et al. 2013; 
http://www.uniprot.org/ 
H19  
The H19 gene product is a long non-coding 
RNA which functions as a tumour suppressor. 
Mutations in this gene have been associated 
with Beckwith-Wiedemann Syndrome and 
Wilms tumourigenesis. 
Medrzycki et al. 2014; Yan et 
al. 2015; 
http://www.uniprot.org/ 
HRAS1 
HRAS1 belongs to the Ras oncogene family, 
and products encoded function in signal 
transduction pathways. Defects in this gene 
are implicated in a variety of cancers, 
including bladder cancer, follicular thyroid 
cancer, and oral squamous cell carcinoma. 
http://www.uniprot.org/ 
LSP1 
LSP1 encodes an intracellular F-actin binding 
protein which is expressed in lymphocytes, 
neutrophils, macrophages, and endothelium. It 
may regulate neutrophil motility, adhesion to 
fibrinogen matrix proteins, and 
transendothelial migration. 
http://www.uniprot.org/ 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  38 
Table 2.5. Low penetrance breast cancer predisposing genes  
Gene name Protein function Reference 
Low penetrance genes 
MAP3K1 
MAP3K1 is a component of a protein kinase 
signal transduction cascade. It activates the 
ERK and JNK kinase pathways by 
phosphorylation of MAP2K1 and MAP2K4 as 
well as CHUK and IKBKB, the central protein 
kinases of the NF-kappa-B pathway. 
Hu et al. 2014; Glubb et al. 
2015; http://www.uniprot.org/ 
RPAP1 
RPAP1 forms an interface between the RNA 
polymerase II enzyme and chaperone/ 
scaffolding protein. It is also required for 
interaction of the RNA polymerase II complex 
with acetylated histone H3. 
Jeronimo et al. 2007; 
http://www.uniprot.org/ 
TNRC19  
The TNRC19 encoded protein is a member of 
the membrane-associated guanylate kinase 
homologue (MAGUK) family that participates 
in the assembly of multi-protein complexes on 
the inner surface of the plasma membrane at 
regions of cell-cell contact.  
http://www.uniprot.org/ 
 
 
Highly penetrant mutations of low prevalence are responsible for early-onset familial breast 
cancer in 5-10% of all affected patients with 3-4 % resulting from mutations in the BRCA1 and 
BRCA2 tumour suppressor genes, across ethnic groups (García et al. 2004). This led to the 
development of diagnostic BRCA mutation screening assays and computer-based algorithms 
for risk assessment routinely applied in clinical practice worldwide, including South Africa 
(Schoeman et al. 2013). The high lifetime risk for developing familial breast cancer estimated at 
65% to 85% for BRCA1 and 45% to 85% for BRCA2 mutation carriers (Chen et al. 2007), led to 
the development and implementation of personalized screening programs, prophylactic surgery 
and/or chemo-preventive therapies in mutation-positive patients and their at-risk family 
members (Schrag et al. 2000; Paradiso and Formenti 2011). It is estimated that known breast 
cancer susceptibility loci account for less than 50% of the familial risk of the disease, with the 
remaining variance likely to be due to genetic variants conferring low-moderate risks (Easton et 
al 2007). The tumour suppressor genes BRCA1 and BRCA2 are involved in maintenance of 
genome stability, specifically the homologous recombination pathway for double-strand DNA 
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repair. Guidelines for diagnostic and susceptibility screening for high penetrance mutations such 
as those in the BRCA1 and BRCA2 genes are well established and carried out routinely in 
clinical practice worldwide. Diagnostic BRCA testing has been available in South Africa since 
2004, and has been facilitated by the identification of common founder mutations in the BRCA1 
and BRCA2 genes in Afrikaner and other local populations (Reeves et al. 2004, van der Merwe 
et al. 2012b). Knowledge of hormone receptor status - as determined by transcriptional profiling 
to select South African patients for chemotherapy (Grant et al. 2013) and anti-HER2 treatment 
(Grant et al. 2015) - is also relevant in relation to familial breast cancer since women with the 
triple-negative and basal-like subtypes are at increased risk for carrying BRCA1 mutations 
(Lakhani et al. 2005).   
Over the preceding decade increasing evidence has been provided in numerous studies 
showing that multifactorial diseases may result from a combined effect of multiple low-
penetrance alleles and environmental factors (Pagon et al. 2002). These include functional gene 
variants underlying shared metabolic pathways that are potential nutritional and drug targets 
across diagnostic boundaries (Li et al. 2009; Ehrnhoefer et al. 2011). Polymorphic variation in 
the MTHFR and CYP2D6 genes are important modifiers of breast cancer development and 
recurrence, respectively, in BRCA mutation carriers (Jakubowska et al. 2007; Pepe et al. 2007; 
Newman et al. 2008). In an effort to optimize strategies for effective recurrence risk prediction or 
prevention of cumulative risk in patients with familial breast cancer, we proposed that CYP2D6 
genotyping is indicated in breast cancer patients who 1) are receiving tamoxifen and 2) are at 
high risk for tumour recurrence due to a family history of breast cancer/BRCA-mutation positive 
or 3) are required to take potential competing antidepressants. 
 
2.9.1. Cytochrome P450 2D6 (CYP2D6) pharmacogenetics 
CYP2D6 is one of the best studied cytochrome P450 enzymes, with numerous variant alleles 
designated *1 to *61. CYP2D6 plays an important role in the oxidative metabolism of various 
drugs such as neuroleptics, tricyclic antidepressants (TCA’s) and selective serotonin reuptake 
inhibitors (SSRI’s), adrenergic-blocking drugs (metoprolol), anti-arrhythmic drugs (sparteine and 
propafenone), opioids (codeine) (Zanger et al. 2004; Lohmann et al. 2001) and cholesterol-
lowering statins (Li et al. 2014). Nearly 99% of poor metabolisers have any two of the following 
alleles: *3, *4, *5, *6, *7 *8 or *11 (Bosch et al. 2006; Bradford et al. 2002). CYP2D6 catalyzes 
the conversion of tamoxifen to more potent metabolites, and poor CYP2D6 enzymatic activity 
has been associated with tamoxifen treatment outcome (Bosch et al. 2006). 
The CYP2D6 gene is located on chromosome 22q13.1 and more than 60 different alleles have 
been linked to this enzyme (Zanger et al. 2008; Zanger et al. 2004). The CYP2D6*4 allele 
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(rs3892097) is the most common variant and results in a stop codon as a direct result of a 
change in the splice site acceptor site (slicing defect, G  to A base change at position 1846 in 
intron 3). Imparting increased risk of adverse reactions from drugs requiring CYP2D6 
metabolism for activation or elimination,  5-10% of individuals in the Caucasian population have 
been shown to inherit the allele 4 null-allele (i.e. poor metabolisers), compared to 1-3% in other 
ethnic groups. Individuals who inherit two copies of the CYP2D6*4 which accounts for more 
than 75% of poor metabolisers in Caucasians (Bradford et al. 2002) may be more susceptible to 
hypersensitivity, toxicity or a lack of response to certain drugs (Griese et al. 1998; Zanger et al. 
2004).  
Therefore, alterations in CYP2D6 activity can negatively affect treatment outcomes in patients 
receiving antidepressant pharmacotherapies that are CYP2D6 substrates (D'Empaire et al. 
2011). Poor metabolisers have two copies of a defective CYP2D6 gene, and as a result they 
metabolise drugs at a much slower rate. This may result in a greater potential for adverse 
events and lower efficacy of drugs requiring CYP2D6 activation (Bernard et al. 2006). Cronin-
Fenton and Lash (2011) suggested that the effects of CYP2D6 inhibition on the response to 
tamoxifen treatment are likely small or non-existent. In this review, the authors concluded that 
extended CYP2D6 genotyping as well as the assessment of other genes related to tamoxifen 
metabolism and clearance should be considered an important avenue for future research. 
Abraham et al. (2010) also concluded that, while the CYP2D6*6 genotype could play a role in 
breast cancer survival in tamoxifen-treated patients, that the relationship between the 
inactivating CYP2D6*4 allele and therapeutic outcomes in relation to endocrine treatment 
remains incompletely described and warrants further investigation.   
A substantial body of evidence implicates genetic variation in the CYP2D6 and CYP2C19 
enzymes, which catalyze the hydroxylation and demethylation of many drugs and 
neurochemical compounds, in the response to antidepressants and other psychiatric 
medications. It is estimated that establishing CYP2D6 metabolizer status through extensive 
genotyping for drug-inactivating alleles will benefit treatment with 30-40% of drugs metabolised, 
equating to nearly 10% of those currently in use. Reduced enzymatic activity associated with 
polymorphisms in the CYP2D6 gene is of particular clinical relevance in the context of 
combination therapy with agents such as certain SSRI’s that may act as inhibitors of this 
enzyme. A greater understanding of a patient’s phenotype and metabolizer status as 
established by genotype has significant clinical implications in many non-communicable 
diseases, particularly in cancer patients using concomitant medications that are substrates and 
inhibitors for CYP2D6. 
Stellenbosch University  https://scholar.sun.ac.za
  41 
Findings from a study by Sestak et al. (2012) failed to support the role of CYP2D6 genotype as 
a determinant of adverse clinical outcomes or the development of side effects related to 
endocrine treatment in patients with breast cancer. Brauch and Schroth (2012) reviewed the 
relationship between CYP2D6 genotype and response to tamoxifen treatment. The authors 
concluded that, given the limitations and potential for study bias inherent to prospective-
retrospective studies, a prospective trial would be necessary to resolve issues related to this 
clinical question. Ongoing trials in the metastatic setting are not considered sufficient to resolve 
this issue, although hormone-insensitive patients are eligible for the Eastern Cooperative 
Oncology Group E3108 (ECOG E3108) clinical trial based on tamoxifen citrate use in patients 
with metastatic or recurrent breast cancer (Brauch et al. 2013). This notion is also relevant to 
results reported following the Breast International Group (BIG) 1-98 CYP2D6 study, in which 
bias introduced due to the use of tumour as opposed to host DNA resulted in massive deviation 
of the CYP2D6 genotype distribution from Hardy-Weinberg equilibrium (Nakamura et al. 2012). 
This led to a call to retract published findings related to this trial. 
The discovery that relatively frequent SNPs in genes coding drug-metabolising enzymes or 
those dependent on vitamin co-factors for optimal activity can explain differences in treatment 
response, drug toxicity and/or recurrence risk, support the development of genetic tests used for 
selection of the most appropriate treatment strategy for each patient (Del Re et al. 2012). In 
addition to CYP2D6, variation in the genes encoding MTHFR for example, are important 
modifiers of breast cancer development and recurrence in BRCA mutation carriers (Jakubowska 
et al. 2007; Pepe et al. 2007; Newman et al. 2008). Knowledge of such risk-modifying factors in 
addition to BRCA mutation status may aid in effective recurrence risk prediction or prevention 
strategies in patients with familial breast cancer.  
  
2.9.2. MTHFR nutrigenetics: folate metabolism and the methylation pathway 
Folate is a nutrient involved in the methionine metabolic pathway, which is essential for DNA 
methylation and is also required for DNA synthesis (Stover 2004). Cumulative data suggests 
that abnormalities in folate metabolism facilitate cross-talk between genetic and epigenetic 
processes by affecting gene expression (DNA methylation) and genome integrity (DNA 
synthesis and repair) (Kim 1999; Choi and Mason 2002). Folate polyglutamates are converted 
to 5,10-methylenetetrahydrofolate (methylene-THF), which is required as a methyl donor by 
dUMP (2′-deoxyuridine-5′-monophosphate) for the synthesis of dTMP (2′-deoxythymidine-5′-
monophosphate) (Figure 2.3).  
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Figure 2.3. Overview showing the action of the MTHFR, MTR and MTRR enzymes in the folate 
and methionine metabolism pathways. TS, thymidylate synthase; DHF, dihydrofolate; Formyl-
THF, 10-formyltetrahydrofolate; Cob I, cob(I)alamin; Cob II, cob(II)alamin; Methyl-Cob III, methyl 
cob(III)alamin; SAH, S-adenosylhomocysteine; Hcy, homocysteine; B6, vitamin B6. Figure 
reproduced with permission from Wettergren et al. (2010). 
 
Methylene-THF is the precursor of metabolically active 5-methyltetrahydrofolate (methyl-THF) 
which is used in the remethylation of homocysteine (sulfur-containing amino acid) to methionine. 
Methionine is then broken down to produce the universal methyl donor S-adenosylmethionine 
(SAM). The conversion of methylene-THF to methyl-THF is dependent on the MTHFR enzyme. 
The gene encoding the MTHFR enzyme is located on chromosome 1, position p36.3 (Goyette 
et al. 1994) and contains 11 exons (Frosst et al. 1995). Variation in the MTHFR gene has been 
linked to reduced enzyme activity resulting in hyperhomocysteinemia when folate status is low.  
The most widely studied variations in the MTHFR gene include two functional polymorphisms at 
nucleotide positions 677 (C>T, rs1801133) and 1298 (A>C, rs1801131). The point mutation 
1298 A>C results in the substitution of alanine to glutamine at amino acid position 429 
(Glu429Ala or E429A) of the regulatory domain of the enzyme (Rozen 1997; van der Put et al. 
1998). MTHFR 677 C>T is caused by a cytosine to thymine change at nucleotide position 677 
and results in a substitution of valine to alanine at amino acid position 222 (A222V) (Frosst et al. 
1995). This gene variant is the most common genetic cause of hyperhomocysteinaemia and has 
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been linked to a reduction in activity and increase in thermoliability of the MTHFR enzyme 
(Jacques et al. 1996; Schwahn and Rozen 2001; Yamada et al. 2001). The MTHFR CT-
heterozygous and TT-homozygous genotypes result in 65% and 30% reduction in enzyme 
activity, respectively (Tajouri et al. 2006). The frequency of the polymorphism varies significantly 
between ethnic groups (Schneider et al. 1998). Homozygosity for the MTHFR 677 TT genotype 
is higher than 20% in certain US populations such Hispanics, Columbians and Amerindians in 
Brazil, whereas in the Black population the frequency is less than 2%. The frequency for the 
Caucasian populations in countries such as Europe, North America and Australia is 8-20% 
(Gilbody et al. 2007) while the MTHFR 677TT genotype occurs in approximately 10% of 
individuals in the North American population. This is similar to the frequency reported in the 
South African Caucasian population, while this genotype was not detected in Black Africans 
studied by Scholtz et al. (2002). These authors reported an intermediate frequency in the South 
African Coloured population of mixed ancestry. 
The 1298 A>C mutation is caused by an A to C substitution at nucleotide position 1298 in exon 
7 (glutamine to alanine amino acid change) of the MTHFR gene. The frequency of the 
homozygous MTHFR 1298 CC genotype in Caucasian populations is 7-12% (North America 
and Europe). A reduced prevalence is observed in Hispanics, with a frequency of 4-5% 
compared to frequencies of 1-4% in the Chinese and Asian populations. Evidence exists for an 
association between this polymorphism and depression (Gilbody et al. 2007). We found that in 
depression patients but not in controls, the minor T-allele of MTHFR 677 C>T was associated 
with high BMI when folate intake was low, which in turn correlated significantly with increased 
homocysteine levels (Delport et al. 2014). 
It is known that MTHFR 677 C>T causes reduced enzyme activity that may impair folate 
metabolism, resulting in genomic DNA hypomethylation (Ulrich et al. 2007) as well as gene-
specific promoter hypermethylation (Oyama et al. 2004), as is frequently observed in cancer. In 
addition, reduced MTHFR activity may lead to increased plasma levels of homocysteine when 
folate status is low. Increased levels of homocysteine may in turn promote inflammatory 
processes by generating reactive oxygen species (ROS) (Mato et al. 2005) thereby playing a 
crucial role in cellular oxidative stress. Homocysteine may furthermore affect hypo- and 
hypermethylation of DNA (Peyrin-Biroulet et al. 2007). Evaluation of the MTHFR 677 C>T 
polymorphism as a predictive marker for colorectal cancer patients treated with 5-FU-based 
chemotherapy points to a link between the MTHFR 677 T allele and tumour response (Cohen et 
al. 2003; Etienne et al. 2004; Derwinger et al. 2009; Chua et al. 2009). Studies have also 
associated this polymorphism with 5-FU-related cytotoxicity (Derwinger et al. 2009; Chua et al. 
2009).  
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The extent to which epigenetic lesions are induced by our genetic background, environment, or 
by interaction of the two resulting in combined effects remains uncertain. Germline variants in 
the MTHFR and MTR genes found to be associated with aberrant patterns in tumour pathology 
in patients with colorectal, breast and lung cancer provides an important example of the 
interplay between genetic and epigenetic factors in the cancer cell (Paz et al. 2002). Carriers of 
the MTHFR 677 T-allele display low levels of 5-methylcytosine in their tumour genomes and do 
not achieve severe degrees of global hypomethylation. Analysis of tumours found to be 
homozygous GG for the methionine synthase (MTR/MS) 2756 A>G variant furthermore showed 
a low number of hypermethylated CpG islands in tumour-suppressor genes. The 2756 A>G 
polymorphism leads to an aspartic acid to glycine change in the protein-binding region of the 
MTR gene (van der Put et al. 1997), which results in a less effective enzyme that causes a 
reduction in vitamin B12 levels (Leclerc et al. 1996; Harmon et al. 1999; Klerk et al. 2003).  
Occasionally, MTR loses its activity through oxidation of cob(I)alamin to cob(II)alamin. The 
methionine synthase reductase (MTRR) enzyme then reactivates MTR in a reaction that 
generates methyl(III)cobalamin (Zijno et al. 2003). The MTRR 66 A>G polymorphism leads to a 
substitution of the amino acid isoleucine with that of methionine at codon 22 (Wilson et al. 1999) 
and results in an enzyme exhibiting a 4-fold reduction in activity compared with the normal 
protein in vivo (Olteanu et al. 2002). Thus, the MTRR 66 G-allele may decrease the availability 
of SAM by reducing the levels of active MTR, and as a result, induces DNA hypomethylation. 
The MTR 2756 GG genotype has been associated with an increased risk of colorectal cancer 
(de Vogel et al. 2009), whereas a reduced risk of colorectal adenoma recurrence has been 
observed in patients possessing one copy of the MTRR 66 A>G variant (de Vogel et al. 2009). 
The effects of the MTR 2756 A>G and MTRR 66 A>G variants are influenced by intake of B-
vitamins (Koushik et al. 2006; Hubner et al. 2006). Kang et al. (2005) recently showed that in 
uterine and cervical cancer patients with heterozygous genotypes with both of these gene 
variants, the average number of methylated genes was lower than in patients with the 
homozygous AA genotypes. 
The importance of the activity of the aforementioned enzymes in the folate-methylation pathway 
makes them attractive candidates for analysis of functional genetic variants in carcinogenesis.  
Several studies confirmed that functional polymorphisms in the MTHFR gene modify the risk of 
breast cancer and may potentially alter the risk of ovarian cancer in women with an inherited 
predisposition (Chen et al. 2005; Jakubowska et al. 2007). The MTHFR 677TT genotype was 
associated with a 2-3 fold increased risk of breast and ovarian cancer among Polish BRCA1 
mutation carriers when compared to individuals with the wild-type and heterozygous genotypes. 
Presence of the MTHFR 677 T-allele was found to confer an increased risk of breast cancer in 
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BRCA1 mutation carriers (p=0.007), while the presence of the 1298 C-allele confers an 
increased risk of breast cancer in sporadic cases (p=0.015) (Pepe et al. 2007). The MTHFR 
677TT genotype has furthermore been linked with congenital abnormalities, spontaneous 
abortions/miscarriages, renal tube defects, acute leukemia, motor dysfunction, seizures and 
thrombosis (De Mattia and Toffoli 2009). Aberrant genomic DNA methylation as a consequence 
of reduced MTHFR enzyme activity may be caused by variation in the MTHFR gene and/or low 
folate status (Friso et al. 2002).  Klerk et al. (2002) performed a meta-analysis in which 
individuals homozygous for the MTHFR 677 C>T polymorphism were found to have a 16% 
higher risk of coronary heart disease in comparison with those homozygous for the wild-type 
allele. According to Wald et al. (2002), lowering homocysteine concentrations by 3 mmol/l by 
increasing dietary folate intake, would reduce the risk of ischemic heart disease by 16%, deep 
vein thrombosis by 25%, and stroke by 24%.  
MTHFR, MTR and MTRR implicated in the development and progression of cancer, CVD, 
depression and treatment-related side effects (Peerbooms et al. 2011) act as treatment targets 
across the disease spectrum due to their involvement in one-carbon metabolic pathway 
essential for DNA synthesis and the epigenetic process of DNA methylation. 
 
2.10. Cancer Epigenetics 
It is well recognized that epigenetic changes contribute to carcinogenesis and provide a 
mechanistic link between lifestyle (environmental and dietary) exposures and disease. 
Epigenetic literally means “in addition to changes in genetic sequence.” (Weinhold 2006). It 
refers to alterations in gene expression/activity without changing the DNA sequence. A 
consensus definition of the concept of epigenetics was formulated at a Cold Spring Harbor 
meeting in 2008, as "stably heritable phenotype resulting from changes in a chromosome 
without alterations in the DNA sequence". Some studies showed that these modifications can 
be transmitted to daughter cells whereas other experiments demonstrated that these changes 
may be reversed (Li et al. 2005; Iglesias-Linares et al. 2010; Wang et al. 2010). Many types of 
epigenetic processes have been identified including methylation, acetylation, phosphorylation, 
ubiquitylation, and sumolyation. With regard to carcinogenesis, these mechanisms exist within 
two overarching processes, namely 1) chromatin remodeling by histone methylation or histone 
acetylation, and 2) DNA methylation via repetitive elements, DNA methyltransferases (DNMTs), 
CpG islands and gene expression. 
One of the most extensively studied epigenetic mechanisms is the formation of CpG sites by the 
pairing of cytosine with guanine by means of a phosphate group which has been a major focus 
of epigenetic research due to its capacity to directly silence gene expression, particularly with 
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respect to tumour-suppressor genes in carcinogenesis. This mechanism involves methylation of 
the fifth carbon of a cytosine nucleotide to create 5-methylcytosine (5mC), the methyl group of 
which lies in the major groove of the DNA helix that interferes with transcription factor binding to 
prevent gene expression. Moreover, there is a class of methylated DNA-binding proteins which 
binds to methylated cytosines and represses gene transcription by blocking transcription factors. 
DNA methylation is highly dysregulated in cancer. Aberrant patterns of methylation arise, 
leading to hypomethylation of distal regulatory regions and repetitive elements along with 
hypermethylation of CpG islands (Bird 2002; Ehrlich 2009). It has been known for some time 
that tumours from different sites display distinct CpG methylation profiles (Esteller et al. 2001) 
and exhibit distinct pathways of carcinogenesis within tumour sites (Sartor et al. 2011; Shen et 
al. 2007). Figure 2.4 illustrates the roles of DNA damage, epigenetic deficiencies in DNA repair 
and mutations in the pathogenesis and progression to cancer, while Figure 2.5 depicts common 
DNA damaging agents including examples of lesions they cause in DNA, together with the 
genes involved in the pathways used to repair these lesions. It also indicates the genes that are 
epigenetically regulated, and which of them display reduced expression in various cancers.  
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Figure 2.4. The roles of DNA damage, epigenetic deficiencies in DNA repair and mutation in 
progression to cancer [reproduced with permission from Bernstein et al. (2013a)]. 
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Figure 2.5. A chart of common DNA damaging agents including examples of lesions they cause 
in DNA, and genes involved in the pathways used to repair these lesions. Also indicated are the 
genes that are epigenetically regulated, and which of them display reduced expression in 
various cancers [reproduced with permission from Bernstein et al. (2013b)]. 
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Variable penetrance of familial breast cancer mutations highlighted the limited predictive value 
of single-gene testing as in the case of BRCA1 and 2 that is modified by gene-gene and gene-
environment interaction. Despite the success of linkage studies in identifying BRCA mutations in 
addition to other rare, causative mutations in single-gene disorders, a gap in knowledge was 
identified regarding limited power in detecting causative variants in complex diseases. In this 
context, the identification of moderate-high risk alleles other than those in the well-known BRCA 
genes may explain some of the “missing heritability”. Moreover, GWAS have identified several 
susceptibility variants which have been implicated as potential risk modifiers both in Mendelian 
and multifactorial diseases such as cancer. A number of common (mostly sporadic) breast 
cancer susceptibility loci have been associated with a slightly increased or decreased risk of 
breast cancer. To date, 74 SNPs have met the criteria for genome-wide “discovery” (Hindorff et 
al. 2013). These can act synergistically with environmental/lifestyle factors or follow the 
polygenic model to account for a small fraction of familial breast cancer cases. Most of these 
low-susceptibility loci have been highlighted through GWAS and initially included a number of 
loci. Although the precise contribution of low penetrance, common susceptibility loci in 
hereditary breast cancer is uncertain, the identification of such alleles may explain a subset of 
breast cancer cases. The identification of low-risk polymorphisms requires a paradigm shift in 
our understanding of the pieces of the susceptibility jigsaw, continuously being collected 
(Khoury et al. 2007).  How they all fit together and what the implications are for genetic 
counselling and clinical care are currently being clarified with regard to interaction between 
different elements of disease susceptibility, both genetic and environmental. The overall 
importance of these polymorphisms remains high, because their effect appears to be 
multiplicative, such that an individual possessing several polymorphisms in DNA repair genes 
may have a significantly increased risk of breast cancer (Antoniou et al. 2008; Pharoah et al. 
2008, Ricks-Santi et al. 2013).  
 
The use of NGS technologies has to a large extent superseded GWAS and has become 
increasingly popular in discovering and validating putative gene variants associated with the 
pathogenesis of breast cancer and associated comorbidities.  
 
2.11. Obesity and associated diseases 
Obesity is an important determinant of cardiovascular risk, especially in younger age groups 
(Krauss et al.1998). Increased weight is a determinant of higher levels of triglycerides, elevated 
low-density lipoprotein (LDL)- cholesterol (C) and low high-density lipoprotein (HDL)-C. Obesity 
therefore has a great influence on lipoprotein metabolism, regardless of ethnic background. 
Results from numerous, large prospective cohort studies have generally showed an increased 
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risk of CVD mortality with increasing BMI (Wilson et al. 2002; McGee 2004; Flegal et al. 2005). 
Several studies have also associated obesity and weight gain with breast cancer risk (Huang et 
al. 1997; Wolket al. 2001; Stephenson and Rose 2003) and there is evidence that weight loss, 
as well as reduced fat intake may lead to decreased risk for breast cancer (Harvie et al. 2005; 
Prentice et al. 2006). In addition to cancer, obesity has been associated with various diseases 
listed in Table 2.6. 
Table 2.6. Obesity and its associated diseases. 
Disease Prevalence/ risk 
Cancers 
Up to 20% of all cancer deaths are attributed to obesity (30% of 
endometrial cancers) (Calle et al. 2003; Chang et al. 2013) 
Metabolic syndrome 
(MetS) 
30% of middle-aged individuals in developed countries display 
symptoms of MetS (Després and Lemieux 2006) 
Depression 
Obesity associated with 55% increased risk of developing 
depression (Luppino et al. 2010)  
Hypertension 
5x risk amongst obese individuals; 66% of hypertensive cases 
linked to excess weight (Foresight report 2007) 
Type 2 Diabetes 
44% of type 2 diabetes attributed to obesity (World Health 
Organization 2013) 
Coronary artery 
disease (CAD) and 
stroke 
3.6x risk of CAD for each unit change in BMI and 6x risk of stroke in 
obese individuals (Prospective Studies Collaboration 2009) 
Osteoarthritis (OA)  
Increasing BMI frequently associated with OA in the elderly; risk of 
disability due to OA equal to CVD and greater than any other 
medical condition in the elderly (Grotle et al. 2008) 
Reproductive function 
6% of primary infertility in females attributable to obesity and 
impotency and infertility in men frequently associated with obesity 
(Hammoud et al. 2008; Arendas et al. 2008) 
Respiratory effects 
40% prevalence of obstructive sleep apnoea in obese individuals 
and up to 48% of patients with pulmonary hypertension were obese 
(Vgontzas et al. 1994; Taraseviciute and Voelkel 2006) 
Gall bladder disease 
3x risk of gall bladder disease in women with of BMI of >32 kg/m2  
and 7x risk with BMI >45 kg/m2 (Bonfrate et al. 2014) 
Liver disease 
Up to 80% of obese patients have non-alcoholic fatty liver disease 
and up to 20% have non-alcoholic  steatohepatitis (Sanyal et al. 
2002; Bugianesi et al 2002) 
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Due to the known effects of obesity, alcohol and smoking on DNA methylation implicated in 
breast cancer and its associated co-morbidities, assessment of MTHFR as part of a 
comprehensive screening approach may facilitate the prevention of cumulative risk across 
diagnostic boundaries. Testing for MTHFR 677 C>T as an invariant marker to assess the risk for 
co-morbidities associated with dysfunctional methylation reflected by plasma homocysteine 
levels, provides added value compared to isolated biochemical analysis which is influenced by 
various environmental and lifestyle factors. For this reason, MTHFR is not only a feasible anti-
cancer treatment target, but also a target for prevention of cumulative risk.  
 
Although the clinical utility of single-gene testing in a high-risk population group is well-
established, evaluation of multiple low-penetrance SNPs is complicated by uncertainty related to 
selection criteria and interpretation of the results for clinical application (Kotze et al. 2013). 
Pathology-supported genetic testing (PSGT) as a proposed solution was developed to 
overcome these limitations and may serve as a screening step for the selection of patients for 
whole exome sequencing (WES). Therefore, the CVD multi-gene assay previously described by 
Kotze and Thiart (2003) has been incorporated as the genetic component of a chronic disease 
screening program ideally suited to bridge the GWAS-related knowledge gap while moving from 
single-gene diagnostic testing to next generation sequencing (NGS) in genetically 
uncharacterized patients (Kotze et al. 2015). This approach may be particularly relevant in 
BRCA-negative breast cancer patients with certain comorbidities and/or experiencing 
therapeutic intolerance not adequately covered by the PSGT approach or accounted for by 
functional SNPs expressed in a high-risk environment. 
  
2.12. Next Generation Sequencing 
NGS applies to genome sequencing, genome resequencing, transcriptome profiling (RNA-Seq), 
DNA-protein interactions (ChIP-sequencing), and epigenome characterization (de Magalhãese 
et al. 2010). The development of NGS technologies has escalated due to the demand for low-
cost, high-throughput DNA sequencing which produces millions of sequences concurrently 
(Church 2006; Hall 2007; Schuster et al. 2008). For the translation of identified rare variants into 
clinical practice, larger sample size and greater ability to interpret the results to facilitate clinical 
diagnosis indicates exome sequencing may convey the most valuable method (Choi et al. 
2009). As a means to check the usefulness of NGS as a tool for clinical testing, a targeted re-
sequencing study of 21 hereditary breast cancer genes' exons were captured in subjects with a 
known mutation, which successfully detected 100% of mutations in all samples (Walsh et al. 
2010).  
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Alterations to high-throughput sequencing methods have been developed depending on costs 
and efficiency needed by the study design: namely custom targeted, WES, or whole genome 
sequencing (WGS). Targeted sequencing allows selective capture of genomic regions of 
interest, either in-solution or by molecular inversion probes, which can then be amplified. 
Specifically for the Illumina platform, these sequences are subjected to the formation of clusters, 
which can be sequenced in parallel, in a single experiment. The sequence reads generated for 
each individual are mapped to a reference genome and variants can be identified and examined 
for pathogenicity. Using this technology, an enormous amount of data can be generated per 
region, thus providing great confidence for variant identification.  
 
2.12.1. Whole Exome Sequencing 
WES involves sequencing of all protein-coding regions (exons) in the genome and provides a 
cost-effective advancement for dissecting the genetic basis of complex diseases such as cancer 
and associated comorbidities. Compared with WGS, WES facilitates handling of data and 
generates higher-quality data, since it can be performed at greater sequencing depth. Various 
factors including the sample source, the specific region being sequenced and the particular 
algorithm used to compile and analyze the results determine the optimal sequencing depth. 
While exons represent only 1% of the genome, they account for approximately 85% of disease-
causing variants, particularly for Mendelian traits (Bamshad 2011). 
WES and WGS enable comparison of allele and genotype frequencies of previously published 
pathogenic rare variants between patient cohorts across ethnic groups (Norton et al. 2012). In 
addition, these sequencing methods can successfully aid clinical diagnosis (Choi et al. 2009; 
Gahl et al. 2012), reveal the genetic basis of rare familial diseases (Ng et al. 2010; Bamshad et 
al. 2011), and explicate novel disease biology (Lupski et al. 2010). This is of particular relevance 
to the elucidation of variants of “unknown clinical significance” (VUS) frequently identified in 
breast cancer patients subjected to NGS of the entire BRCA1 and 2 genes (Cheon et al. 2014), 
increasingly used to replace limited BRCA1/2 sequencing in familial cases.  
A limitation of WES is that it predominantly identifies variants in the coding region of genes and 
is not able to detect disease-associated structural variation identifiable using other more 
comprehensive methods such as WGS (Ng et al. 2009). While the application of WES in the 
field of medical science is vast and highly advantageous, every step along the path to identifying 
potential disease-causing/contributory gene variants is complicated by technical, clinical and 
ethico-legal challenges.  
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Even when sequencing individual exomes, a large quantity of data and sequence information is 
generated and requires a significant amount of data analysis. Various challenges associated 
with the analysis of this data include differences in programs used to align and assemble 
sequence reads (Kahvejian et al. 2008; Dewey et al. 2011). Sequence technologies also have 
different error rates and generate varying read-lengths which may pose challenges when 
comparing results from different sequencing platforms. Furthermore, genetic heterogeneity due 
to ethnicity is a major limitation as it may increase the number of false positive and false 
negative findings in relation to the reference genome used, making the identification of 
candidate genes more difficult. The most striking technical challenges currently faced include 
the discrepancies between different sequencing platforms and low concordance among multiple 
variant-calling pipelines used (Boland et al. 2013). Low concordance among variant-calling 
pipelines limits the application of WES in clinical practice (O’ Rawe et al. 2013).  
Several tools have been developed to process exome sequence data. Generally, these tools 
are combined into a semi-automated workﬂow or pipeline, which include the following major 
steps. 
 
2.12.2. Quality control of raw data  
NGS platforms generate millions of sequence reads per run that each have a per-base quality 
score, which must be used as part of the analysis pipeline to identify problems that occurred 
during the generation of the data. This enables detection of problems that originated from the 
sequencer or library material used during the sequencing process, thereby preventing error from 
promulgating and producing false variant calls. It also provides an opportunity to salvage 
valuable data by clipping off the poor quality segments that generally occur at the 3’end of 
reads. 
The most commonly used software for quality analysis is FASTQC (http://www.bioinformatics. 
bbsrc.ac.uk/projects/fastqc), which supports several input ﬁle formats produced by the various 
sequencing platforms. It can be run in two diﬀerent modes, one as part of the sequence 
analysis pipeline producing an HTML QC report suitable for systemic processing of large 
numbers of datasets, or as an interactive application. Several analysis modules produce a 
range of quality metrics for sequence data. These modules range from basic statistics, such as 
overall nucleotide composition to various sequence quality scores. Systemic error is indicated 
when the quality score of the sequences is low overall and indicates poor sample 
quality/preparation or instrument failure. Contamination of the library or other issues during 
sequencing are also detected by an imbalance in the GC content at any read position, which 
should be very similar to the overall GC content of the underlying genome. 
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2.12.3. Mapping of reads to a standard reference genome 
Sequence alignment is a critical step in exome sequencing analysis as it allows for mapping of 
the sequences to the reference genome, thereby detecting mismatches that represent SNPs, 
point mutations and insertion-deletion mutations (indels). Popular open source software tools 
used for this purpose are Tmap (https://github.com/iontorrent/TMAP), BWA (Li and Durbin 
2009), Bowtie (Langmead et al. 2009) and BFAST (Homer et al. 2009). These tools display 
relatively equal performance and several are utilized in clinical sequencing applications. A 
shared shortcoming however, is their ability to manage genuine indels in short read data such 
as Illumina and SOLiD (Oliver 2012). A commercial aligner, NOVOALIGN (http://novocraft.com) 
has been shown to outperform the free software tools in this regard and recent releases have 
further improved its ability to accurately detect relatively large indels. A recent study has shown 
that it not only outperforms other popular aligners in the detection of indels, but also in the 
identiﬁcation of SNPs close to indels (Pattnaik et al. 2012). Accuracy of the reference genome 
mapping step is paramount to identifying true variants.  
 
2.12.4. Variant calling 
In line with the third challenge identified in this study, accurate detection of genetic variants from 
mapped NGS reads is a crucial part of the WES analysis pipeline and determines the 
usefulness of a program’s application in clinical practice. As even the best read mappers 
erroneously map a small fraction of reads, it is important that software for calling variants based 
on those alignments is able to detect and rectify mapping errors.  
Several variant calling suites exist, including the Ion Torrent Variant Caller software plugin, the 
Ion Reporter’s Ingenuity variant Caller (http://mendel.iontorrent.com/ion-docs/Ion-Reporter-
Software-Features-Related-to-Variant-Calling.html), SAMtools (Li et al. 2009), the Genome 
Analysis Toolkit (GATK) (https://www.broadinstitute.org/gatk/index.php), CRISP (Bansal 2010), 
DiBayes (http://solidsoftwaretools.com/gf/project/dibayes/), BWT (Liand and Durbin 2009), 
VarScan (Koboldt et al. 2009) and SNPSeeker (Druley et al. 2009). GATK in particular is a 
multiple-sample, technology-aware single nucleotide variant caller. It is the most widely used 
variant calling toolkit (McKenna et al. 2010), which includes two modules called the GATK 
UnifiedGenotyper and HaplotypeCaller, the latter being superior in relation to indel detection. 
Software tools used to compensate for the presence of false-negative and false-positive variant 
calls include the RAREVATOR, a Perl script that executes the UnifiedGenotyper module of 
GATK, devised to filter and annotate resulting variants (Magi et al 2015). It largely deals with 
human datasets and processes pre-aligned short reads mapped to a reference genome to 
produce a very accurate set of SNP and indel calls for downstream analysis. The GATK pipeline 
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has two functionalities: a data processing pipeline and a variant detection pipeline. The data 
processing component includes recalibration of base quality scores, ﬁxing miss-mapped reads 
proximal to or spanning indels, while the variant calling component generates a list of SNPs, 
indels and structural variations (SVs) by performing a local de-novo assembly. Genotype 
reﬁnement is a very powerful GATK functionality, which assesses called variants based on 
concordance with data in publically available mutation/SNP databases such as dbSNP and the 
1000 Genomes Project (McKenna et al. 2010; Campbell et al. 2012). 
 
2.12.5. Variant annotation and filtering 
A WES experiment generates a large amount of genetic variants many of which, in the context 
of a disease study, are not relevant as they are very unlikely to have a functional effect at the 
protein and/or systemic level. Methods for identifying the functional variants that have the 
potential to be involved in disease development or treatment response have therefore become 
very important, especially since use of WES is becoming increasingly prominent in personalized 
medicine applications. Functional SNP prediction tools such as ANNOVAR (Wang et al. 2010), 
dbNSFP (Liu et al. 2011) and SeattleSeq (http: //gvs.gs.washington.edu/SeattleSeqAnnotation/) 
are popular tools for annotating variants and predicting deleterious effects. 
GeneTalk is a relatively new, professional network and online tool for analyzing human 
sequence variants (https://www.gene-talk.de/). It is used for annotation and filtering of variants 
and is based on publically available SNP/mutation databases such as dbSNP and NCBI.   
ANNOVAR (http://www.openbioinformatics.org/annovar/) was speciﬁcally developed to annotate 
SNPs, indels and SVs from high-throughput sequencing data for classiﬁcation of functional 
variation to generate a small subset of potential causative mutations resulting in protein-coding 
changes (Wang et al. 2010). Additionally, ANNOVAR annotates variants located in exonic, 
intronic, intergenic, splicing site, 5’/3’ untranslated regions (UTRs), or upstream/downstream 
regions of genes and uses standardized nomenclature (Den Dunnen and Antonarakis 2000) to 
annotate non-synonymous SNVs and indels in relation to known cDNAs and proteins. Other 
important functions include measurements of evolutionary conservation calculated using 
PhastCons (Siepel et al. 2005) and PhyloP (Pollard et al. 2010), which can be implemented to 
predict the tolerability of a missense variant at a speciﬁc position. In addition to annotation of 
known and novel variants, ANNOVAR uses multiple algorithms to predict the functional effect of 
missense variants. Other such software tools include PolyPhen-2 (Ramensky et al. 2002), SIFT 
(Ng and Henikoﬀ 2003), PROVEAN (Choi et al. 2012), LRT (Chun and Fay 2009) and 
MutationTaster (Schwarz et al. 2010). ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) accessible 
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from the NCBI website, is a freely accessible, public archive of reports of the relationships 
among human variations and phenotypes, with supporting evidence from the literature.  
SIFT serves the same purpose but is based on the degree of conservation of amino acid 
residues in sequence alignments derived from closely related sequences. Thus, by using 
sequence homology, it predicts the effects of all possible substitutions at each position in the 
protein sequence. SIFT is available as an online tool (http://sift-dna.org) and can be applied to 
naturally occurring non-synonymous polymorphisms or laboratory-induced missense mutations 
(Kumar et al. 2009). PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) predicts the possible 
impact of amino acid substitutions on the stability and function of human proteins using 
structural and comparative evolutionary considerations (Adzhubei et al. 2013). A more recent 
software tool called PROVEAN (Protein Variation Effect Analyzer), is documented to be 
comparable to SIFT or PolyPhen-2 (Choi et al. 2012). PROVEAN predicts whether an amino 
acid substitution or indel has an impact on the biological function of a protein and is useful for 
filtering gene variants to identify nonsynonymous or indel variants that are predicted to be 
functionally important (Choi and Chan 2015). 
 
2.13. Genetic Counselling 
Genetic counselling of patients considering genetic testing is essential to discuss the benefits 
and limitations of genetic testing. The value of breast cancer genetic testing does not only 
derive from the information obtained, but also from the ability to effectively communicate the 
implications of the test results to clinicians and their patients in ways that positively affect 
behavioural responses to receiving genetic information (Wilfond et al. 1997). Figure 2.6 
illustrates the genetic counselling process implemented at Tygerberg Hospital, Western Cape, 
to ensure optimal use of scarce human resources. BRCA1/2 founder mutations are tested in a 
population-specific manner in South African breast cancer patients following consultation by the 
treating clinician (pre-test counselling). Post-test counselling by a registered genetic counsellor 
is performed after the BRCA report is provided in order to determine the appropriateness of 1) 
extended mutation analysis of the entire BRCA1/2 genes in mutation-negative breast cancer 
patients and 2) family screening in mutation-positive cases. 
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Figure 2.6. Genetic counselling and testing process in South Africa, 2010 – 2011 (reproduced 
with permission from Schoeman et al. 2013). Multiplex ligation-dependent probe amplification 
(MLPA) is a multiplex PCR method for the detection of abnormal copy numbers of genomic 
DNA or RNA sequences.  
 
Since a positive DNA test may also imply increased risk in healthy family members, inadequate 
counselling may result in ethical, social, and legal implications. Genetic counselling should 
therefore form an integral part of the testing process in breast cancer patients (American 
Society of Clinical Oncology 1996). In South Africa, BRCA genetic testing is offered in 
accordance with guidelines developed in collaboration with genetic counsellors, surgeons and 
oncologists (Kotze et al. 2005; Schoeman et al. 2013), after careful consideration of potential 
ethical implications related to genetic discrimination (Kotze et al. 2004). Compliance to pre-
determined guidelines and an ethics approved process for return of genetic information ensures 
that patients referred by clinicians are informed of the implications and limitations prior to the 
testing process (Kotze et al. 2015). When the test results are provided, appropriate medical 
management options need to be offered to the patient. With regard to pre-symptomatic genetic 
testing, a system should be in place preferably for ongoing monitoring of patients to measure 
the impact of treatment intervention in BRCA mutation carriers compared to sporadic or BRCA-
negative familial cases. Managing patient expectations prior to genetic testing in relation to risk 
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implications and treatment options based on a positive or negative test result is of the utmost 
importance to ensure a meaningful genetic testing experience. 
 
2.14. Risk assessment across the disease spectrum 
Existing approaches to breast cancer prevention and treatment are being challenged by recent 
developments in genomic research which allows for a personalized approach to the prediction 
and management of disease across diagnostic boundaries. A genomics-based approach to 
breast cancer risk screening based solely on high-penetrance mutation screening is insufficient 
to explain familial inheritance related to breast cancer subtypes as well as adverse treatment-
related side effects. Increasing recognition of the limitations imposed by a genomics-only 
approach to risk screening for breast cancer and associated comorbidities led to the 
development of a novel pathology-supported genetic testing approach (PSGT) which utilizes a 
combined research and service delivery platform to allow for the assessment of genetic risk in 
the context of relevant environmental determinants of phenotypic expression in a high-risk 
clinical setting (Kotze et al. 2015). Such a multidisciplinary approach to chronic disease risk 
screening has been proposed as a means of determining eligibility for extended genetic 
testing/WES performed alongside the evaluation of tumour morphology and hormone receptor 
expression profiles to allow for a subtype-specific approach to critical risk reduction intervention. 
Our PSGT approach is ideally suited as an intermediary step between GWAS and the clinical 
application of NGS used for the identification of novel causative variants of large clinical effect in 
genetically uncharacterized breast cancer patient subgroups. 
One of the major challenges for translation of genetic research into clinical practice is the 
shortage of health practitioners educated in the field of genomics. A combined service and 
research approach that seeks to evaluate and learn from real world health outcomes of genomic 
applications was therefore applied in this study.  
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CHAPTER 3 
AIMS AND RATIONALE OF THE STUDY  
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The present study was based on the hypothesis that the availability of a pathology-supported 
pharmacogenetics test for breast cancer, performed in conjunction with a medical and lifestyle 
assessment, may facilitate the diagnosis of treatable disease subtypes and prevention of 
cumulative risk with the ultimate aim to implement effective treatment strategies across 
diagnostic boundaries.  
 
3.1. Aims  
The study was performed in three phases aimed at the development of a comprehensive 
pathology supported genetic testing (PSGT) service for breast cancer informed by tumour 
pathology. The specific aims were to identify subgroups of breast cancer patients most likely to 
benefit from:  
1) Pharmacogenetic CYP2D6 genotyping to reduce recurrence risk  
2) Participation in a chronic disease screen to identify shared disease pathways  
3) Exome sequencing to identify actionable mutations in genetically uncharacterised breast 
cancer patients 
 
3.2. Rationale  
Identification of a high-penetrance BRCA1 or BRCA2 mutation in female patients with breast 
cancer indicates a significantly increased risk for bilateral breast cancer and ovarian cancer. A 
positive test provides a mutation-specific assay for screening of close relatives to exclude or 
confirm the familial risk prior to implementation of preventive steps in affected individuals. 
Documentation of the age at diagnosis of breast cancer and evaluation of the family history are 
well-established indications of referral for BRCA mutation testing. A need however exists to 
develop a screening tool for selection of genetically uncharacterized breast cancer patients 
most likely to benefit from whole exome sequencing (WES).  
The knowledge that breast cancer in women with germline BRCA1 mutations are mostly 
estrogen receptor (ER)-negative and typically lack expression of the progesterone receptor (PR) 
and overexpression of human epidermal growth factor receptor-2 (HER2) in their tumours, 
prompted the development of a pathology-supported pharmacogenetic test ideally suited to 
bridge the gap between single-gene and multi-gene testing using WES. This test performed as 
part of a newly-developed exome pre-screen algorithm (EPA) has the potential 1) to reduce 
recurrence risk caused by inappropriate/ineffective treatment due to variation in the CYP2D6 
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gene and 2) to prevent co-comorbidities in breast cancer patients frequently associated with 
cardiovascular risk and treatment-related side effects.  
Given the clinical dilemma created by frequent detection of variants of uncertain significance 
(VUS) when using next generation sequencing (NGS), careful consideration is necessary before 
embarking on WES in any patient. Difficulties related to correct interpretation of the clinical 
meaning of VUS were addressed in this study by access to a genomics database resource 
developed at the interface between the laboratory and clinical practice. The research findings 
were published in scientific journals in the form of an original article and two congress abstracts 
listed below:  
1. van der Merwe N, Bouwens CHS, Pienaar FM, van der Merwe L, Yako YY, Geiger DH, 
Kotze MJ (2012) CYP2D6 genotyping and use of antidepressants in breast cancer 
patients: test development for clinical application. Metabolic Brain Disease 27: 319-326 
2. van der Merwe N, Pienaar R, van Rensburg SJ, Bezuidenhout J, Kotze MJ (2013) 
Identification of breast cancer patients at increased risk of “chemobrain”: Case study and 
review of the literature. S Afr J Psychiatry 19(3): 125  
3. van der Merwe N, Peeters AV, van Rensburg SJ, Pienaar R, Bezuidenhout J, Kotze MJ 
(2015) Implications of discordance between reference genomes applied in breast cancer 
exome sequencing. Breast 24(Suppl 1): S121 
 
The rationale for each of these sub studies is provided below in the form of an introduction to 
each phase of the study, in order to highlight the respective knowledge gaps addressed at the 
time. The focus of the two congress abstracts were modified during preparation of the full 
manuscripts prior to submission for publication in line with the information provided below. 
 
3.3. PHASE I – Gene-drug Interaction 
Depression is the most common psychiatric problem in cancer patients. As the age at diagnosis 
of breast cancer decreases in the general population, the risk of depression becomes higher 
(Kim et al. 2010). Younger patients suffer more from psychiatric distress, resulting in negative 
effects on quality of life and survival rate. The treatment of depression as part of a 
comprehensive risk reduction approach is therefore an important consideration in patients with 
breast cancer. It has been reported that between 20 % and 30 % of breast cancer patients 
treated with tamoxifen to reduce recurrence risk, also use antidepressants for depression or hot 
flashes (Nelson et al. 2006; Kim et al. 2010). Tamoxifen is the most commonly used anti-
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estrogen drug for treatment of breast cancer, due to its active metabolites, hydroxytamoxifen 
and endoxifen. Selective serotonin reuptake inhibitor (SSRI) antidepressants can decrease the 
effectiveness of tamoxifen because these drugs compete for the cytochrome P450 2D6 
(CYP2D6) enzyme that metabolises tamoxifen (Jin et al. 2005; Bernard et al. 2006). 
Consequently, antidepressants that act as CYP2D6 inhibitors may increase the risk of breast 
cancer relapse (Goetz et al. 2007). Antidepressants such as paroxetine, fluoxetine, and 
bupropion strongly inhibit CYP2D6 enzyme activity, whereas sertraline, duloxetine and 
diphenhydramine are considered moderate inhibitors. Escitalopram (Lexapro, Cipralex) 
venlafaxine (Effexor) and citalopram appear to have a very mild or no inhibiting effect on 
CYP2D6 activity (Preskorn et al. 2007; Lash et al. 2008; Holzman 2009). 
Reduction in CYP2D6 activity due to enzyme inhibitors or polymorphisms in the CYP2D6 gene 
has been shown to reduce endoxifen levels (Borges et al. 2006) and may be associated with 
poorer outcome in women with breast cancer who have been treated with tamoxifen (Jin et al.  
2005; Goetz et al. 2007; Newman et al. 2008). In addition to antidepressants and tamoxifen, 
CYP2D6 also metabolises antipsychotics, antiarrhythmic agents (propafenone, flecainide), beta-
blockers (timolol, metoprolol, alprenolol), and opioids such as codeine and dextromethorphan. 
Due to CYP2D6 expression in the brain this enzyme furthermore mediates neuroprotection 
through inactivation of neurotoxins and break down of endogenous neural compounds such as 
catecholamines (Mann et al. 2011). Poor metabolisers have two copies of a defective CYP2D6 
gene, and as a result they metabolise drugs at a much slower rate. This may result in a greater 
potential for adverse events and lower efficacy of drugs requiring CYP2D6 activation (Bernard 
et al. 2006).  
Strong evidence has been provided that treatment failure due to impaired drug metabolism may 
increase the risk of recurrence of many different cancer types, not only in sporadic cases but 
also in patients with familial breast cancer (Newman et al. 2008). Various genes have been 
implicated in the development of breast cancer and those most studied include the BRCA1 and 
BRCA2 genes. Germline mutations in these two highly penetrant susceptibility genes explain 
the majority of familial breast cancer and additionally increase the risk for developing ovarian 
cancer (Sluiter and van Rensburg 2011). The lifetime risk for developing breast cancer is 65 % 
to 85 % for BRCA1 and 45 % to 85 % for BRCA2 mutation carriers (Chen and Parmigiani 2007). 
Increased frequencies of specific BRCA1 and BRCA2 mutations have been described in the 
South African Caucasian (Afrikaans-speaking) and Coloured (Mixed ancestry) populations 
(Reeves et al. 2004; Agenbag 2005; van der Merwe et al. 2012b). Three founder mutations 
[(BRCA1 c.1374delC (1493delC), BRCA1 c.2641G>T (2760 G>T, E881X) and BRCA2 
c.7934delG (8162delG)] account for approximately 90 % of all BRCA mutation-positive families 
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in the Afrikaner population of European descent (van der Merwe and van Rensburg 2009). A 
relatively frequent BRCA2 founder mutation c.5771_5774delTTCA (5999del4) has also recently 
been identified in 3.4 % of Coloured and 25 % of Black Xhosa breast cancer patients studied in 
the Western Cape region of South Africa (van der Merwe et al. 2012b).  
The vast majority of breast cancers in postmenopausal women are estrogen-receptor (ER)-
positive (Punglia et al. 2008). However, in premenopausal breast cancer patients who are more 
likely to be carriers of BRCA1 or BRCA2 familial mutations, tumours display differences with 
regard to hormone receptors. While BRCA1 tumours are frequently ER and progesterone 
receptor negative, BRCA2 tumours are more commonly positive for both receptors (Lomen et al. 
1998). The lack of hormone receptor positivity in most BRCA1 tumours suggests that treatment 
with tamoxifen or other hormonal therapy may be less effective in this patient population. In a 
study performed by Newman et al. (2008), in which tamoxifen-treated familial breast cancer 
patients were investigated for the effect of reduced CYP2D6 activity on clinical outcome, it was 
shown that the poor metabolizer status predicted worse overall survival in patients with familial 
breast cancer. Contrary to several other studies, the effect on enzyme function caused by both 
genetic variation in the CYP2D6 gene and concomitant use of a potent CYP2D6 inhibitor was 
taken into account. Patients with BRCA2 mutations had a significantly worse overall survival 
compared to patients with BRCA1 tumours (median survival: 7 versus 28 years; P=0.008; 
adjusted hazard ratio, 9.7). Based on the evidence provided in this study, it is of utmost 
importance to identify genetic subgroups of breast cancer patients most likely to benefit from 
CYP2D6 genotyping. Similar to BRCA mutation testing performed only in selected patients who 
fulfill the test criteria, CYP2D6 genotyping may only be applicable in a subgroup of breast 
cancer patients (e.g. patients with BRCA2- and ER-positive tumours considering concomitant 
use of tamoxifen and antidepressants).  
In light of the increased frequency of particularly BRCA2 mutations in three different South 
African population groups and the fact that use of certain antidepressants can significantly 
reduce the function of the CYP2D6 gene, implementation of a pharmacogenetics CYP2D6 
assay is an important consideration. The aim of this study (Phase I) was therefore twofold: 1) to 
determine the frequency of the relatively common inactivating CYP2D6*4 allele in South African 
breast cancer patients (validation data set) and 2) to determine the prevalence of 
depression/use of anti-depressants in breast cancer patients referred for genetic testing 
(implementation data set). Ultimately, breast cancer patients may benefit from the 
implementation of pathology supported genetic testing (PSGT) that combines relevant clinical 
and laboratory information for clinical decision-making. Although evidence based guidelines 
should ideally be developed before implementation of genomic applications, Khoury et al. 
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(2007) acknowledged the need to fill the remaining information gaps through ongoing data 
collection and health outcome studies. PSGT involves a combined service and research 
approach that seeks to evaluate “real world” health outcomes of genomic applications (Kotze 
and van Rensburg 2012), whereby overlapping aspects of translation research could provide 
feedback loops to allow integration of new genetic knowledge into clinical care (Khoury et al. 
2007).  
 
3.4. PHASE II – Gene-environment Interaction 
Many studies to date have failed to demonstrate a significant overall survival difference between 
sporadic and familial breast cancer caused by mutations in the two major tumour suppressor 
genes, BRCA1 and BRCA2 (Bordeleau et al. 2010). These findings confirm the importance of 
lifestyle factors and genetic risk modifiers as determinants of adverse clinical outcome across 
breast cancer subtypes.  Li et al. (2009) reported a more than seven-fold increased risk of a 
second primary contralateral breast cancer in women who smoke and consume seven or more 
alcoholic beverages per week. These authors found a 40-50% elevation in risk associated with 
obesity, which is consistent with the results from women enrolled in the National Surgical 
Adjuvant Breast and Bowel B-14 randomised trial of adjuvant tamoxifen performed in node-
negative estrogen receptor (ER)-positive patients (Dignam et al. 2003).  Breast cancer survivors 
in the highest quartile for body mass index (BMI) have at least 50% increased risk of a second 
primary breast cancer compared to women in the lowest BMI quartile (Trentham et al. 2007). 
King et al. (2003) demonstrated that the negative effect of obesity and lack of exercise also 
applies to breast cancer patients with familial breast cancer caused by mutations in the 
BRCA1/2 genes. 
In breast cancer survivors, ten-year risk for cardiovascular disease (CVD) equals or exceeds 
that for cancer recurrence (Bardia et al. 2009). Genetic and environmental risk factors 
implicated in CVD furthermore overlap with those for major depressive disorder (Delport et al. 
2014), multiple sclerosis (Davis et al. 2013) and Alzheimer’s disease (AD) (Luckhoff et al. 2015) 
as recently confirmed in the South African population, with the metabolic syndrome considered 
as a unifying risk factor (Kotze et al. 2015). This constellation of vascular risk traits including 
central obesity, hypertension, insulin resistance and dyslipidemia is also associated with 
different breast cancer subtypes (Rosato et al. 2011).   
In view of the above, and given the genetic link found between BRCA1 mutations and heart 
failure (Shukla et al. 2011), it is clear that a simplified approach based purely on genetic 
information obtained from BRCA1/2 gene screening is not sufficient for risk management of 
familial breast cancer and other forms of lifestyle-related cancers. A pathology-supported 
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genetic testing (PSGT) strategy has proven useful for the evaluation of functional polymorphic 
variants as non-deterministic modifiers of disease risk and severity in patients predisposed 
towards CVD and AD (Kotze and van Rensburg 2012). In this context, a number of functional 
polymorphisms implicated in drug, lipid, iron, folate and homocysteine metabolism as well as 
thrombophilia were included in a CVD multi-gene assay found to be applicable in a wide 
spectrum of chronic diseases with a genetic component (Kotze et al. 2015).  Integration of 
genetic information with relevant clinical, lifestyle and environmental factors as recently 
suggested by van der Merwe et al. (2012a) for breast cancer patients at increased risk of 
depression may therefore allow the development of a similar PSGT approach. Early detection of 
low-penetrance mutations or functional single nucleotide polymorphisms (SNPs) that affect the 
activity or amino acid sequence of BRCA modifier genes may facilitate the prevention of 
cumulative risk as a consequence of gene-environment interaction.   
Several studies have shown that severe obesity is associated with increased risk for the 
development of hormone receptor negative breast cancer in pre-menopausal women 
(Petekkaya et al. 2013; Turkoz et al. 2013). In accordance with this notion, Kwan et al. (2015) 
also recently reported that obese patients have a higher likelihood of developing tumours 
associated with increased proliferation and a poor prognosis, including luminal B and basal-like 
breast cancer. Smoking and alcohol consumption were modestly associated with increased risk 
of ER-positive breast cancer (Kabat et al. 2011). Due to the known effects of obesity, alcohol 
and smoking on DNA methylation implicated in breast cancer and its associated comorbidities 
such as depression and CVD, genes involved in the folate-homocysteine pathway have been 
identified as important therapeutic targets in relation to both gene-diet (Heijman et al. 2003, 
Beilby et al. 2004) and gene-drug (De Mattia and Toffoli 2009) interaction. It is in this context of 
the emerging fields of nutrigenomics and pharmacogenomics that impaired folate homeostasis 
is considered a shared pathogenic mechanism for the risk of the metabolic syndrome, 
depression, vascular disease, cognitive impairment and breast cancer. In particular, a functional 
polymorphism (677C>T) in the methylenetetrahydrofolate (MTHFR) gene associated with 
disrupted one-carbon transfer and DNA mismatch repair is considered an important genetic risk 
factor for these medical conditions (Macis et al. 2007; Maruti et al. 2009; Peerbooms et al. 2011; 
Wu et al. 2013; Weiwei et al. 2014; Kakkoura et al. 2015). The low-penetrance MTHFR 677C>T 
mutation has also been linked to luminal B subtype of breast cancer (Naushad et al. 2012) in a 
similar way that BRCA1 mutations predominate in patients with the basal-like triple negative 
breast cancer subtype (Fostira et al. 2012; Rummel et al. 2013). MTHFR, methionine synthase 
(MTR) and methionine synthase reductase (MTRR) are among at least 30 different enzymes 
involved in the folate pathway. Altered enzyme activity may result in demethylation and 
increased cancer susceptibility (Choi and Mason 2002). Extensive alcohol consumption and 
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smoking are well-established triggers of the deleterious effects of variation in the MTHFR and 
apolipoprotein E (APOE) genes. While alcohol consumption in the presence of MTHFR gene 
variants have been documented as a risk factor for breast cancer, the APOE e-4 polymorphism 
has more recently been associated with breast cancer risk (Zunarelli et al. 2000; Moore et al. 
2004; Chang et al. 2005). The APOE gene provides a genetic link between CVD and dementia, 
with the cholesterol-raising APOE e-4 allele considered an important risk factor for the metabolic 
syndrome, ischemic heart disease, stroke and AD. Together, APOE e-4 and MTHFR 677 C>T 
have been associated with treatment-related cognitive impairment in breast cancer patients.  
Adherence to a Mediterranean-style diet high in folate-rich foods could increase levels of 
bioactive folate necessary for DNA synthesis, repair and methylation in MTHFR 677 T-allele 
carriers. Kakkoura et al. (2015) highlighted the biological importance of variation in the MTHFR 
and MTR genes in the association between the Mediterranean diet, the one-carbon metabolism 
pathway and breast cancer by acting as effect modifiers. In addition to its anti-neoplastic effects, 
folate may provide a host of benefits in patients with major depression including enhanced 
efficacy of antidepressants in non-responders (Papakostas et al. 2012). MTHFR 677 T-allele 
carriers also show a more optimal response to lifestyle-based interventions aimed at 
normalizing metabolic parameters implicated in increased vascular risk, including increased 
body weight and hypertension (Di Renzo et al. 2014). Individual genetic differences in the 
absorption and utilisation of such nutrients underscores the rationale for a PSGT approach that 
collectively incorporates the influence of multiple genetic and environmental risk factors in 
relation to protective nutrients in a new integrative medical model focused not only on cancer 
risk reduction, but health optimisation across the metabolic syndrome disease spectrum.  
In this study, we sought to determine whether a PSGT strategy may be used to assess high BMI 
and other CVD risk factors in breast cancer patients stratified according to ER status, to 
facilitate the development of an exome pre-screening algorithm (EPA) for the selection of 
uncharacterized individuals set to derive optimal benefit from extended genetic testing including 
next-generation sequencing. A multidisciplinary approach to chronic disease risk screening 
incorporating a genomics component enabled consideration of both current and future risk 
implications in therapeutic decision-making across the diagnostic spectrum. 
 
3.5. Phase III – From PSGT to Exome Sequencing 
Microarray analysis of tumour genetics led to the identification of four intrinsic breast cancer 
subtypes, namely luminal A, luminal B, HER2-enriched and basal-like breast cancer (Perou et 
al. 2002) Next-generation sequencing (NGS) has however expanded the number of putative 
breast cancer subtypes from four to at least ten (Curtis et al. 2012; Ali et al. 2014). Given the 
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increasing availability and decreasing cost of NGS, this emerging technology is now able to 
provide clinicians and researchers with the opportunity to identify novel causative variants and 
potential drug targets across different breast cancer phenotypes (Patel et al. 2013). Whole 
genome (WGS) and whole exome sequencing (WES) can assist in the clinical diagnosis of 
breast cancer (Choi et al. 2009; Gahl et al. 2012), reveal the genetic basis of rare familial 
diseases (Ng et al. 2010; Bamshad et al. 2011) and allow for a novel approach to the 
characterization of disease pathology (Lupski et al. 2010). WES is an advanced method in the 
analysis of genes responsible for a subset of familial breast cancer (eg. P53 and CHEK2) that 
currently remains uncharacterized due to the laborious nature of a gene-by-gene sequencing 
process when mutations in the BRCA1/2 genes are excluded. In BRCA mutation-negative 
patients where early-onset breast cancer and drug failure or side effects cannot be explained by 
known mutations or functional single nucleotide polymorphisms (SNPs) expressed in a high-risk 
environment, WES performed in patients with familial breast cancer is a viable option for 
identification of potential novel causative genes/mutations. 
The clinical utility of single-gene testing for causative mutations such as BRCA1/2 in a high-risk 
population group is well-established. However, the evaluation of multiple low-penetrance 
mutations/SNPs identified by genome wide association studies (GWAS) is complicated by 
uncertainty related to selection criteria and interpretation of the results for clinical application 
(Kotze et al. 2013). In this context, a pathology-supported genetic testing (PSGT) strategy was 
developed which allows for a multidisciplinary approach to chronic disease risk management 
used to inform clinical and therapeutic decision making across diagnostic boundaries (Kotze et 
al. 2015). This approach is facilitated by the assessment of genetic risk factors alongside 
relevant data concerning biochemical testing, tumour pathology and lifestyle factors. A 
combined research and service delivery approach provides an ideal platform for the assessment 
of current as well as future disease risk, based on the characterization of treatable chronic 
disease subtypes as an alternative approach to direct-to-consumer testing.  
The clinical application of a validated multi-gene risk assay as part of this approach could also 
prove useful in the development of a pre-screen algorithm used to select genetically 
uncharacterized patients and/or those with severe treatment-related side effects eligible for 
extended genetic testing including WES (Kotze et al. 2015). This could allow for the 
identification of novel causative or risk-modifier genes in known pathogenic pathways in distinct 
high-risk patient subgroups across the disease spectrum. 
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The extension of the aforementioned PSGT platform to incorporate WES however presents a 
number of challenges related to technical issues associated with variegated aspects concerning 
the processing, analysis and interpretation of large-scale genetic data. These concerns highlight 
the pressing need to address challenges presented at every level of extended genetic testing 
including NGS to facilitate the integration of genomics-based chronic disease risk screening with 
WES. A pertinent issue which needs to be addressed in this context is the high level of 
discordance between different references genomes and variant-calling pipelines.  
The commonly used National Centre for Biotechnology Information (NCBI) human reference 
genome hg19 (GRCh38) Pruitt et al. (2007) is derived from DNA samples obtained from 
anonymous donors and represents a small sampling of the vast array of human genetic 
variation. In addition, the detection of alternate alleles in high-throughput sequence data may be 
affected by preferential mapping of short reads containing the reference base over those 
containing an alternate base (Degner et al. 2009). Therefore, up to 30% of variants identified 
with hg19 are false-positives due to the presence of minor alleles at > 1.5 million loci, 4000 of 
which are associated with disease traits.  
Dewey et al. (2011) developed three novel, ethnically concordant major allele reference 
sequences (MARS) from European [European ancestry from Utah (CEU)], African [(Yoruba 
from Nigeria (YRI)], and East Asian [(Han Chinese from Beijing and Japanese from Tokyo 
(CHB/JPT)] HapMap population groups using estimated allele frequency data at >7.9 million, 
>10.9 million and >6.2 million positions, respectively, catalogued in the 1000 genomes project. 
Low coverage pilot sequencing data comprising the majority of population-specific variation data 
had a sensitivity for an alternative allele of >99% at allele frequencies >10% and thus 
possesses high sensitivity for detecting the major allele (Durbin et al. 2010). Substitution of the 
ethnicity-specific major allele for the reference base resulted in single base substitutions at >1.5 
million positions in all three populations. They demonstrated that the use of a MARS reduced 
genotyping error in common disease-associated variant loci by >40%.  
The clinical application of WES in oncogenomic research and medical practice is vast and 
highly advantageous in the context of patient management. Discrepancies between different 
sequencing platforms and low concordance among multiple variant-calling pipelines however 
poses a major limitation which impedes the more widespread clinical adoption of extended 
genetic testing including WES (Boland et al. 2013; O’ Rawe et al. 2013). In an attempt to 
overcome these obstacles we used the PSGT platform previously developed by Kotze et al. 
(2015) to formulate an exome pre-screen algorithm (EPA) for selection of genetically 
uncharacterised breast cancer patients set to derive optimal benefit from WES. After exclusion 
of high-impact mutations in the BRCA1 and BRCA2 genes in three patients selected for WES 
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using the EPA, we searched for potentially causative gene variants in known cancer-related 
genes that may match or contribute to the pre-determined clinical, pathology and genetic risk 
profile identified by PSGT using the newly developed EPA for breast cancer (Figure 5.1). The 
performance of the publicly-available hg19 and synthetic MARS was also compared between 
patients and controls.   
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CHAPTER 4 
SUBJECTS AND METHODS  
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4.1. Ethical Approval 
Ethical approval was granted for this translational research project by the Ethics Review 
committee of the University of Stellenbosch. Reference number N07/07/158 relates to 
recruitment of breast cancer patients at Tygerberg Hospital referred to as the validation data 
set. Reference number N09/08/244 relates to inclusion of participants in a chronic disease 
screening program referred to as the implementation data set. These were selected from the 
Gknowmix database generated at the interface between the laboratory and clinic using a 
combined service and research approach.  
 
4.2. Study population 
The study population consisted of 813 individuals (Figure 4.1), including 175 South African 
breast cancer patients from two different population groups: 62 Coloured patients of Mixed 
Ancestry and 113 Caucasian patients of European Ancestry. Eighty eight cases (implementation 
data set) were selected from 625 South African Caucasian individuals who participated in a 
genomics-based chronic disease screening program (2010-2015) after providing informed 
consent for inclusion of their data in a secure centrally maintained research database (accessed 
at www.gknowmix.org). The remaining 87 patients (validation data set) were recruited at the 
Tygerberg Hospital Breast Cancer Clinic (Agenbag 2005). Of the 625 chronic disease screen 
participants, 214 controls without a family history of cancer were selected from the genomics 
database for comparative studies. A further 101 elderly females above the age of 65 years and 
without a diagnosis of cancer were included in the study. 
Phase I of this study involved pharmacogenetic testing of 87 breast cancer patients from the 
validation data set and 23 patients from the implementation data set, as previously described by 
van der Merwe et al. (2012a). When this study was performed, the implementation data set 
merely consisted of 23 breast cancer patients which was later expanded as new samples 
became available. Agenbag performed full BRCA1/2 mutation screening in DNA samples from 
the validation data set, while assessment of human epidermal growth factor receptor-2 (HER2) 
status was not performed in these breast cancer patients at the time. Breast cancers were 
tumour biopsy-confirmed, and results on ER and progesterone (PR) status based on 
immunohistochemistry (IHC). 
Phase II includes a subset of the validation data set (including a total of 87 patients) comprising 
83 (60 Coloured and 23 Caucasian) breast cancer patients for whom ER-status was available. 
This patient group was combined with 81 (with known ER status) of the 88 breast cancer 
patients in the implementation data set derived from the chronic disease risk screening 
program. HER2 status (determined only in the implementation data set) was confirmed by 
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fluorescence in situ hybridisation (FISH) in equivocal IHC2+ cases. Age was used as a proxy for 
menopausal status using a cut-off age of 50 years to define postmenopausal status.  All patients 
were screened using a CVD multi-gene assay first described by Kotze and Thiart (2003) to 
determine the extent to which treatment-related comorbidities matched or were discordant with 
the test results. A combined service delivery and research approach was used to identify breast 
cancer patients in the implementation data set considered for BRCA mutation screening based 
on well-established referral guidelines including early age of onset and a family history of cancer 
(Kotze et al. 2015). 
Phase III of this study included the total number of 175 breast patients (87 from the validation 
data set and 88 from the implementation data set) as well as the total number of 315 control 
individuals (101 elderly females above the age of 65 years and 214 females participating in the 
chronic disease screening program for validation of variants identified by whole exome 
sequencing (WES). 
 
Inclusion criteria: Patients histologically diagnosed with familial or sporadic breast carcinoma. 
 
Exclusion criteria: Patients with benign neoplasms of the breast or other malignancies as well 
as those who did not provide consent for genetic testing.  
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Figure 4.1. Description of the study population including patients participating in a chronic disease screening program and a validation data set 
described in van der Merwe et al. (2012a). 
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4.3. Questionnaire-based Nutrition and Lifestyle Assessment  
All prospective participants of the chronic disease screen completed a medical history and 
lifestyle questionnaire (available at www.gknowmix.com) developed in collaboration with a 
registered dietician. This was used to document socio-demographic and clinical data including 
1) age of breast cancer diagnosis/onset and associated comorbidities as well as, 2) disease 
recurrence, 3) family history of cancer, 4) tumour pathology and receptor status, 5) alcohol 
consumption, 6) body mass index (BMI), 7) smoking status, 8) level of physical activity, 9) and 
use of hormone replacement therapy (HRT), 10) oral contraceptive pills (OCPs) and 
medications such as antidepressants.  
The questionnaire further denoted the number of days per week participants ate at least 5 fruits 
and vegetables and certain foods rich in fiber and folate over the course of the preceding three 
months. This information was used to calculate a fruit, vegetable and fiber score, which was 
considered to be low when less than 13, moderate between 14 and 18, and high when above 
19. The folate score was considered to be low when less than 11, moderate between 11 to 13, 
and high when above 13. Intake of saturated/trans fat was considered low below 21, moderate 
from 22-26, and high above 27. An optimal BMI ranges between 18.5-24.9 kg/m2 and 
individuals with a BMI above 30 kg/m2 are generally classified as obese. Physical activity was 
documented for both day-time / occupational activity and participation in recreational sport 
(occasionally or at least 1 time per week), or structured exercise on a weekly basis (none, 2-3 
times or 4 or more times) with each activity lasting more than 30 minutes. A physical activity 
score was then calculated from these two assessments. 
The metabolic syndrome was defined based on the revised 2006 International Diabetes 
Federation (IDF) criteria (Alberti et al. 2006) (Table 4.1). Any additional information required was 
retrieved from patient records and included in the database. Written informed consent was 
obtained from all study participants. 
 
Table 4.1 Clinical features for diagnosis of the metabolic syndrome based on three or more of 
five characteristics defined by universal evaluation values 
Diagnosis of MetS 
Components 
5 Clinical 
Indicators 
Universal Evaluation 
Values 
Personal Medical History 
(questionnaire) 
Central Obesity 
Waist 
circumference 
>102 cm (Males) 
>88 cm (Females) 
Obesity/overweight  
BMI > 30 kg/m2 
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Diabetes type II Glucose, fasting ≥5.6 mmol/L 
Insulin resistance  
Type II diabetes 
Dyslipidaemia  
Triglycerides ≥1.7 mmol/L 
Dyslipidaemia  
(excluding familial 
hypercholesterolaemia/high 
cholesterol) 
HDL-cholesterol 
<1.0 mmol/L (Males) 
<1.3 mmol/L (Females) 
High Blood Pressure Systolic  ≥130 mmHg  Hypertension 
 
 
 
4.1. DNA extraction and spectrophotometry 
The DNA samples used in the study were generally extracted from whole blood using the 
QIAGEN QIAamp® DNA Blood Maxi Kit DNA extraction protocol (spin protocol) for whole blood 
(Appendix I). Subsequent to DNA extraction, the NanoDrop® ND-1000 spectrophotometer 
(v3.5.2 software package) (NanoDrop®, Technologies, USA) was used to determine the 
concentration and purity of the DNA samples.  
Nuclease free water was used in the dilution of all the DNA samples to obtain a final 
concentration of 10 ng/µl, as required for Real-Time (RT)- PCR instruments.  
 
4.5. Polymerase chain reaction amplification 
Our initial focus was on CYP2D6 as the most widely studied pharmacogenetics marker of 
relevance in many clinical domains. Using polymerase chain reaction (PCR)-based methods, 
molecular analysis included detection of the allele 4 variant in the CYP2D6 gene (1846 G>A). 
DNA control samples were amplified using conventional PCR. Sequencing of these PCR 
products served as the gold standard and provided a basis for screening the larger population 
group. The results were then compared to validate real-time PCR results. Real-time PCR was 
carried out using the Applied Biosystems® TaqMan® Genotyping assay with the ABI 7900HT 
system as well as with the Corbett Rotorgene. 
 
In phase 2 of this study, CYP2D6 genotyping was extended to the application of the CVD multi-
gene assay described by Kotze and Thiart (2003) at the Pathology Research Facility (PRF). 
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4.5.1. CYP2DD6 allele 4 oligonucleotide primers 
Oligonucleotide primers were designed to screen specific exonic regions of CYP2D6 allele 4. 
Reference sequences were obtained from the National Centre of Biotechnology (NCBI, 
www.ncbi.nlm.nih.gov) and/or UCSC Genome Browser (https://genome.ucsc.edu/). Using the 
BLAST (Basic Local Alignment Search Tool) function in NCBI, primers for CYP2D6 allele 4 
(rs3892097) (Table 4.2) used in conventional PCR experiments were designed. Custom made 
primers and probes used for real-time PCR where designed and supplied with the Roche 
LightCycler® 480 II and ABI 7900HT genotyping assays (section 4.5.3). 
 
4.5.2. Conventional PCR Protocol and Cycling Parameters 
The protocol used for analysis of CYP2D6 allele 4 is shown in Tables 4.3, with the cycling 
conditions for this assay shown in Table 4.4. DNA concentrations of samples varied therefore 
volumes of DNA added to the reaction mix were adjusted according to DNA content. Nuclease 
free water volumes were adjusted so that DNA and water amounted to a total volume of 18.9 µl.  
 
Table 4.3. FastStart Fedility (Roche Diagnostics) PCR Protocol for CYP2D6*4 genotyping 
Reagents 
1x reaction (µl) 
for 50 µl reaction  
1x reaction (µl) 
for 25 µl reaction 
Final 
concentration 
Nuclease-free water 36.8 18.4  
10x buffer without 5 2.5 1x 
DMSO 2.5 1.25 5% 
MgCl (25 mM) 2 1 1 mM 
dNTP mix (10 mM) 1 0.5 0.2 mM 
Forward primer (20 µM) 0.6 0.3 0.24 µM 
Reverse primer (20 µM) 0.6 0.3 0.24 µM 
Table 4.2. CYP2D6*4 primer parameters for conventional PCR experiments 
Primer Name Sequence (5' to 3') 
GC 
Content 
(%) 
TM  
(°C) 
TA 
(°C) 
Amplicon  
Size (bp) 
CYP2D6*4_Forward AGGGAGCAAGGTGGATGCAC 60.0 60.1 
61 515 
CYP2D6*4_Reverse TAGGTCCAGCAGCCTGAG 61.1 56.4 
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FastStart Taq 0.5 0.25 2.5 U 
DNA  1 0.5 50ng/µl 
Final volume 50 25  
 
 
Table 4.4. Cycling conditions for conventional PCR experiments 
Program Cycles Temperature Time 
Initial Denaturation 1 95°C 2 min 
Amplification: 
28 
  
Denaturation 95°C 30 
Annealing 54°C 30 
Extension 72°C 30 
Final extension 1 72°C 4 min. 
 
4.5.3. Real-time PCR protocol and Cycling parameters 
The ABI™ TaqMan® SNP Genotyping assay for CYP2D6 1846G>A (rs3892097; ID 
C_27102431_D0) was used with the ABI™ 7900HT instrument for the real-time PCR 
experiments. This assay consists of prioritized primers and two allele-specific TaqMan® MGB 
probes to differentiate between the wild-type form and the SNP of the gene under investigation. 
Each probe is labeled with a different fluorophore, which is a fluorescent molecule that acts as a 
reporter dye. The fluorophores used by the probes in the assay are FAMTM and VICTM.  The 
pre-designed assays are suitable for end-point genotyping by allelic discrimination analysis. 
FAM-labeled probes only bind to the alleles that contain an adenine nucleotide (A) in genomic 
nucleotide position 1846 of the CYP2D6 gene, corresponding to the SNP (allele 4). FAM has an 
excitation wavelength of 470 nm and is detected in the green channel by the fluorometer of the 
ABI 7900HT due to its emission wavelength of 510 nm. VIC-labeled probes exclusively bind to 
the alleles that contain a guanine nucleotide (G) in genomic nucleotide position 1846 of the 
CYP2D6 gene, corresponding to the wild-type allele. VIC has an excitation wavelength of 530 
nm and is detected in the yellow channel by the fluorometer of the ABI7900HT due to its 
emission wavelength of 555 nm. 
The 40X TaqMan assay was diluted to 20X in double distilled SABAX water. The components of 
a 20 µl reaction were: 20 ng/µl of template DNA (2.0 µl), 10 µl of TaqMan Universal PCR Master 
Mix (P/N 4304437), 20X TaqMan SNP Genotyping Assay (1.0 µl) and 7.0 µl SABAX double 
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distilled water (Table 4.5). The amplification was carried out according to the standard Life 
Technologies ABI™ TaqMan® SNP Genotyping assay protocols. This includes a thermal 
cycling program consisting of an initial hold step at 95 C̊ for 10 minutes, 40 cycles of 
denaturation at 92 C̊ for 15 seconds and annealing/extension at 60 C̊ for 1 minute (Table 4.6), 
followed by the allelic discrimination run. Measurements were acquired at the end of the 
annealing/extension step of the run. 
 
Table 4.5. CYP2D6 allele 4 standard TaqMan ABI™ allelic discrimination PCR reaction 
mix 
Reaction Components 
Volume/well 
(5µl Vol rxn) 
Volume/well 
(20 µl Vol rxn) 
Final 
concentration 
Nuclease free water 0.25 7  
TaqMan universal PCR Master mix 2.5 10 1x 
20x Genotyping assay mix 0.25 1 1x 
Genomic DNA 2 2  
 
 
Table 4.6. ABI™ thermal cycling conditions for CYP2D6 allele 4 genotyping 
Parameters: Initial denaturation denaturation anneal/extend 
Cycles 1 40 
Hold 10 min 15 sec 1 min 
Target 95 92 60 
 
 
4.6. Gel Electrophoresis 
PCR products were resolved on a 2% (w/v) agarose gel to separate amplified DNA fragments 
based on the size of amplicons. The gel mix consisted of 2g agarose in 100 ml 1xTBE [90 mM 
Tris-HCl, 90 mM boric acid and 2.2 mM EDTA (pH 8.0)]. To enable visualization of the PCR 
products, 0.0001% (v/v) ethidium bromide (EtBr) was added to the electrophoresis buffer (70 µl 
of EtBr in 700 ml 1xTBE). A total volume of 8 µl of amplification product was loaded onto a gel 
consisting of 3 µl Ficoll Orange G loading buffer [0.1% (w/v) Orange G, 20% (w/v) Ficoll, 10 mM 
EDTA at pH 7.0] and 5 µl of amplification product. To ascertain the amplification of the correct 
PCR product, a molecular size marker (Promega 100 bp DNA ladder) was loaded together with 
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the PCR products on the agarose gel. Electrophoresis of the PCR products was performed for 
45 minutes at 100 volts in 1xTBE buffer. Visualization of PCR products was achieved (using a 
Life Technologies TFX-35M trans-illuminator- GIBRO BRL) by ultraviolet light transillumination.  
 
4.7. DNA Sequencing  
PCR products obtained for CYP2D6*4 and were sent to the Central DNA Sequencing facility of 
Stellenbosch University for automated sequencing as well as post-PCR clean up and the 
electropherograms analyzed using FinchTV Version 1.4.0 (developed by Geospiza Research 
Team). The application of the software was to view the nucleotide sequences of each gene and 
compare it directly to the reference sequence as obtained from the NCBI (National Centre for 
Biotechnology Information) database for detection of SNPs.  
 
4.8. Extended genotyping using the CVD multi-gene assay 
Genotyping of 8 SNPs forming part of a CVD multi-gene assay initially described by Kotze and 
Thiart (2003) (Table 4.7) was performed as part of a chronic disease screening program using 
the standard operating procedures (SOPs) developed in the Pathology Research Facility, 
Stellenbosch University. ABI™ TaqMan® SNP Genotyping assays with the standardized 
reaction mixes listed in Table 4.5 and cycling parameters denoted in Table 4.6 was used on the 
Corbett Rotor-Gene™ 6000 and Roche LightCycler® 480 II. The primers and probes used were 
described by Fisher (2011). The gene variants listed in Table 4.7 selected for genotyping was 
extended to include MTR 2756 A>G (rs1805087), MTRR 66 A>G (rs1081394).  
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Table 4.7. Summary of the low-penetrance mutations evaluated as part of the CVD multi-
gene assay representing the genetic component of a chronic disease screening program. 
Genetic 
variation 
Biological 
pathway 
Disease Association References 
MTHFR 677 
C>T, A222V 
(rs1801133)  
 
 
 
MTHFR 1298 
A>C 
(rs1801131) 
Homocysteine 
and Folate 
metabolism 
Various cancers including 
breast cancer  
Liu et al. 2012; Shen et al. 2001; 
Graziano et al. 2006; Siemianowiczet 
al. 2003 
CVD 
Di Renzo et al. 2014; Wald et al. 
2002;  Kotze and van Rensburg 2012 
Neurocognitive diseases 
including Alzheimer’s 
disease, dementia, 
multiple sclerosis, 
cognitive impairment 
Lewis et al. 2006 
DVT 
Elhassan and Abdalla 2015; Andreassi 
et al. 2006; Den et al. 2005 et al. 2015 
Recurrent pregnancy loss Wu et al. 2012 
APOE 3937 
T>C, allele E4 
(rs429358)  
 
 
APOE 4075 
C>T, allele E2    
( rs7412) 
Lipid and 
Lipoprotein 
metabolism 
Breast Cancer  Saadat 2012 
CVD 
van Rensburg et al. 2000, Lengacher 
et al. 2015 
Neurocognitive diseases 
including Alzheimer’s 
disease, dementia, 
Parkinson’s and cognitive 
impairment 
Seshadri et al. 1995;  Anttila et al. 
2004; Genin et al. 2011 
Factor V 
Leiden 1691 
G>A (rs6025)        
 
Factor II 
20210 G>A 
(rs1799963) 
Haemostasis 
CVD 
Volzke et al. 2005;  Keijzer et al. 
(2002);  Reznikoff-Etiévan et al. 2001; 
Mierla et al. 2012 
Recurrent pregnancy loss 
Reznikoff-Etiévan et al. 2001; Mierla 
et al. 2012 
Blood clotting disorders 
including DVT 
Elhassan and Abdalla 2015; 
Andreassi et al. 2006; Den et al. 2005 
HFE 845 
G>A, C282Y 
(rs1800562) 
 
 
HFE 187 
C>G, H63D 
(rs1799945) 
Iron 
metabolism 
and oxidative 
stress 
Haemochromatosis 
Bartzokis et al. 2011;  Gurrin et al. 
2008; 
Various cancers including 
breast cancer 
Osborne et al. 2010; Liu et al. 2013 
CVD, cardiomyopathy 
Klipstein-Grobusch et al. 1999; Kiechl 
et al. 1997; Roest et al. 1999; Silva et 
al. 2010 
Arthritis Cauza et al. 2005 
Alzheimer’s disease 
Pulliam et al. 2003; Connor and Lee 
2006; Ding et al. 2009 
Diabetes 
Moczulski et al. 2001;  Fernandez-
Real et al. 1999; Kwan et al. 1998 
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4.9. Whole exome sequencing  
Genetic analysis of breast cancer patients was initiated with BRCA mutation screening which 
was extended to 1) CYP2D6 genotyping for prediction of drug response/recurrence risk, 2) the 
chronic disease screen using the CVD multi-gene assay to assess cardiometabolic risk in 
patients with ER-positive versus ER-negative tumours and 3) to select patients for whole exome 
sequencing (WES) based on mutation status and the questionnaire based assessment (Kotze 
et al. 2015). Where extended mutation analysis of the entire BRCA1 and 2 genes as well as the 
CYP2D6 gene were warranted in cases where the most common variants generally tested were 
unable to explain breast cancer or the occurrence of drug side effects, WES to identify possible 
novel causative genes/mutations was performed rather than sequencing genes individually. 
Sequencing of BRCA1 and BRCA2 alone are particularly costly and does not include other 
causative cancer-related genes (P53, CHECK2, PTEN etc.). 
Selected genetically uncharacterised breast cancer patients were subjected to WES to identify 
potential intermediate risk variants or ‘BRCA-like’ mutations that confer similar risk and may be 
responsible for the development of breast cancer. This process may only be initiated 
subsequent to following an ethically approved process including genetic counseling due to the 
complex nature of possible unintended information that may be obtained. As much of the exome 
data would be unrelated to breast cancer, feedback of results will only be focused on breast 
cancer and associated co-morbidities caused by a combination of genetic and environmental 
factors. 
 
4.9.1. Cases selected for WES 
In order to identify potential causative variants in genetically uncharacterized patients diagnosed 
with breast cancer, a combination of pathology and genetic tests was used to select individuals 
for WES upon obtaining ethical approval from Stellenbosch University (Ethics number: 
N09/08/224).  
 
WES was performed at the Central DNA Sequencing facility of Stellenbosch University in three 
South African Caucasian patients and three population-matched controls. The BRCA1/2 
mutation-negative index patient was diagnosed with invasive ductal carcinoma of the Luminal B 
subtype at the early age of 29 years. Her mother was diagnosed with bilateral (both ductal and 
lobular) breast cancer of the Luminal A subtype at the age of 57 years. The third patient 
included in this phase of the study was unrelated to the index patient and was diagnosed with 
triple-negative breast cancer at the age of 43 years (Table 4.7).  
 
Stellenbosch University  https://scholar.sun.ac.za
  82 
 
Table 4.7. Histopathologic classification of the three breast cancer patients.  
Case ER status PR status HER2 status 
Tumour 
subtype 
Index Positive Positive Positive Luminal B 
Index mother Positive Positive Negative Luminal A 
Unrelated patient Negative Negative Negative Basal-like 
 
 
Next generation sequencing methods produce a large number of gene variants that need to be 
prioritized based on their potential deleterious effects. As no single tool can predict all the 
possible outcomes of effects of gene variants, this study has utilized multiple software tools 
based on different algorithms and resources to produce a prioritized list of functional variants 
 
4.9.2. Whole exome capture and sequencing 
WES was performed by the Ion Proton™ System for NGS, using already-extracted DNA 
(100ng/µl) from three breast cancer patients and three controls. The library preparation protocol 
used was the Ion AmpliSeq™ Exome RDY Library Preparation (Publication Number 
MAN0010084). Template amplification was performed using the Ion PI™ Template OT2 200 Kit 
v3 (Publication Number MAN0009133). Semi-conductor sequencing on Ion Proton system was 
performed using the Ion PI™ Sequencing 200 Kit v3 (Publication Number MAN0009136) with 
the Ion PI™ Chip Kit v2. This method is designed to target all human exons. The sequencing 
run time on the Proton™ System is approximately 4 hours which enables the entire workflow 
from library construction to primary data analysis and result generation to be done in under 24 
hours. The Torrent Suite™ proprietary software is the standard program through which this 
NGS apparatus operates and offers simple run setup using predesigned workflows and run 
monitoring in real-time. The analysis pipeline generated FASTQ ﬁles as a quality control 
validation, reporting identiﬁed errors that occurred during data generation.  
 
4.9.3. WES analysis 
WES analysis comprised several intermediate steps involved in the read-processing pipeline 
(Figure 4.2). First, sequence reads were aligned to the publically available human reference 
genomes hg19 using the torrent mapping alignment (TMap) program. TMAP is alignment 
software for short and long nucleotide sequences produced by NGS technologies 
Stellenbosch University  https://scholar.sun.ac.za
  83 
(https://github.com/iontorrent/TS/tree/master/Analysis/TMAP). This was followed by read 
analysis and processing using the preinstalled Torrent Suite™ Software and variant calling with 
the Torrent Variant Caller plug-in. This Torrent Variant Caller plug-in is a web-based application 
that combines analytical tools and integrated biological and chemical content to identify and 
prioritize potential causal variants based on published data. Mapped reads are processed in 
BAM [indexed sequence alignment/map format (SAM)] file format. Furthermore, the Torrent 
Variant Caller also performs functional annotation and filtering of variants outputted in variant 
call files (VCFs). The finding that hg19 contains minor alleles at >1.5 million loci led to repeated 
mapping of the reads to a synthetic Caucasian major allele reference sequence (CEU-MARS) 
following the same process. Resulting VCFs were then processed using GeneTalk 
(https://www.gene-talk.de/), a web-based tool for filtering and annotation of uploadable VCFs.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. The next generation sequencing read-processing pipeline. 
 
A minimum Phred quality score (Q score) of 50 was used for confidently calling bases, which 
translates into a base call accuracy of 99.999% (Ewing et al. 1988) - higher Q scores 
corresponds to higher quality. Furthermore, a minimum coverage depth of 100 was used for 
confident variant calls. Coverage provides counts of read depth (DP) at two different levels; the 
sample level where the DP value is the count of reads that passed the caller's internal quality 
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control metrics and at the site level where this value is the unfiltered depth over all samples. In 
addition to the aforementioned quality filters applied, variants were filtered on a population 
frequency of <0.01%, variant function (all synonymous variants excluded), and the most 
comprehensive cancer gene panel, the Ion AmpliSeq™ Comprehensive Cancer Panel including 
all-exon coverage of 409 genes (https://www.thermofisher.com/order/catalog/product/4477685) 
(Figure 4.3).  
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Figure 4.3. The Ion AmpliSeq™ Comprehensive Cancer Panel including all-exon coverage of 
409 genes. The shaded blocks contain the 50 oncogenes and tumor suppressor genes that 
form part of the Ion AmpliSeq™Cancer Hotspot gene panel. 
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Resulting variants were subsequently evaluated in relation to publicly available mutation and 
SNP databases - including the Single Nucleotide Polymorphism Database (dbSNP) of the 
National Centre for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov/SNP) and 
SNPedia (http://www.snpedia.com/index.php/SNPedia) that extracts information from PubMed 
on a daily basis to support genome annotation and  interpretation - to verify their minor/risk 
allele status, prior to analytical validation of potentially deleterious gene variants in the 
laboratory. Clinvar on the NCBI (http://www.ncbi.nlm.nih.gov/clinvar/), Polymorphism 
Phenotyping v2 (PolyPhen-2), the Sorting Tolerant From Intolerant (SIFT) algorithm and the 
Protein Variation Effect Analyzer (PROVEAN) were used to predict the effect of variants on the 
biological function of resulting proteins. Finally, the obtained variants were confirmed with the 
use of the Integrative Genome Visualization (IGV) - a high-performance visualization tool used 
for interactive exploration of large, integrated data sets (www.broadinstitute.org/igv/).  
 
4.10. Confirmation of WES-identified variants 
Following the identification of potential causative gene variations with use of WES, confirmation 
was performed by the PRF laboratory by the PRF research team (Appendix 1). The selected 
variants were then screened for in the extended breast cancer patient (validation and 
implementation data sets) and control groups. 
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4.11. Statistical Analysis 
Genotype distribution and allele frequencies were determined by allele counting and Hardy-
Weinberg equilibrium (HWE) established using an exact test. Clinical and environmental risk 
factors relevant to the gene variants studied were compared between breast cancer patients 
from two different population groups, Caucasian and Coloured/Mixed Ancestry. Single and 
combined allelic effects of the selected SNPs were determined after adjustment for ethnicity in 
all cases, in addition to other potential confounding factors as appropriate. Possible alleleic 
combinations, together with their probabilities for each individual, were derived for selections of 
SNPs using functions from the R package haplo.stats. The qualitative characteristics were 
described using cross tabulation and frequency tables whereas the median and interquartile 
range were used for the quantitative phenotypes. Logistic regression models were used to 
compare pairs of groups, such as patients to controls, whereas linear regression models were 
used to compare the quantitative characteristics between the genotypes. Quantitative outcomes 
with non-symmetric distributions were log-transformations for analyses. The R software and R 
package genetics, freely available from http://www.r-project.org, were used for analyses. 
Results corresponding to p-values below 0.05 are described as significant.   
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CHAPTER 5 
RESULTS AND DISCUSSION 
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The results of the study performed in three phases are presented below. In Phase I, we 
determined the appropriateness of combining CYP2D6 pharmacogenetic testing with diagnostic 
BRCA mutation screening aimed at the reduction of recurrence risk in patients with familial 
breast cancer. In Phase II, cardiometabolic risk factors were assessed in breast cancer patients 
stratified according to ER status, in order to facilitate the development of an exome pre-
screening algorithm (EPA). The knowledge derived from these two studies was used in Phase 
III of this investigation to select three breast cancer patients from two unrelated families for 
whole exome sequencing (WES) in comparison with three cancer-free controls. We furthermore 
conducted a comparative effectiveness study using the standard human reference genome 
(hg19) and a synthetic major allele reference sequence (MARS), whilst investigating both rare 
variants in a familial context and low-penetrance single nucleotide  polymorphisms (SNPs) at 
the population level as potential pharmacogenetic biomarkers that may be unique to each 
individual patient studied.  
 
5.1. PHASE I RESULTS 
The clinical characteristics of the 87 breast cancer patients previously screened for mutations in 
the BRCA1 and 2 genes are summarised in Table 5.1 The majority of patients were 
postmenopausal. Approximately half of these patients in the validation data set had a family 
history of cancer, with early onset (<50 years) breast cancer reported in 26% of patients.  
 
Table 5.1. Clinical Characteristics of 87 Coloured and Caucasian female breast cancer 
patients included in the validation data set. 
Parameter 
Coloured 
patients (n=62) 
Caucasian 
patients (n=25) 
Total Group 
(n=87) 
Mean age (yrs) 54 57 55 
Family cancer history (yes) 27 (44%) 18 (72%) 45 (52%) 
BRCA mutation positive 2 (3%) 3 (12%) 5 (6%) 
Premenopausal 17 (27%) 6 (24%) 23 (26%) 
Postmenopausal 45 (73%) 19 (76%) 64 (74%) 
 
 
The age at diagnosis of breast cancer in the study population was significantly associated with a 
family history of cancer (p<0.01), independent of various possible confounders including 
ethnicity, body mass index, alcohol intake, smoking or CYP2D6*4 genotype (Table 5.2). A 
family history of cancer, expected to be closely related to BRCA mutation status, reduced the 
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expected average age at diagnosis/onset of breast cancer with 8 years. A similar effect on age 
of breast cancer diagnosis was not observed in relation to the presence or absence of the 
CYP2D6*4 allele.  
 
Table 5.2. Analysis of clinical, lifestyle and genetic factors in Coloured and Caucasian 
study groups, in relation to age at diagnosis of breast cancer. 
P-values for tests of association with age at diagnosis P-values 
Single Confounders Single 
Ethnicity  0.3360 
Genotypes Ethnicity 0.8334 
Alleles Ethnicity 0.5830 
Family history of cancer Ethnicity 0.0082 
Family history of cancer Ethnicity, CYP2D6 genotype 0.0097 
Body mass index (BMI) Ethnicity 0.0582 
Body mass index Ethnicity, CYP2D6 genotype 0.0610 
Body mass index Ethnicity, Smoking 0.0948 
Body mass index Ethnicity, CYP2D6 genotype, alcohol 0.3713 
Body mass index Ethnicity, genotype, alcohol, smoking 0.4072 
 
 
Successful amplification of the DNA fragments spanning CYP2D6 allele 4 (1846 G>A) was 
obtained in the PCR reactions carried out using DNA controls K1-K5. The PCR products 
obtained with the conventional primers designed for detection of CYP2D6 1846 G>A were 
visualized with ethidium bromide in a 2% agarose gel, presented in figure 5.1. The sizes of the 
amplicons produced were 298 bp, following PCR amplification using CYP2D6 1846 G>T primer 
sets. No non-specific amplification was observed for any of the DNA samples and distinct bands 
were visible, which therefore deemed all products suitable for further analysis. The PCR 
protocol was standardised based on these results and the same parameters were then used in 
the amplification of additional DNA samples.  
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Figure 5.1: A 2% (w/v) agarose gel visualized with 0.0001% (v/v) ethidium bromide (EtBr). 
Lane 1 (from left to right) contains the DNA marker (100 bp) and while lanes 2-6 contain 
amplicons of 298 bp, following PCR amplification using the CYP2D6*4 allele (1846 G>T) 
primer set. Lane 7 contains the non-template control (NTC) PCR reaction product. 
 
Figure 5.2 depicts the Sanger sequencing results for the CYP2D6*4 allele, performed by the 
Central Analytical Facility (CAF) of Stellenbosch University. The sequencing results are 
presented as electropherograms for the DNA controls. In the five DNA control samples (K1-K5) 
subjected to direct DNA sequencing, all three genotypes for the CYP2D6*4 allele were 
observed: three DNA samples were homozygous GG (figure 5.2), one heterozygous GA (figure 
5.3) and one wild-type GG (figure 5.4). Both forward and reverse sequencing were performed, 
with the forward sequencing reactions depicted in the electropherograms. These control 
samples of known genotype were subsequently used to validate the real-time PCR 
methodology. 
 
 Figure 5.2. Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product of control sample K1 obtained with the CYP2D6*4 allele (1846 G>A) primer set. The 
 1    2      3      4    5      6      7 
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nucleotide position of the CYP2D6*4 allele is indicated by the highlighted region and 
corresponds to a genotype of GG, which represents a homozygous wild-type genotype.  
 
Figure 5.3: Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product of control sample K4 obtained with the CYP2D6*4 allele (1846 G>A) primer set. The 
nucleotide position of the CYP2D6*4 allele is indicated by the highlighted region and 
corresponds to a genotype of GA, which represents a heterozygous genotype. 
 
Figure 5.4: Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product of control sample K5 obtained with the CYP2D6*4 allele (1846 G>A) primer set. The 
nucleotide position of the CYP2D6*4 allele is indicated by the highlighted region and 
corresponds to a genotype of AA, which represents a homozygous mutant genotype. 
 
Direct DNA sequencing confirmed the real-time PCR result of CYP2D6*4 homozygosity as 
obtained with the TaqMan genotyping assay using the ABI 7900HT, as well as the Corbett 
Rotor-Gene real-time PCR (Figures 5.5-5.8).  
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Figure 5.6. Allelic Discrimination Analysis for sample batch one using 
the ABI TaqMan® CYP2D6*4 1834 G>A [Allele Y (A- FAM labelled) vs 
Allele X (G- VIC labelled)]. Black = NTC, Red = Wild type, Green = 
Heterozygous, Blue = Homozygous    
 
Figure 5.5. RT PCR amplification of sample batch one using the ABI 
TaqMan® CYP2D6*4 1834 G>A assay (ΔRn vs number of cycles). ΔRn 
= unit of fluorescence. 
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Figure 5.7. RT PCR amplification of sample batch two using the ABI 
TaqMan® CYP2D6*4 1834 G>A assay (ΔRn vs number of cycles). ΔRn = 
unit of fluorescence. 
Figure 5.8. Allelic Discrimination Analysis for sample batch two using the 
ABI TaqMan® CYP2D6*4 1834 G>A [Allele Y (A- FAM labelled) vs Allele 
X (G- VIC labelled)]. Black = NTC, Red = Wild type, Green = 
Heterozygous, Blue = Homozygous    
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The allelic distribution of CYP2D6*4 was found to be in Hardy Weinberg Equilibrium in both the 
breast cancer patients and the controls. Genotype distribution and allele frequencies differed 
significantly between the Caucasian and Coloured population groups (p<0.001). The frequency 
of the CYP2D6*4 allele and the poor metaboliser status characterised by the homozygous 
genotype were highest in the Caucasian breast cancer patients. No significant differences in 
genotype distribution or allele frequencies were observed between the Caucasian patient and 
control groups (Table 5.3). The 21 male controls were excluded from this comparative analysis 
performed only in female breast cancer patients.  
 
Table 5.3. Comparison of genotype distribution and allele frequencies for CYP2D6*4 
between the Caucasian and Coloured study groups 
 
Control 
group 
(n=42) 
Caucasian 
patient 
group 
(n=25) 
Coloured 
patient 
group 
(n=62) 
Caucasian 
patients to 
controls: 
P-value 
Caucasian 
to Coloured 
patients: 
P-value 
Allele    
P= 0.335 P< 0.0001 
G 70(83%) 38(76%) 120(97%) 
A 14(17%) 12(24%) 4(3%) 
Genotype   
GG 29(69%) 16(64%) 59 (95%) 
P= 0.282 P= 0.0001 GA 12(29%) 6(24%) 2 (3%) 
AA 1(2%) 3(12%) 1(2%) 
 
 
As indicated in Table 5.4, two of the six (33 %) BRCA-positive patients included in the study 
were homozygous for the inactivating CYP2D6*4 allele. Both poor metabolisers (Caucasian) 
were ER-positive; one patient tested positive for a mutation in the BRCA1 gene and the other 
was BRCA2-positive. The BRCA2 mutation-positive patient (sample 22) provided an example of 
how CYP2D6 genotyping may affect clinical management. Instead of tamoxifen, an alternative 
endocrine treatment was administered after the patient underwent a hysterectomy due to her 
risk profile.  
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Table 5.4.  Breast cancer patients with BRCA mutations in relation to CYP2D6 genotype. 
Sample Age Ethnic group ER status 
BRCA  
mutation 
positive 
CYP2D6*4 
77 41 Caucasian Negative BRCA1 Wild-type  
140 52 Caucasian Positive BRCA1 Homozygous 
22 48 Caucasian Positive BRCA2 Homozygous 
23 45 Coloured NA BRCA2 Wild-type 
38 63 Caucasian NA BRCA2 Wild-type 
66 63 Coloured NA BRCA2 Wild-type 
NA, not available  
 
The above-mentioned findings prompted extended CYP2D6 mutation analysis in an 
implementation data set of 27 breast cancer patients, to also assess the use of antidepressants 
in tamoxifen-treated breast cancer patients or patients who considered tamoxifen treatment. 
Ten patients (37 %) referred by participating clinicians reported a medical history of depression, 
with current use of antidepressants reported in four patients (15 %). None of these patients 
were homozygous for CYP2D6*4, while 4 heterozygotes were identified (Table 5.5).  
 
Table 5.5.  Breast cancer patients with a medical history of depression analysed 
during the implementation phase of the study. 
Sample     Age  CYP2D6*4 Antidepressant 
A 48 Wild-type Not provided 
B 58 Wild-type Wellbutrin 
C 47 Wild-type Not provided 
D 54 Wild-type Zoloft, Wellbutrin 
E 45 Wild-type Cipralex 
F 60 Heterozygous Not provided 
G 46 Wild-type Not provided 
H 59 Heterozygous Not provided 
I 68 Heterozygous Not provided 
J 57 Heterozygous Cipramil, Cipralex,  Wellbutrin 
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Knowledge of the different classes of CYP2D6 inhibitors is very important in the heterozygous 
patients as their ability to effectively metabolise tamoxifen could be affected by reduced enzyme 
activity caused by both the intermediate metaboliser status due to CYP2D6*4 heterozygosity 
and concomitant use of antidepressants. For example, one CYP2D6*4 heterozygous breast 
cancer patient (sample J) was diagnosed with depression at the age of 48 years and had been 
on various medications, including Wellbutrin (bupropion) known to strongly inhibit CYP2D6 
function (Table 5.5). Drug side effects with use of antidepressants and various other 
medications were also reported. This ER-positive overweight patient with high cholesterol levels 
had bilateral breast cancer with 4 recurrent events between the ages of 39 and 57 years. She 
tested negative for three founder mutations in the BRCA1 and BRCA2 genes.  
The pedigree of this ER-positive patient with two additional family members diagnosed with 
breast cancer is shown in Figure 5.9. She was referred by her oncologist for a comprehensive 
genetic screen that includes both a diagnostic and risk management component based on 
gene-diet (nutrigenetics) and gene-drug (pharmacogenetics) interactions, using a combined 
service and research approach. Further detail was obtained about the family history and age of 
cancer onset/diagnosis during the genetic counselling session (data not shown). 
  
Figure 5.9. Pedigree of the index case diagnosed with breast cancer at the age of 48 years. 
 
 
The genetic test was performed in conjunction with a medical and lifestyle assessment to 
identify a combination of risk factors that, if left untreated, could cause or contribute to disease 
development or recurrence. Table 5.6 provides a summary of the clinical characteristics and 
lifestyle risk factors entered into the Gknowmix Database at referral. 
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Table 5.6. Clinical and lifestyle information documented at referral of Sample 22 
Family History 
Family Medical Conditions Age of onset/diagnosis Relationship 
Stress / Anxiety / Depression   Sister 
Breast cancer 55 years Mother 
Breast Cancer  Sister 
Health Status 
Personal Medical Conditions Age of Onset Medication 
Breast cancer, BRCA2 
mutation positive 
48 years 
Considers Tamoxifen 
treatment 
Clinical Assessment Value Evaluation Values 
Weight 68.8 kg   
Height 1.73 m   
Body mass index (BMI) 22.99 kg/m2 18.5-24.9 kg/m2 
Contraceptive pill No   
Hormone replacement therapy No   
Lifestyle Assessment Score  
Physical activity 
None / occasionally , Daily: Sedentary – Low 
  
Smoker 
Current: No , Previous: Yes 
  
Alcohol consumption 
1-13 Units / Week – Moderate 
  
Nutrition Assessment Score  
Fat intake, saturated & trans 
fats 
Moderate 
  
Fruit, vegetables, fiber intake 
High 
  
Folate intake 
Low 
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5.2. PHASE I DISCUSSION 
Identification of genetic subgroups of the population that are at increased risk of cancer 
initiation, progression or recurrence due to heritable susceptibility or ineffective therapeutic 
approaches is an important clinical consideration. Currently, DNA-based BRCA 1 and 2 gene 
testing and RNA-based transcriptional profiling including the determination of ER status are 
offered as a routine service to South African patients who fulfill the criteria for these tests (Kotze 
et al. 2005). This study aimed to determine the appropriateness of adding CYP2D6 genotyping 
to the breast cancer genetic test panel. The first step was to determine the frequency of the 
most common inactivating CYP2D6*4 allele in South African breast cancer patients (validation 
data set). The clinical usefulness of providing information related to CYP2D6 genotype to 
participating clinicians was furthermore assessed in a pilot study focused on the prevalence of 
depression and use of antidepressants in breast cancer patients subjected to diagnostic genetic 
testing (implementation data set). Since reduced CYP2D6 activity can be caused by variation in 
the CYP2D6 gene and/or the use of certain antidepressants, both aspects were considered in 
this study.  
Breast cancer is most prevalent amongst South African Caucasian and Asian women and is the 
second most common cancer among Black and Coloured women (Vorobiof et al. 2001). This 
observation raises the question of whether genetic risk factors may explain ethnic differences in 
breast cancer risk. In this study, a significantly higher frequency of the CYP2D6*4 allele was 
detected in Caucasian (24%) compared with Coloured breast cancer patients (3 %). This finding 
is, however, unlikely to account for the higher prevalence of breast cancer in the Caucasian 
compared to Coloured group, since CYP2D6*4 affects drug response and has not been 
associated with an increased risk of primary breast cancer (Goetz et al. 2007). This is in 
accordance with the failure to detect a difference in allele frequencies for CYP2D6*4 between 
the Caucasian patient and control groups. Since CYP2D6*5 is relatively common in the 
Coloured population (Gaedigk and Coetsee 2008), future mutation analysis should be extended 
to include this assay. More than 75 CYP2D6 allelic variants have been identified to date 
(Bernard et al. 2006) and six inactivating alleles (*3, *4, *5, *6, *7 and *8) are responsible for 
approximately 95 % of the poor metaboliser status in most populations (Arneth et al. 2009).  
The current debate in the literature as to whether CYP2D6 pharmacogenetic testing of breast 
cancer patients has clinical relevance highlights the importance of defining the selection criteria 
for a subgroup of patients where the potential benefits would outweigh the risk of unnecessary 
genetic testing. No statistically significant associations were observed between CYP2D6 
genotype and recurrence risk in tamoxifen-treated patients in recent clinical trials (Rae et al. 
2012; Regan et al. 2012). In contrast, strong evidence provided by numerous previous studies 
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showed that CYP2D6 genotype is directly (Newman et al. 2008) as well as indirectly (Jin et al. 
2005) associated with the survival of breast cancer patients treated with tamoxifen (Kiyotani et 
al. 2010). In a study by Schroth et al. (2009) performed in 1,325 patients, recurrence rates were 
14.9 % for extensive (wild-type genotype), 20.9 % for intermediate (heterozygotes) and 29 % for 
poor metabolisers (homozygotes) at 9 years of follow-up. All-cause mortality rates were 16.7 %, 
18.0 % and 22.8 %, respectively. Conflicting results reported in the literature may be attributed 
to differences related to tamoxifen combination therapy, genotyping comprehensiveness, and 
CYP2D6 inhibitor coadministration (Hertz et al. 2012). These include frequent use of 
antidepressants prescribed to treat depression in breast cancer patients and/or menopausal 
vasomotor symptoms such as hot flashes. Tamoxifen treatment may induce or aggravate 
depression or anxiety, and commonly causes hot flashes (Kim et al. 2010). During the research-
focused implementation phase of our study, it was found that 37% (10/27) of breast cancer 
patients from the implementation data set suffer from depression, while the use of 
antidepressants for depression were documented in four patients (15%). These findings are in 
agreement with previous studies which reported that between 20% and 30% of tamoxifen-
treated breast cancer patients also use antidepressants (Nelson et al. 2006; Kim et al. 2010).  
Tamoxifen is the standard 5 year endocrine treatment for premenopausal and postmenopausal 
women with ER-positive breast cancer. In contrast, aromatase inhibitors are frequently 
prescribed for postmenopausal women (Kim et al. 2010). The use of aromatase inhibitors has 
been prohibited in premenopausal breast cancer patients due to the activation of ovarian 
functions implicated in polycystic ovarian diseases. In premenopausal patients for whom the use 
of aromatase inhibitors is inappropriate, tamoxifen is the treatment of choice. Given the link 
between CYP2D6 genotype status and clinical outcome in risk allele carriers on tamoxifen, it is 
likely that aromatase inhibitors would be the preferred treatment for postmenopausal women 
with deficiencies in tamoxifen metabolism (Kim et al. 2010; Punglia et al. 2008). Newman et al. 
(2008) suggested that for postmenopausal patients with BRCA2 mutations and the CYP2D6 
poor metaboliser genotype, an aromatase inhibitor would be the drug of choice.  
The above-mentioned recommendation was of particular relevance in at least one patient with a 
founder BRCA2 mutation found to be homozygous for the CYP2D6*4 allele (sample 22). This 
ER-positive breast cancer patient reported a strong family history of breast cancer, which was 
shown in this study to be associated with an 8 year (on average) earlier onset of breast cancer 
irrespective of whether a mutation has been identified in the BRCA1 or BRCA2 genes. Based 
on this patient’s CYP2D6*4 genotype and the fact that she had a hysterectomy, the treating 
oncologist prescribed an aromatase inhibitor instead of tamoxifen treatment. The proven clinical 
utility of CYP2D6 genotyping resulting in a change in clinical management in this patient, has 
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led to increased awareness of the potential consequences of CYP2D6 inactivation. This has 
also translated into avoidance of concomitant use of tamoxifen and inactivating antidepressants 
in an increasing number of breast cancer patients. The CYP2D6*4 heterozygote who had at 
least four episodes of recurrent breast cancer between the ages of 39 and 57 years (sample J) 
provides an example of where this information could have been relevant if provided when she 
first presented with bilateral breast cancer. She had been diagnosed with depression at the age 
of 48 years and has subsequently been treated with three different antidepressants, of which 
the use of Wellbutrin (bupropion) reported at entry into this study is known to strongly inhibit 
CYP2D6 activity. This ER-positive breast cancer patient reported side effects with use of 
antidepressants and various other medications. Arimidex (anastrozole), an aromatase inhibitor, 
was subsequently prescribed due to her current postmenopausal status. This case provides 
insight of how a patient’s quality of life and well-being could be adversely affected by reduced 
CYP2D6 activity compromised further by use of antidepressants metabolised by CYP2D6. 
Extended mutation analysis of the CYP2D6 gene as well as the entire BRCA1 and 2 genes are 
considered in this patient to further investigate the cause of her poor treatment outcome.  
The above-mentioned information explains what is meant by Khoury et al. (2007), who stated 
that evaluation of the interaction between providers and patients would enable the assessment 
of risks and benefits outside the context of randomized clinical trials. These authors 
acknowledged that while the translation research pathway for therapeutics is relatively 
straightforward, it is less clear for genetic tests that may provide useful information only in a 
subgroup of patients in some populations. Lorizio et al. (2011) found that CYP2D6 genotyping in 
breast cancer patients affects choice of therapy even in the absence of definitive data on clinical 
impact. This confirms the value of genetic information to guide treatment decisions on an 
individual basis, compared to a one-size-fits-all approach applied in most clinical trials. CYP2D6 
genotyping is particularly relevant in the local population due to the increased frequency of 
BRCA2 founder mutations (van der Merwe et al. 2012a) and the high recurrence risk associated 
with reduced CYP2D6 activity in mutation-positive patients (Newman et al. 2008). Since 
CYP2D6*4 is virtually absent in the Black South African population (Wright et al. 2010), 
genotyping for this allele would not be appropriate in this particular ethnic group.  
We believe that the same path used for development and implementation of genetic tests for 
high-penetrance genetic variations identified in the BRCA1 and 2 genes should be followed for 
low-penetrance genetic variations such as those in the CYP2D6 gene, with the exception that 
known environmental exposures must also be taken into account. Integration of CYP2D6 
genotype information into the clinical decision-making process would require careful 
consideration of all possible determinants of CYP2D6 metabolic activity. Although all 
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determinants of CYP2D6 metabolic activity have not yet been identified and some are poorly 
understood, current knowledge related to the consequences of concomitant use of tamoxifen 
and CYP2D6 inhibitors is well-documented and needs to be communicated to clinicians and 
their patients. The phenotypic expression of genetic variation in the CYP2D6 gene is modulated 
by various external factors including physiological states (e.g. pregnancy) and certain herbal 
products. Borges et al. (2010) used genotype, concomitant medication and phenotype data to 
develop a CYP2D6 activity score that incorporates both CYP2D6 genotype and CYP2D6-
mediated drug interactions. Correlation of this score with CYP2D6 phenotype represented a 
significant improvement over the use of CYP2D6 genotype alone.  
Multiple gene/mutation testing in the context of the patient’s medical and/or family history 
provides a basis for development and formulation of personalised cancer prognostication, drug 
treatment and lifestyle-related risk reduction programs (Cleator and Ashworth 2004). CYP2D6 
genotyping has recently been included as the pharmacogenetics component of a multi-gene test 
for CVD (Kotze et al. 2003; Kotze and van Rensburg 2012), due to increased risk of muscle 
pain in patients taking cholesterol-lowering medication metabolised by CYP2D6 (Frudakis et al. 
2007). Due to the potential significance of CYP2D6 genotyping in breast cancer patients and the 
increased risk of thrombophilia and cardiac complications with the use of chemotherapy and 
hormonal treatment (e.g. tamoxifen, HRT), the development and validation of a comprehensive 
screening strategy is hereby warranted to improve well-being and quality of life. In this study the 
PSGT approach - initially developed for risk management of CVD and related medical 
conditions (Kotze and van Rensburg 2012) - was applied during the implementation phase of 
this study to assess the clinical usefulness of combining diagnostic and pharmacogenetic 
testing in breast cancer patients. Assessment of CVD risk factors in breast cancer patients is 
supported by the direct link between an increased risk of postmenopausal breast cancer and the 
metabolic syndrome characterised by central obesity, insulin resistance, hypertension and/or 
hyperlipidemia (high triglycerides and/or low HDL-cholesterol levels) (Rosato et al. 2011). These 
findings support the implementation of CYP2D6 genotyping as part of a multi-gene test that 
takes co-morbidities such as obesity (King et al. 2003; Li et al. 2009), family history, ethnicity, 
ER status, BRCA mutation status and use of antidepressants into account prior to tamoxifen 
treatment of breast cancer patients. Although CYP2D6*4 is not deterministic by itself to cause 
disease, it may become clinically relevant in the presence of environmental co-factors or co-
inheritance with other genetic risk factors (Mellick 2006; Newman et al. 2008).  
We demonstrated the value of combining diagnostic BRCA mutation screening and 
pharmacogenetic testing in South African patients diagnosed with breast cancer. This study has 
contributed to an increased awareness of the important role clinicians can play in identifying 
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breast cancer patients who may benefit from CYP2D6 genotyping, based on their unique 
genetic background and concomitant use of tamoxifen and certain antidepressants. While it 
remains uncertain whether a pharmacogenetic profile should be obtained prior to initiating 
tamoxifen treatment, we conclude that genetic testing performed as part of a comprehensive 
risk reduction strategy could prove useful in informing clinical and therapeutic decision making 
in selected breast cancer patients. CYP2D6 genotyping has important relevance in several 
clinical domains and represents one of several pieces of information that clinicians may 
consider in guiding the selection of appropriate treatment tailored to the unique needs of the 
individual. This includes an important role in cardiovascular pharmacogenomics that may be 
relevant in some breast cancer patients. The weight of current scientific evidence in relation to 
risk-benefit assessment supports CYP2D6 genotyping in breast cancer patients who (1) are 
receiving tamoxifen and (2) are at high risk for tumour recurrence (e.g. family history, BRCA1/2 
mutation-positive) or (3) are required to take potentially competing antidepressants. 
 
5.3. PHASE II RESULTS 
The study population was selected from 625 South African individuals enrolled in a chronic 
disease screening program, of whom 88 (14%) were previously diagnosed with breast cancer. 
The majority of these patients (53, 60%) reported a family history of cancer. Eighteen (20%) 
patients had advanced metastatic disease, of whom 14 (78%) had ER-positive carcinoma. A 
total of 264 individuals (194 females, 70 males; mean age 48.0 years) reported to be cancer-
free at entry into the study were identified as obese. In addition, 118 obese patients (45%) had 
hypertension, 68 (26%) had hypoalphalipoproteinemia, 53 (20%) had hypertriglyceridemia and 
49 (19%) had insulin resistance. In total, 94 obese patients had no other concurrent metabolic 
syndrome features, while 99 had one additional component. In total, 71 obese patients (27%) 
had concurrent metabolic syndrome, based on the presence of two or more additional features 
except visceral adiposity. Of the 214 female control individuals reported to be cancer-free and 
without a family history of cancer, 175 were classified as obese (BMI>30 kg/m2).  
For comparative analysis among breast cancer patients, all cases were subdivided according to 
ER status. Histopathology reports were available for 81 (92%) of the 88 breast cancer patients 
participating in the chronic disease screening program. In addition to the information gathered 
from this patient group referred to as the implementation data set, ER status was also available 
for 83 breast cancer patients from the validation data set previously described by van der 
Merwe et al. (2012). HER2 status was not performed/ available for these patients, all of whom 
were previously screened for mutations in the BRCA1 and BRCA2 genes (Agenbag 2005). 
Table 5.7 summarises the clinical characteristics of the combined patient study group, including 
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104 (63%) Caucasian and 60 (37%) Coloured breast cancer patients (n=164, p-value=0.160) 
stratified according to ER status.  
 
 Table 5.7. Comparison of clinical and lifestyle characteristics between ER-positive and ER-
negative breast cancer patients, adjusted for ethnicity and age.  
 
   
ER status P-value, adjusted for: 
 
 Parameter           ER- ER+  
Ethnicity 
and age  
           49 115 
Ethnicity 
 
Median (range) N    
  
  
 
Age 164 49 (30-77) 54 (31-83) 0.013   
 
Age at diagnosis/onset 164 48 (30-77) 53 (31-83) 0.022 0.794 
 
Body mass index 146 25 (17-47) 26 (17-41) 0.014 0.035 
 
*Folate Score 81 8 (2-15) 8 (3-31) 
All 
Caucasians 
0.232 
 *Fruit, veg and fibre 
score 
81 10 (3-20) 14 (4-25) 0.082 
 
*Fat Score 81 11 (2-29) 12 (1-34) 0.865 
 
Count (percentage)     
 
  
 
Ethnicity, Coloured 164 22 (45) 38 (33) 
 
  
 
HRT, yes 163 9 (19) 15 (13) 0.170 0.089 
 
OCPs, yes 163 20 (42) 32 (28) 0.247 0.687 
 
Current smoking, yes 160 17 (35) 34 (30) 0.898 0.831 
 
Alcohol intake, yes 156 25 (52) 62 (57) 0.838 0.545 
 
Physical activity, yes 162 33 (67) 74 (65) 0.427 0.392 
 
Family history of cancer 163 30 (61) 59 (52) 0.164 0.371 
 
BRCA mutation-positive 106 7 (19) 6 (9) 0.095 0.143 
HRT, hormone replacement therapy; OCPs, oral contraceptive pills. *Only available for a subset of 
Caucasian patients i.e. participants of chronic disease screen (n=81), no ethnicity adjustment possible. 
 
Within the two ethnic groups, there was no significant difference between the number of patients 
aged 50 years or older, used as a proxy for menopausal status. There were also no significant 
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differences between age (p=0.595) and age at diagnosis/onset of breast cancer (p=0.265) 
between Caucasian and Coloured breast cancer patients. However, modifiable lifestyle factors 
differed significantly between these two South African population groups as shown in Figure 
5.10. BMI (p=0.0001) and current smoking (p<0.0001) were highest in the Coloured population, 
while level of physical activity (p=0.0001) and weekly alcohol consumption (p=0.0002) were 
highest in the Caucasian patients. Use of hormone replacement therapy (HRT) was significantly 
higher in Caucasian breast cancer patients compared to Coloured patients (p=0.0038), while 
use of oral contraceptive pills (OCP) was the highest in the Coloured breast cancer patients 
(p<0.0001). 
Figure 5.10. Comparison of modifiable lifestyle factors between breast cancer patients from the 
Caucasian and Coloured populations of South Africa. 
 
All 87 patients included in the validation data set were previously screened for high-penetrance 
mutations in the entire BRCA1/2 genes (van der Merwe et al. 2012), while BRCA mutation 
analysis was performed in only 23 patients in the implementation data set. Selection criteria for 
BRCA mutation screening following genetic counselling in the latter group included early age at 
diagnosis (<40 years) and / or a strong family history of breast/ovarian cancer. Detection of 
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high-penetrance mutations in BRCA1 and BRCA2 genes were more commonly reported in 
patients with ER-negative (19%) compared to ER-positive (9%) tumours, as may be reflected by 
the higher proportion of patients in the former group who reported a family history of cancer. 
This finding also concurs with a significantly younger age at entry into the study (p=0.013), as 
well as a significantly earlier age at diagnosis/onset of breast cancer in patients with ER-
negative versus ER-positive cancer, after adjustment for ethnicity (p=0.022). As indicated in 
Table 5.7, BMI was furthermore found to be significantly higher in patients with ER-positive 
compared to ER-negative breast cancer, after adjustment of age and ethnicity (p=0.035). Each 
extra unit of BMI increased the odds of being ER-positive with 8% (95% CI: 1-16). 
Due to the high prevalence of lifestyle risk factors identified in the breast cancer patients 
studied, genotype-phenotype association studies were performed using a CVD multi-gene 
assay including 8 SNPs considered clinically useful across diagnostic boundaries (Table 4.7). 
These SNPs in the APOE, MTHFR, FII, FVL, and HFE genes are the most common hereditary 
causes for hypercholesterolaemia, hyperhomocysteinaemia, thrombophilia and iron overload, 
respectively, in the general population worldwide. The allelic distribution of all 8 SNPs were in 
Hardy-Weinberg equilibrium for the total and both subgroups of breast cancer patients studied 
(p>0.05).  No significant differences in genotype distribution and allele frequencies were 
observed for the 8 SNPs included in the CVD multi-gene assay between patients with ER-
positive and ER-negative breast cancer (Table 5.8).  
 
Table 5.8. Comparison of genotype distribution and allele frequencies for 8 SNPs included in 
the CVD multi-gene assay between ER-positive and ER-negative breast cancer patients (112 
Caucasian and 62 Coloured), after adjustment for ethnicity. 
  Genotype Additive allele 
 Gene variant Unadjusted 
Ethnicity-
adjusted 
Unadjusted 
Ethnicity-
adjusted 
ApoE2 C>T 0.195 0.234 0.195 0.234 
ApoE4 T>C 0.143 0.198 0.150 0.242 
MTHFR 677 C>T 0.644 0.747 0.570 0.904 
MTHFR 1298 A>C 0.529 0.567 0.892 0.987 
Factor II G>A 0.226 0.241 0.085 0.092 
FVLL G>A 0.575 0.635 0.575 0.635 
HFE 845 G>A 0.271 0.168 0.271 0.168 
HFE H63D C>G 0.227 0.333 0.121 0.200 
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Minor allele frequencies for the 8 SNPs studied were similar to those previously reported for the 
general South African population, stratified by ethnicity (Table 5.9).  
 
Table 5.9. Comparisons of minor allele frequencies (MAFs) of variants included in the CVD 
multi-gene assay applied in 112 Caucasian and 62 Coloured breast cancer patients in relation 
and MAFs of the respective SNPs according to the literature.  
Gene variant 
MAF 
Caucasian 
patients 
MAF 
Caucasians 
(literature) 
MAF 
Coloured 
patients 
MAF 
Coloureds 
(literature) 
GMX database 
and/or South 
African 
published data 
APOE e-2 0.07 0.08 0.1 0.11 
Kotze et al. 
1993 and GMX 
database 
APOE e-4 0.16 0.17 0.28 0.26 
Kotze et al. 
1993 and GMX 
database 
FVL Leiden 0.04 0.05 0.02 0.02 GMX database 
FII 0.02 0.02 0.01 0.02 GMX database 
MTHFR 677 C>T 0.36 0.36 0.12 0.18 
Scholtz et al. 
2002 
MTHFR 1298 A>C 0.25 0.37 0.32 0.3 
Scholtz et al. 
2002 
HFE C282Y 0.04 0.09 0.03 0.02 
de Villiers et al. 
1999 
HFE H63D 0.15 0.12 0.125 0.07 
de Villiers et al. 
1999 
GMX database = Gknowmix database accessible to registered users at www.gknowmix.org 
 
Extended genotype-phenotype association studies demonstrated (Figure 5.11) that presence of 
the E4 allele of the ApoE polymorphism (rs429358) reduces the mean age of breast cancer 
diagnosis/onset by an average of 10 years in South African breast cancer patients, regardless 
of ethnicity, alcohol consumption, current smoking and a family history of cancer (P=0.003).  
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Figure 5.11. Box plot depicting the additive allelic reducing effect of APOE allele E4 on age of 
onset/diagnosis of breast cancer patients. 
 
The functional MTHFR 1298 (A>C) polymorphism (rs1801131) was furthermore found to be 
significantly associated with BMI, after adjustment for ethnicity and a family history of cancer 
(p=0.01), as shown in Figure 5.12.   
 
 
 
 
 
 
 
 
 
 
Figure 5.12. Box plot depicting the additive allelic increasing effect of MTHFR 1298 A>C on 
body mass index (BMI).  
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Association analysis was performed between body mass index (BMI) and the dietary intake in 
214 female Caucasian control individuals and 81 breast cancer patients from the 
implementation data set who completed the nutrition questionnaire (Figure 5.13).  A difference 
in association was detected between the patient and control groups (p=0.049). The patient 
group showed a significant increasing trend of BMI with higher saturated/trans fat score 
(p=0.032), whereas the same association was not found in the control group.  When the 
association between BMI and the fat score was assessed in the implementation data set, 
separated by ER status, no significant difference was observed between the two breast cancer 
patient groups. The positive correlation between BMI and the fat score was stronger in ER-
positive compared to ER-negative breast cancer patients, but the sample size may have been 
too small to reach statistical significance.  
 
Figure 5.13. Association between BMI and saturated/trans fat score. Left: Comparative analysis 
in 214 female Caucasian control individuals and 81 breast cancer patients from the 
implementation data set who completed the nutrition questionnaire, showing a difference in 
association between groups (p-value=0.049). Right:  Association between BMI and fat score in 
implementation data set, separated by ER status.   
 
Seventeen patients included in the implementation data reported treatment-related side effects, 
including chemotherapy-induced cognitive dysfunction and/or drug resistance/side effects 
related to the concomitant use of tamoxifen/aromatase inhibitors. In addition, four patients 
reported side effects with the use of aromatase inhibitors and other drugs. Genotype-phenotype 
correlation of these 17 cases showed that in eight patients, the clinical profiles matched their 
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genetic test results. Four (4.5%) breast cancer patients reported symptoms of cognitive 
impairment, two of whom tested positive for both the risk-associated APOE e-4 allele and the 
MTHFR 677 C>T mutation previously linked to this condition. A total of 27 (30%) breast cancer 
patients reported a comorbid diagnosis of depression, 12 (44%) of whom were MTHFR 677 T-
allele carriers. Of the nine patients who tested positive for mutations in the FVL 
Leiden/prothrombin gene, four MTHFR 677C>T carriers (out of 7 patients) also experienced 
deep vein thrombosis (DVT) and/or recurrent pregnancy loss (Table 5.10).  
 
Table 5.10. Clinical characteristics and comorbidities in breast cancer patients 
enrolled in the chronic disease screen, subjected to the CVD multi-gene assay. 
Comorbidity  Breast cancer patients (n=88) 
BRCA mutation analysis (mutation positive) 23 (10) 
Depression (%) 27 (31%) 
Depression (antidepressant treatment) (%) 10 (11%) 
Medication side effects (%) 17 (19%) 
Tamoxifen use 7  
Antidepressant use 5 
Tamoxifen + Antidepressant 1 
Other including AIs 4 
Deep vein thrombosis (%) 2 (2%) 
Recurrent pregnancy loss (%) 5 (5%) 
Cognitive Impairment (%) 4 (4%) 
 
 
5.4. PHASE II DISCUSSION 
Comparison between patients with ER-positive and ER-negative breast cancer showed a 
statistically significantly higher BMI in hormone-responsive patients after adjustment for age and 
ethnicity (p=0.035). Differences in several modifiable lifestyle factors were observed between 
Caucasian and Coloured breast cancer patients, including BMI found to be significantly higher in 
the Coloured patients. The MTHFR 1298 A>C SNP was significantly associated with increased 
BMI (p=0.01) in the present study, after adjustment for ethnicity and a family history of cancer. 
This finding may be related to the association reported by Naushad et al. (2012) linking variation 
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in the MTHFR gene with the luminal B tumour subtype. Two of the 13 South African patients 
who were HER2 positive were found to be homozygous for MTHFR 677 C>T; both ER-positive 
and therefore classified as luminal B as opposed to the HER2-enriched subtype characterised 
by ER-negative status.  
The E4 allele of the apolipoprotein E (APOE) polymorphism (rs429358) reduced the mean age 
of cancer diagnosis/onset by an average of 10 years, regardless of the aforementioned 
confounders (P=0.003). The APOE e-4 allele included in the CVD multi-gene assay previously 
described by Kotze and Thiart (2003) has previously been associated with breast cancer risk 
and clinical outcome across different population groups (Zunarelli et al. 2000; Moore et al. 2004; 
Chang et al. 2005).The APOE gene provides a genetic link between CVD and dementia, with 
the cholesterol-raising APOE e-4 allele considered an important risk factor for metabolic 
syndrome, vascular disease and cancer. Women with one or two copies of the e-4 allele of 
APOE and those with high concentrations of triglycerides had a four-fold risk of developing 
breast cancer, compared to women with low triglyceride levels. This increased risk was 
suggested to be attributed to factors including the effect of reduced triglyceride clearance from 
the plasma which results in sustained elevated concentrations and consequently a decrease in 
the levels of sex hormone-binding globulins (Moysich et al. 2000). This is in agreement with the 
findings of Chang et al. (2005), Surekha et al. (2008) and a meta-analysis performed by Saadat 
(2012) in 2008 breast cancer patients and 1 827 healthy controls. Saadat (2012) concluded that 
the APOE e-4 allele may be a low-penetrant risk factor for development of breast cancer. Other 
studies however reported no association between the presence of either the APOE e-4 allele 
and the rate of tumour cell proliferation or clinical outcome in breast cancer patients (Zunarelli et 
al. 2000). The deleterious effect of the APOE e-4 allele is not only exerted through increased 
cholesterol levels, but also independently through increased risk of LDL-oxidation and 
inflammation. Genin et al. (2011) demonstrated the association of APOE e-4 with early-onset 
Alzheimer’s disease (AD) and calculated AD life-time risk in approximately 10 000 cases and 
controls of Caucasian ancestry. This risk increased with the presence of the APOE e-4 from 
11% to 51% in males and 14% to 60% in female carriers at the same age. They contended that 
similar to BRCA gene mutations, the aforementioned risks when compared to that conferred by 
low-risk common alleles, are consistent with the semi-dominant inheritance of moderately 
penetrant genes.  
Lengacher et al. (2015) studied chemotherapy-related changes in cognitive function in breast 
cancer survivors participating in the Mindfulness-Based Stress Reduction (MBSR) for Breast 
Cancer program. The results showed that variation in four genes including APOE and MTHFR 
were associated with cognitive impairment. In APOE e-4 allele carriers, co-inheritance of the 
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MTHFR 677C>T variant has been shown to exacerbate risk for cognitive dysfunction as a 
known chemotherapy-induced side-effect. In a recent South African study conducted by 
Luckhoff et al. (2015) the authors demonstrated that the expression of a hypercholesterolaemic 
phenotype in e-4 allele carriers, as well as its mitigation by regular physical activity, were 
dependent on the interaction between APOE genotype and AD family history. In an extended 
data set which included all participants enrolled in this study, APOE genotype was also shown 
to modify the association between alcohol intake and metabolic risk traits including BMI and 
total cholesterol levels, with a deleterious increase in both being restricted to APOE e-4 allele 
carriers (unpublished data).These findings served to validate the clinical relevance of assessing 
non-genetic data including lifestyle factors as part of a multidisciplinary approach to chronic 
disease screening incorporating APOE genotyping to inform clinical and therapeutic decision 
making in the context of vascular risk management. APOE genotyping could therefore prove 
useful in prioritizing the need for tailored lifestyle-based interventions in e-4 allele carriers with 
the goal of decreasing cumulative cardio-metabolic risk to prevent the onset and progression of 
CVD/AD with advancing age. This emphasizes that the clinical application for APOE genotyping 
performed as part of a multidisciplinary framework is not applied to provide diagnostic 
confirmation of a fatalistic diagnosis, but as a means of developing and providing lifestyle-based 
treatment plans aimed at overcoming an “apparently insurmountable” genetic disease 
predisposition (Kotze et al. 2015). 
In this study, four breast cancer patients reported symptoms of cognitive impairment at the time 
of enrolment into the chronic disease screening program, two of whom tested positive for both 
the risk-associated APOE e-4 allele and MTHFR 677 C>T variant (heterozygous and 
homozygous, respectively) and another heterozygous for MTHFR 677 C>T. One of the patients 
who were homozygous for MTHFR 677 C>T and heterozygous for APOE e-4 was ER-positive 
while the patient heterozygous for MTHFR 677 C>T was ER-negative (triple-negative). Co-
inheritance of these two functional polymorphisms or single effects in combination with relevant 
lifestyle risk factors detected with use of the CVD assay may therefore explain the cognitive 
changes observed in a subset of breast cancer patients following anti-cancer treatment.  This 
was in accordance with a meta-analysis conducted by Jim et al. (2012) in 807 patients 
previously treated with standard-dose chemotherapy showing that deficits in cognitive 
functioning were observed in patients relative to controls or pre-chemotherapy baseline results 
with regard to verbal ability and visuospatial ability. In addition, patients treated with 
chemotherapy performed worse than controls in relation to verbal ability and worse than 
patients treated without chemotherapy with regard to visuospatial ability. Possible confounders 
including age, education, endocrine treatment and duration since treatment did not moderate 
cognitive deficits in verbal ability or visuospatial ability. A study by Stewart et al. (2006) 
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supported these results. Continued monitoring of patients through our combined PSGT service 
and research approach enables the identification and investigation of treatment-related 
comorbidities. This approach proved useful for breast cancer patients subjected to the CVD 
multi-gene assay covering all major disease pathways implicated in cancer and other non-
communicable diseases. 
Results from numerous, large-scale prospective cohort studies confirmed the increased risk of 
CVD mortality with increasing BMI (McGee 2004; Flegal et al. 2005; Wilson et al. 2002). Several 
studies have also reported an association between obesity as well as weight gain and breast 
cancer risk (Wolket al. 2001; Huang et al. 1997). There is also evidence that weight loss as well 
as reduced fat intake may lead to a decreased risk for breast cancer (Harvie et al. 2005; 
Prentice et al. 2006). In addition to being an established risk factor for CVD, a direct association 
between metabolic syndrome and postmenopausal breast cancer risk has been clearly 
demonstrated (Agnoli et al. 2015, Rosato et al. 2011, Davis et al. 2012). Metabolic syndrome is 
also a common comorbidity in patients with depression, which according to various studies 
affects about 30% of breast cancer patients (Vahdaninia et al. 2010; Saniah et al. 2010). This 
finding is in agreement with the prevalence of depression in our study group representing an 
expansion of the “validation data set” previously studied by van der Merwe et al. (2012a). In 
contrast to a bi-directional pathogenic relationship, it has been suggested that a consistent 
overlap between common metabolic abnormalities and neuropsychiatric features shared across 
the affective spectrum could support the existence of a distinct metabolic-mood syndrome 
disease subtype. The association between cardio-metabolic risk and depression can also be 
ascribed to side effects related to common antidepressants, including weight gain which was 
reported by one patient included this study. These findings emphasize the importance of early 
detection of a genetic predisposition to allow for classification into different treatment groups 
and enable the implementation of measures to prevent cumulative risk that may underlie the 
development of breast cancer and associated comorbidities. 
The MTHFR 677 C>T mutation was previously shown to be associated with increased BMI in 
South African patients with major depressive disorder (Delport et al. 2014). The clinical 
validation of MTHFR 677 C>T as a contributing factor to cumulative metabolic risk was 
demonstrated in the South African population by the interrelationship detected between dietary 
folate intake, MTHFR mutation status, BMI and homocysteine levels (Delport et al. (2014). 
These findings are supported by an earlier study of Tiemeier et al. (2002) who also showed that 
the effect of folate deficiency was mediated by obesity, which was identified as a major 
comorbidity in patients with depression. Our data supported by international studies therefore 
provides a scientific basis for personalized dietary recommendations based on an individual's 
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genetic makeup and nutritional status that may be reflected by relevant biochemical 
abnormalities. Since depression is the most common psychiatric problem in cancer patients, 
treatment focused on both conditions using a comprehensive risk reduction approach guided 
from the genetic background has become an important consideration in the local population 
(van der Merwe et al. 2012a). Up to 30% of patients treated with tamoxifen to reduce recurrence 
risk also use anti-depressants (for depression or hot flushes) (Nelson et al. 2006; Kim et al. 
2010) which may interfere with anti-cancer treatment.  
In our study, one breast cancer patient also identified as being homozygous for the MTHFR 
677C>T variant (BRCA mutation negative) presented with side effects attributed to tamoxifen 
use which could not be accounted for by the presence of inactivating CYP2D6 alleles. This 
patient was subjected to gene expression profiling using the MammaPrint test which revealed 
the presence of bilateral low-risk breast cancer. The daughter of this patient also developed 
breast cancer approximately two years after her mother. Based on the clinical presentation and 
assessment of her genetic risk profile, this patient was selected for extended genetic testing in 
the form of next-generation/whole exome sequencing. 
Co-inheritance of MTHFR 677C>T with high-penetrance causative mutations in the BRCA1/2 
genes may also increase the risk of early-onset breast and ovarian cancer (Chen et al. 2005; 
Jakubowska et al. 2007; Pepe et al. 2007). In the South African setting, elucidation of the role of 
MTHFR as a modifier gene in familial breast cancer is of particular relevance, given the 
detection of founder BRCA1/2 mutations at increased frequencies in the Afrikaner, Coloured 
and Xhosa population groups (Reeves et al. 2004; van der Merwe et al. 2012b). Similar to the 
low-penetrance MTHFR 677C>T mutation, distribution of BRCA1/2 mutation status was the 
same in ER-positive and negative patients included in this study. This finding supports the 
relevance of susceptibility genetic testing across the spectrum of breast cancer subtypes, 
ranging from the luminal-type associated with variation in the MTHFR gene (Naushad et al. 
2012) to the more severe HER2 enriched and basal-like triple negative breast cancers strongly 
associated with BRCA1 mutations. The distribution of HER2 overexpression was similar in 
patients with ER-negative (20%) and ER-positive (15.5%) cancers. Of the 10 (5 ER-positive and 
5 ER-negative) patients who tested positive for mutations in the BRCA1 and BRCA2 genes, at 
least one patient with ER-positive breast cancer was previously found to be homozygous for the 
inactivating CYP2D6 allele 4 allele as highlighted in the study by van der Merwe et al. (2012a) 
due to a change in treatment based on the genetic findings. Extension of CYP2D6 genotyping to 
using the CVD multi-gene assay in the same patient revealed homozygosity for the MTHFR 677 
C>T mutation  as well as homozygosity for the APOE e-4 allele, both considered established 
risk factors for Alzheimer’s disease and susceptibility for cancer development. Another example 
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of how early intervention was enabled by participation in the chronic disease risk screen was 
demonstrated by the case of a healthy but obese 51 year old female encouraged to have 
genetic counselling and BRCA testing based mainly on her family history of cancer documented 
as part of the medical and lifestyle assessment. She requested re-evaluation of a recent 
mammogram performed that led to further testing and finally a diagnosis of early-stage triple 
negative (ER/PR/HER2-negative) breast cancer. Subsequent full gene BRCA screening as part 
of the MyRisk test performed by Myriad Genetics, resulted in the identification of the BRCA1 
c.2457del mutation. This information has now been added to our genomics database after 
exchange from “control” to “case” in order to ensure the accuracy of the information made 
available for future research. In relation to cancer diagnosis two other patients included in this 
study reported a change in disease status during the 5-year study period. In our study, one 
breast cancer patient also identified as being homozygous for the MTHFR 677C>T variant 
(BRCA mutation negative) presented with side effects attributed to TAM use which could not be 
accounted for by the presence of inactivating CYP2D6 alleles. This patient was subjected to 
gene expression profiling using the MammaPrint test which revealed the presence of bilateral 
low-risk breast cancer. The daughter of this patient also developed breast cancer approximately 
two years after her mother. Based on the clinical presentation and assessment of her genetic 
risk profile, this patient was selected for extended genetic testing in the form of next-
generation/whole exome sequencing. 
The selection of this patient for next-generation sequencing was based on the need to establish 
whether MTHFR 677C>T homozygosity would be sufficient to confer significant genetic risk for 
breast cancer. Results from such investigation could help to test the hypothesis that low-
penetrance functional polymorphisms in genes such as MTHFR are associated with genetic 
predisposition towards breast cancer in the presence of a high-risk environment including an 
increased BMI. It is important to determine whether stop-codon mutations in genes such as 
RAD50 identified for these patients should be considered causative in the presence of non-
deterministic genetic risk modifiers such as MTHFR 677C>T. This notion is in accord with 
findings from a recent study in which the authors showed that the majority of familial 
aggregation for breast cancer can be attributed to low- to- moderate-penetrance mutations in 
non-BRCA1/2 mutated cases. 
The finding that tamoxifen use is associated with increased risk of thromboembolic events (TEs) 
in women with breast cancer is of particular relevance to patients with a genetic predisposition 
for DVT. Although our sample size is too small to obtain conclusive results, it is noteworthy that 
none of the patients with ER-negative breast cancer has the FVL Leiden or prothrombin 
mutations detected in 10% and 5% of patients with ER-positive tumours, respectively. In a study 
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by Garber et al. (2010) studying 124 women who had experienced TEs while taking adjuvant 
tamoxifen (±5 years) for breast cancer, a significant association with the FVL 1691G>A (Leiden) 
mutation was identified. Other statistically significant factors associated with TE risk were 
personal history of TE and smoking also captured as part of the medical and lifestyle 
assessment performed as part of the chronic disease screening program. Since women who 
experienced TEs while taking adjuvant tamoxifen for early-stage breast cancer were five times 
more likely to carry the FVL Leiden mutation than those who did not have a TE, it was 
suggested that postmenopausal women should be evaluated for the FVLL mutation before 
prescription of adjuvant TAM if a positive test would alter therapeutic decision making.  
The CVD multi-gene assay used in this study as the genetic component of the chronic disease 
screening program includes both the FVL and FII / prothrombin mutations (Kotze and Thiart 
2003). These low-penetrance mutations are the two major coagulation factors essential for 
proper blood clot formation and are the most common inherited risk factors for venous 
thrombosis. Risk for thrombosis in carriers of these mutations is further increased with the use 
of estrogen-containing oral contraceptives (Swen et al. 2011). This pharmacogenetic interaction 
underpins the importance of FVL as an established risk factor for CVD, also in breast cancer 
comorbid risk assessment. Due to differences reported in the prevalence of venous 
thromboembolism in major population groups, Pepe et al. (1997) determined the distribution of 
the FVL mutation in European and various non-European groups. They confirmed that in non-
Europeans, the prevalence of FVL mutation is at least 7 times lower than in Europeans, which 
may explain the low prevalence of thrombotic event in these groups.  MTHFR 677 C>T has also 
been documented as a risk factor for venous and arterial thrombosis and the risk may be further 
increased in the presence of the FII and FVL mutations (Elhassan and Abdalla 2015; Andreassi 
et al. 2006; Den et al. 2005). Keijzer et al. (2002) reported a relative risk for thrombophilia of 
between 1.4 and 1.6 in the presence of the MTHFR 677 T-allele and a combined risk of 18.7 if 
detected in the presence of the FVL Leiden mutation. The development of thrombosis has been 
associated with various clinical conditions including arterial thrombosis (myocardial infarction, 
ischemic cerebrovascular disease, and peripheral vascular disease) and venous thrombotic 
disorders [deep vein thrombosis (DVT) and pulmonary embolus]. Furthermore, both the APOE 
e-2 and e-4 alleles included in the CVD multi-gene assay have been associated with DVT 
(Nagato et al. 2012), supporting the relevance of this gene in both CVD and breast cancer risk 
management.  Finally, the APOE e-2, APOE e-4, FVL, FII and MTHFR 677 C>T polymorphisms 
have been associated with recurrent pregnancy loss (Reznikoff-Etiévan et al. 2001; Mierla et al. 
2012; Li et al. 2014).  Of the nine patients who tested positive for the FII and FVL gene variants 
in our study, four also carried the MTHFR 677 C>T variant and reported a history of prior DVT 
and/or recurrent pregnancy loss. This result provides a good example of concordance between 
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the genetic test result and clinical expression, which supports the clinical relevance of using the 
CVD multi-gene assay in breast cancer patients as part of a comprehensive chronic disease 
screening program.  
In addition to its anti-neoplastic effects, several clinical studies have demonstrated that 
tamoxifen exerts favourable effects on serum lipid profiles and metabolic risk, being associated 
with lower levels of total and low-density lipoprotein (LDL)-cholesterol (de Medina et al. 2004). 
Cholesterol which is a precursor for estrogen production, is packaged into LDL which when 
inhibited with the use of statins, was shown to reduce the incidence and increase patient 
survival (Beck et al. 2003; Cauley et al 2006). In light of the CVD risk faced by breast cancer 
survivors, lowering of cholesterol levels has been suggested as therapy for targeting both 
diseases. The alternative to lowering cholesterol levels without use of medication is dietary 
intervention. Various diets have been investigated for their potential effect on cancer risk, with 
conflicting results. Toledo et al. (2015) suggest a beneficial effect of a Mediterranean diet 
(MeDiet) supplemented with extra-virgin olive oil (EVOO) in the primary prevention of breast 
cancer. In this study, women allocated to the MeDiet supplemented with EVOO showed a 62% 
relatively lower risk of malignant breast cancer than those allocated to the control diet (95% CI, 
0.16-0.87). While HRT was associated with favourable changes in lipid and metabolic 
parameters in carriers homozygous for the C-allele of MTHFR 677, this effect was not evident in 
carriers of the risk-associated T- allele. The MTHFR C677T polymorphism was suggested to 
modify the effect of HRT on lipid and metabolic parameters in postmenopausal women 
(Lambrinoudaki et al. 2013). The homozygous mutant TT genotype was associated with 
increased levels of total and LDL cholesterol, while the heterozygous CT and wild type CC 
genotypes were associated with a reduction of total cholesterol and LDL cholesterol after 1 year 
of HRT (p = 0.032 for total cholesterol and p = 0.002 for LDL cholesterol). Devlin et al. (2012) 
suggested that the high prevalence of MetS as a side-effect of treatment with second generation 
antipsychotics in children, is attributed to the role of the MTHFR C677T variant in the metabolic 
alterations that link these two constructs.  
Mutations in the hemochromatosis (HFE) gene also included in the CVD multi-gene assay 
account for up to 90% of type I hereditary hemochromatosis (HH) in patients of Northern 
European descent (Adams and Barton 2007). Variation in the HFE gene is associated with 
increased risk for iron overload as well as other related comorbidities including cardiomyopathy 
and chronic liver disease (Gurrin et al. 2008). In addition, iron as an essential trace element can 
be carcinogenic through a variety of mechanisms including host immune response suppression 
(Porto and De Sousa 2007), catalysing the formation of mutagenic hydroxyl radicals (Ames et 
al. 1983) and by stimulating growth of tumour cells (Stevens et al. 1990). Iron metabolism was 
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shown to be frequently altered in breast cancer, with considerably higher iron in postmenstrual 
women. Moreover, a synergistic effect on cellular proliferation between estrogen and iron has 
been demonstrated in BRCA1-associated hormone responsive breast cancer (Mittal et al. 
2014). Zghair et al. (2014) contended that establishing a link between estrogen and iron 
metabolism has a potentially significant prognostic value in predicting clinical outcome in 
BRCA1-associated ER-positive breast cancer patients. Kallianpur et al. (2004) concluded that 
impaired iron homeostasis in HFE C282Y mutation carriers predisposes towards the 
development of breast cancer in Caucasian females. In a prospective cohort study, Osborne et 
al. (2010) assessed the relationships between the low-penetrance HFE C282Y mutation and 
risk for the development of several neoplasms including breast, colorectal, and prostate cancers 
in nearly 30 000 participants. Males homozygous for the C282Y mutation had an increased risk 
of colorectal cancer compared to non-carriers, while female mutation carriers had an increased 
risk for breast cancer. Overall, HFE C282Y homozygotes had a two-fold increased risk of breast 
and colorectal cancer compared with those who tested negative for the C282Y. None of the 
breast cancer patients included in the present study were homozygous for the C282Y mutation.  
The small sample size and use of age as a proxy for menopausal status limited our ability to 
replicate the findings of Lambrinoudaki et al. (2013), who identified MTHFR 677C>T as a 
modifier of the effect of HRT on metabolic risk in postmenopausal females. Since accurate 
designation of menopausal status is complicated by various factors including surgery and the 
use of hormone therapy, we based our decision to use an age of 50 years and older as in 
indication of postmenopausal status on the findings of Phipps et al. (2010). These authors 
reported that different methods used to define menopausal status translated to only slight 
differences in status-specific breast cancer incidence or detection rates. Inclusion of only 
Caucasian patients of European Ancestry is another important limitation of the study, which can 
be justified by the low frequencies of most of the SNPs included in the CVD multi-gene assay in 
non-Caucasians. Homozygosity for the MTHFR 677 T-allele was reported to be approximately 
10% in the Caucasian population, while virtually absent in in the Black population of South 
Africa (Scholtz et al. 2002) and reported to be underrepresented in Sub-Saharan Africa 
(Bauduer and Lacombe 2005). The frequency of the MTHFR 677 T-allele was approximately 
7% in South African patients of Indian descent correlating with an increased risk for coronary 
artery disease (Ramkaran et al. 2015). Significant population differences were also reported for 
SNPs analysed in the FII, FVL and HFE genes (Hira et al. 2003; de Villiers et al. 1999), while 
the risk implications of the APOE polymorphism found to be the same or higher in non-
Caucasian populations may be different in Africans (Luckhoff et al. 2015). The strength of this 
study however lies in the description of the added value of facilitating the clinical application of 
the CVD multi-gene risk assay in patients with breast cancer to concurrently assess risk for 
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relevant comorbidities with a particular emphasis on metabolic syndrome and vascular risk. In 
addition, this study was conducted in an uncontrolled research setting, which limited the 
potential for pre-selection of a specific disease phenotype.  
In this study we demonstrated the potential value of the CVD multi-gene assay positioned 
alongside the assessment of relevant non-genetic data to guide clinical and therapeutic decision 
making across diagnostic boundaries. A multi-disciplinary approach to chronic disease risk 
management could assist clinicians in the development and timely implementation of 
personalized lifestyle-based intervention strategies aimed at decreasing cumulative cardio-
metabolic risk in patients with or at risk for breast cancer. In addition to its added value in the 
context of chronic disease risk screening, the clinical application of our PSGT approach could 
also assist clinicians in the identification of patients set to derive optimal benefit from extended 
genetic testing including BRCA screening and ultimately whole genome sequencing in 
genetically uncharacterised patients or those experiencing drug side effects or failure. A 
genomic solution is provided to facilitate the lowering of cumulative risk and at the same time 
identify the need for further analysis beyond the limitations of the CVD multi-gene assay.  
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5.5. PHASE III RESULTS  
WES was performed in a total of three breast cancer patients and three controls selected for 
comparison, using the newly developed exome prescreen algorithm (EPA) as illustrated in 
Figure 5.14.  
 
 
 
 
 
 
 
 
 
Figure 5.14. Outline of PSGT utilizing an open-innovation platform in order to facilitate targeted 
treatment as well as identify genetically uncharacterized patients eligible for whole exome 
sequencing. Adapted with permission from Kotze et al. (2015).  
  
5.5.1. Discordance between Exome variant calling using different reference genomes 
Filtering of variants on the minimum phred quality score and coverage resulted in a discordance 
rate of >20% in the index case (Figure 5.15) and unrelated breast cancer patient and controls 
(Table 5.15). Alignment of the exome sequence reads to hg19 resulted in many more variants 
detected compared to the MARS.  
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Figure 5.15. Venn diagram depicting the discordance between variants (filtered on a Q score of 
50 and coverage of 100x) detected with read alignment to hg19 (53 743 in total) compared to 
CEU-MARS (79 153 in total), using low-stringency variant call settings.   
 
Table 5.11. Comparison of variants obtained using hg19 versus the MARS in the unrelated 
breast cancer patients and three controls.  
Exome 
hg19      
variants 
MARS    
variants 
Overlapping    
variants 
Discordance 
Unrelated patient  20 153 15 383 11 795 24% 
Control 1 (1908) 21 676 16 569 12 437 24% 
Control 2 (2550) 22 571 17 855 13 057 21% 
Control 3 (3711) 20 632 16 142 12 264 22% 
 
 
5.5.2. BRCA1 and BRCA2 mutation screening 
Evaluation of WES results obtained for the BRCA1 and BRCA2 genes in the index patient with 
familial breast cancer and the unrelated patient with sporadic TNBC confirmed the absence of 
three high-penetrance founder mutations responsible for more than 80% of BRCA mutations in 
the Afrikaner population of South Africa: BRCA1 1493delC, BRCA1 2760G>T (p.Glu881X) and 
BRCA2 8162delG (Reeves et al. 2004; Van der Merwe and van Rensburg 2009). In addition, 
three Ashkenazi Jewish founder mutations (BRCA1 185delAG, BRCA1 5382insC and BRCA2 
6174delT) as well  as a recently described mutation (BRCA2 5999del4)  found to be more 
common in patients of Xhosa and Mixed Ancestry in the Western Cape region of South Africa 
were not detected in these two patients.  
  
15 171         
variants 
19 351       
variants 
7 848        
variants 
MARS HG19 
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Fifteen BRCA1 and nine BRCA2 SNPs were previously identified in the index patient at a 
commercial laboratory that performed targeted gene sequencing for familial breast cancer 
combined with multiplex ligation dependent probe amplification (MLPA) to detect deletions and 
insertions in BRCA1 and 2 genes (NewGene, UK). These included a BRCA2 missense variant 
(rs144848) with a minor allele frequency (MAF) of 0.25 identified in the index patient, but not in 
her mother nor in the unrelated breast cancer patient. This SNP was predicted to have no 
deleterious or damaging effect on the resulting protein according to PROVEAN and SIFT. 
Another BRCA1 SNP (rs799917) (MAF=0.46) identified in this patient was predicted to have no 
deleterious or damaging effect on the protein function, according to PROVEAN and SIFT. One 
of the BRCA1 polymorphisms (rs16941) (MAF=0.34) was predicted to have a potentially 
deleterious/damaging effect on the resulting protein according to PROVEAN and SIFT. This 
prediction however did not correspond with the result of Clinvar. An additional SNP in the 
BRCA1 gene (rs1799966) (MAF=0.36) was predicted to be benign using Clinvar and 
PROVEAN, while predicted to be potentially damaging by SIFT. These two single nucleotide 
polymorphisms were not identified in the mother of the index patient simultaneously subjected to 
WES. Seven BRCA1 and four BRCA2 SNPs were identified in the unrelated TNBC patient, 
including the aforementioned BRCA1 variants rs16941, rs799917 and rs1799966. The 
remaining BRCA1/2 variants identified by WES were predicted to be neutral by all three 
analytical prediction tools used. Table 5.12 lists the BRCA1 and BRCA2 variants detected by 
WES aligned to the MARS in the unrelated breast cancer patient and indicates which variants 
are shared with the family. 
 
Table 5.12. BRCA variants identified in the triple negative breast cancer patient, using WES aligned 
to the MARS 
Chr position rs number 
Ref/ 
alternate 
allele 
Gene 
Clinical 
significance 
(NCBI 
Clinvar) 
Function 
prediction 
(PROVEAN) 
Function 
prediction 
(SIFT) 
17: 41223094*** rs1799966 T,C BRCA1 
Benign/ 
conflicting 
Neutral Damaging 
17: 41234470 rs1060915 A,G BRCA1 Benign Neutral Tolerated 
17: 41244000*** rs16942 T,C BRCA1 Benign Neutral Tolerated 
17: 41244435*** rs16941 T,C BRCA1 Benign Deleterious Damaging 
17: 41244936** rs799917 G,A BRCA1 Benign Neutral Tolerated 
17: 41245237** rs16940 A,G BRCA1 Benign Neutral Tolerated 
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17: 41245466 rs1799949 G,A BRCA1 Benign Neutral Tolerated 
13: 32911888 rs1801406 A,G BRCA2 Benign Neutral Tolerated 
13: 32912299 rs543304 T,C BRCA2 Benign Neutral Tolerated 
13: 32913184 .-- A,G BRCA2 -- Neutral Tolerated 
13: 32915005 rs206076 G,C BRCA2 Likely Benign Neutral Tolerated 
13: 32906729* rs144848 A,C BRCA2 Benign Neutral Tolerated 
* SNP present only in index patient;                                                                                                                      
** SNP present in both the index patient and unrelated breast cancer patient                                                       
*** SNP present in all three breast cancer patients 
 
 
Using the Integrative Genome Viewer (IGV) software tool for visualization of the exome-
sequenced data, we observed high coverage along the exomes of the BRCA1 and 2 genes 
(Figures 5.16 and 5.17). 
 
Figure 5.16. Snapshot of coverage of the BRCA1 gene for the three exomes using the 
Integrative Genome Viewer (IGV). 
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Figure 5.17. Snapshot of coverage of the BRCA2 gene for the three exomes using the 
Integrative Genome Viewer (IGV). 
 
5.5.3. Comprehensive cancer panel screen using WES 
Subsequent to searching for mutations in the BRCA1/2 genes using WES to determine the 
performance of the WES platform used in comparison with targeted BRCA1/2 sequencing 
previously performed in the index case, we shifted our focus to identification of rare variants of 
high-intermediate penetrance. This was followed by evaluation of common low-penetrance 
mutations involved in DNA mismatch repair as potential pharmacogenetic targets.  
The analysis of variants included in the Ion AmpliSeq™ Comprehensive Cancer Panel (filtered 
on a coverage of 100x and phred score of 50) identified nineteen variants in the index patient, 
five of which were shared with her mother. Compared to the sequence quality of the index 
patient (minimum phred score and coverage of 548 and 291, respectively), her mother’s 
minimum phred score and coverage (28 and 16, respectively) for shared variants were 
substantially lower. This low coverage and quality scores prompted use of the integrative 
genomics viewer (IGV) software tool for confirmation of the variants detected by WES. 
Subsequent to viewing the index patient and her mother’s BAM files [binary version of a SAM 
(Sequence Alignment/Map) file] in IGV for investigation of the gene variants, we selected 7 
apparently true variants for further analysis.  
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These 7 gene variants include two PDE4DIP variants (rs11295415 and rs11268079), MYH9 
(chr22:36717864), MUC1 (chr1:155160668), two IGF2R variants (chr6:160471661 and 
chr6:160471662) and RAD50 (rs139372231) (Table 5.11). The RAD50 missense mutation 
(rs139372231) (MAF=<0.001) (http://exac.broadinstitute.org/variant/5-131924480-C-T) was 
documented as an intermediate-risk variant for breast cancer. IGV confirmed heterozygosity of 
RAD50 rs139372231 in the family but not in the unrelated breast cancer patient and 3 controls.  
Using IGV, a few variants including PDE4DIP (chr1: 144873963), EPHA (chr6: 94120780) and 
KMT2D (chr12: 49444818) were confirmed to be false positives. These as well as other gene 
variants appeared to be either artifacts, or not associated specifically with breast cancer based 
on a comprehensive literature search. They were therefore excluded from extended analysis 
and verification using Sanger sequencing/ Taqman genotyping. 
Stellenbosch University  https://scholar.sun.ac.za
  126 
Table 5.13. Comparison of potential causative variants identified with WES using the MARS subsequent to PSGT in the index 
patient and her mother diagnosed with breast cancer 
Chr: pos Rs number 
Gene 
name 
Ref/  
Alt 
allele 
Patients 
Index 
patient 
Genotype 
Mother 
Genotype 
Index 
patient 
Coverage 
Mother 
Coverage 
Variant function 
1:144873963 . PDE4DIP T,C Both Wildtype Wildtype 1010 38 Missense 
1:144917827 rs11295415 PDE4DIP CA,C Both Hetero Hetero 291 63 frameshift-deletion 
1:144923823 rs11268079 PDE4DIP **,T Both Homo Homo 503 47 Splicing 
1:155160668 . MUC1 G,C Daughter Hetero  248  Missense 
1:179077247 . ABL2 G,A Daughter Hetero  144  Missense 
3:142224045 . ATR CTTT,C Daughter Hetero  161  
nonframeshift-
deletion 
4:62812800 . LPHN3 A,T Daughter Hetero  120  Missense 
5:112176324 . APC GA,G Daughter Hetero  300  frameshift-deletion 
5:131924480 rs139372231 RAD50 C,T Both Hetero Hetero 359 16 Missense 
6:94120780 . EPHA A,G Daughter Wildtype  194  Missense 
6:160471661 . IGF2R C,G Daughter Hetero  574  Missense 
6:160471662 . IGF2R T,A Daughter Hetero  573  Missense 
7:91652178 rs10644111 AKAP9 A,AAAC Daughter Hetero  157  
nonframeshift-
insertion 
7:126086302 . GRM8 C,T Daughter Hetero  240  Missense 
12:49437499 rs186948725 KMT2D G,A Daughter Hetero  337  Missense 
12:49444818 . KMT2D A,G Daughter Wildtype  380  missense 
20:41514485 . PTPRT G,C Daughter Hetero  222  missense 
22:36717864 . MYH9 C,T Both Hetero Hetero 593 80 
synonymous, 
splicing 
x:70586328 . TAF1 A,G Daughter Homo  106  missense 
**TAGGAAGAAACGGCA 
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Due to the important associations found with SNPs involved in the folate-methylation pathway in 
phase II of this study, we shifting our focus to common variants implicated in the DNA mismatch 
repair that could serve as potential pharmacogenetics treatment targets. Two functional 
polymorphisms in the methionine synthase (MTR) and methionine synthase reductase (MTRR) 
genes included in the Comprehensive Cancer Panel, previously shown to be involved in the 
folate-homocysteine-methylation pathway, were identified in the three breast cancer patients 
(Table 5.14).  
 
Table 5.14. Comparison of genotypes resulting from WES (aligned to MARS) selected for 
investigation and validation by Sanger sequencing/ Taqman genotyping in the three breast cancer 
patients included in this study. Amino acid positions are noted according to ExAC Browser and 
PROVEAN. 
rs number/ 
chr pos. 
Gene 
WES 
Genotypes 
(a/b) 
WES 
Genotypes 
(c) 
Variant 
effect 
Amino 
acid 
change 
Sanger 
sequencing/ 
TaqMan 
genotyping 
PROVEAN/ 
SIFT 
prediction 
Rare variants 
rs139372231 RAD50 
Hetero/ 
Hetero 
Wild type Missense R385C Confirmed 
Neutral/ 
damaging 
22:36717864 MYH9 
Hetero/  
Hetero 
Wild type 
Splice 
region 
G236G Confirmed 
Neutral/ 
tolerant 
1:155160668 MUC1 
Hetero/         
-- 
Wild type Missense Q67E Confirmed 
Probably 
damaging/ 
Deleterious 
6:160471661 IGF2R 
Hetero/         
-- 
Wild type Missense L981V 
Not 
confirmed 
Neutral/ 
damaging 
6:160471662 IGF2R 
Hetero/         
-- 
Wild type Missense L891H 
Not 
confirmed 
Deleterious/ 
damaging 
Common variants  
rs1130409 APEX1 
Homo TT/ 
Homo TT 
Homo GG Missense D148E Confirmed 
Neutral/ 
tolerant 
rs1805087 MTR 
Wild type/ 
Hetero 
Hetero Missense D919G Confirmed No record 
rs1081394 MTRR 
Hetero/ 
Hetero 
Homo Missense I22M  Confirmed No record 
a= index patient, b= mother, c= unrelated breast cancer patient 
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MTR 2756 A>C (rs1805087) (MAF=0.22) was detected with the use of both the MARS and 
hg19 whereas MTRR 66 A>G (rs1081394) (MAF=0.36) was detected with hg19 and not with the 
MARS. A more frequently occurring SNP in the Apurinic endonuclease 1 (APEX1) gene 
(rs1130409) (MAF=0.37) in the family and not in the unrelated breast cancer patient. This 
variant was detected with use of the MARS but not with alignment of the sequence reads to the 
hg19 reference genome. 
 
5.5.4. Verification of gene variants identified using WES 
WES identified an intermediate-risk variant (frequency <0.001) in the RAD50 gene 
(rs139372231), shared by both the index patient and her daughter, and a rare variant in the 
MUC1 gene (Q67E). Heterozygosity for RAD50 rs139372231 and MUC1 Q67E detected in the 
family was confirmed by allele-specific Taqman genotyping. Although this variant was absent in 
an additional 456 individuals (160 patients and 296 controls) selected from a genomics 
database resource, one control individual (36 year female) with the same rare variant was 
identified using TaqMan genotyping.  
Extended family screening for the same variant excluded the RAD50 variant in a cousin 
diagnosed with breast cancer at the age of 43 years. Figure 5.15 illustrates the clinical, 
histopathological and genetic heterogeneity in the family of the index patient. 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  129 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18. Pedigree of family selected for exome sequencing, depicting the clinical (age of 
onset), pathology (cancer subtypes) and genetic (gene variation including 2 SNPs from the CVD 
multi-gene assay) heterogeneity in the family. Wt = homozygous for the common allele, Het = 
heterozygous, Hom = homozygous for the rare allele. 
 
Assessment of allelic combinations of MTHFR 677 C>T, MTHFR 1298 A>C, MTR 2756 A>G 
and MTRR 66 A>G revealed that the TAGG combination is significantly associated with ER-
positive breast cancer (p=0.034), after adjustment for age, ethnicity and BMI (Table 5.15). The 
effect of MTHFR 677 C>T, MTHFR 1298 A>C, MTR 2756 A>G and MTRR 66 A>G TAGG allelic 
combinations are depicted in a barplot which compares breast cancer patients stratified by ER 
status with respect possibly carrying and not carrying the TAGG genotype (Figure 5.15). 
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Figure 5.19.  Effect of MTHFR 677 C>T, MTHFR 1298 A>C, MTR 2756 A>G and MTRR 66 
A>G TAGG allelic combinations.  Barplot comparing ER-negative and ER-positive breast cancer 
patients with respect to not carrying and possibly carrying the TAGG genotype. 
Table 5.15. P-values for genotype distribution and additive allelic differences in 
ER status. 
 Genotype Additive allelic 
Genotype 
Unadjusted 
Ethnicity-
adjusted 
Unadjusted 
Ethnicity-
adjusted 
MTHFR 677 C>T 0.644 0.747 0.570 0.904 
MTHFR 1298 A>C 0.529 0.567 0.892 0.987 
MTR 2756 A>G 0.259 0.333 0.348 0.391 
MTRR 66 A>G 0.524 0.530 0.380 0.318 
4 SNPs CAAA   0.273 0.205 
4 SNPs CAAG   0.236 0.304 
4 SNPs CAGA   0.416 0.506 
4 SNPs CAGG   0.554 0.638 
4 SNPs CCAA   0.379 0.544 
4 SNPs CCAG   0.807 0.828 
4 SNPs CCGA   0.719 0.702 
4 SNPs CCGG   0.122 0.150 
4 SNPs TAAA   0.930 0.801 
4 SNPs TAAG   0.854 0.525 
4 SNPs TAGA   0.053 0.095 
4 SNPs TAGG   0.019 0.034 
4 SNPs TCAA   0.163 0.165 
4 SNPs TCAG   0.174 0.132 
4 SNPs TCGG   0.333 0.435 
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5.6. PHASE III DISCUSSION 
The aim of the study was to identify potential causative gene variants in three genetically 
uncharacterised breast cancer patients from two unrelated families in a comparative study of the 
publicly-available hg19 and the ethnically concordant MARS. The newly-developed EPA for 
breast cancer was used to identify genetically uncharacterised patients for extended mutation 
analysis after exclusion of genetic risk factors that could explain or contribute significantly to the 
disease profile. These include obesity in patients without a family history of breast cancer and 
high-penetrance BRCA mutations in patients with early-onset breast cancer, in order to identify 
the cause for breast cancer in the selected genetically uncharacterised patients. Confirmation of 
presence or absence of gene variants included in the EPA contributed to the analytical 
validation of the sequencing platform used for WES in this study, as confirmed with use of both 
hg19 and the MARS.  
 
5.6.1. Discordance between exome variant calling using different reference genomes  
Variant calling using both hg19 and the MARS following WES performed in DNA samples of the 
three patients and three population-matched controls, revealed >20% discrepancy in the 
number of gene variants identified in the same samples. Alignment of sequence reads to hg19 
resulted in a substantially higher number of variants detected with the exomes of the study 
participants, most likely false-positives due to the presence of minor alleles in hg19.  This 
incorrect designation of minor alleles may adversely affect the sequence read alignment as well 
as subsequent variant calling used in WES. The result is that in individuals who possess two 
copies of the minor allele contained in the reference genome, the gene variant at that locus will 
not be detected by variant calling and the opportunity for interpretation of clinical relevance will 
therefore be missed. Homozygotes for incorrectly designated minor alleles would furthermore 
be reported as potential disease-associated variants at such loci. This highlights the importance 
and supports the development of a catalog of clinically annotated variants (SNP knowledge 
database) (Kotze et al. 2014) as a vital component of the PSGT platform containing information 
extracted from the literature on the risk allele and disease associations previously replicated in 
different populations (Kotze et al. 2015). A relatively new resource released in 2004 is The 
Catalogue of Somatic Mutations in Cancer (COSMIC) which is currently the most 
comprehensive global resource on somatic mutations in human cancers. Full curation of the 
scientific literature for genes known to be involved in cancer, as defined in the Cancer Gene 
Census (Futreal et al. 2004), improved the clinical usefulness of published somatic mutation 
data and has been further extended to include tumour resequencing results from the Cancer 
Genome Project (CGP) at the Wellcome Trust Sanger Institute. Results from meta-analyses are 
also freely available and accessible online from databases including the Single Nucleotide 
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Polymorphism Database of the National Centre for Biotechnology Information 
(www.ncbi.nlm.nih.gov/SNP), SNPedia that gathers information from PubMed on a daily basis to 
support genome annotation and interpretation (http://www.snpedia.com/index.php/SNPedia) 
and ExAC Browser (Beta)/ Genome Aggregation Consortium (http://exac.broadinstitute.org/) 
who aggregate and match exome sequencing data from various large-scale sequencing 
projects including 1000 Genomes, The Cancer Genome Atlas (TCGA) and many more.  
 
5.6.2.  BRCA1 and BRCA2 mutation screening 
BRCA1 plays a pivotal role in maintaining genomic stability and acts as a tumour suppressor. It 
is a versatile protein that interacts with DNA damage sensing proteins, DNA damage response 
effectors and cell cycle regulators. It therefore functions in multiple DNA repair pathways 
including homologous recombination, single-strand annealing and non-homologous end joining 
as well as in cell cycle checkpoint regulation (Dever et al. 2012; Roy et al. 2012; Medema and 
Macůrek 2012). Numerous BRCA1 and BRCA2 polymorphisms have been reported to confer 
small increased risk to various types of cancer. A BRCA2 SNP (rs144848) identified in the index 
patient was reported to confer a 1.31x increased risk (CI: 1.07-1.61) for breast cancer (Healey 
et al. 2000). Furthermore, a BRCA1 SNP (rs799917) identified in this index patient was 
previously shown to impact the interaction between BRCA1 messenger RNA (mRNA) and miR-
638 (Nicoloso et al. 2010) and has recently been associated with increased risk of esophageal 
cancer (Zhang et al. 2013). This SNP as well as two other BRCA1 SNPS (rs16941 and 
rs1799966) also identified in the unrelated TNBC patient without a positive family history were 
shown to interact with environmental factors (obesity, smoking, alcohol) to increase risk for 
esophageal cancer (Nicoloso et al. 2010) and postmenopausal breast cancer (Figueiredo et al. 
2011; Ricks-Santi et al. 2013). WES showed 100% concordance with the results of a BRCA1/2 
full gene screen performed in the index patient, suggesting that this relatively new technology 
may be sufficient in detecting variants in the BRCA1/2 genes. Given the increasing availability 
and decreasing cost of NGS, this technology may in the very near future replace limited BRCA1 
and BRCA2 mutation screening in eligible patients, to provide a valuable healthcare resource 
for disease diagnosis and characterization over the course of an individual’s lifespan. Yeo et al. 
(2014) compared the performance of the Ion Torrent platform using different versions of the 
Torrent Suite (TS) software for detection of indels in the BRCA1 and 2 genes in 17 breast 
cancer patients. They contended that although older software versions have generated many 
false-positive calls in detecting insertions and deletions which potentially hindered its clinical 
utility, new versions of the TS have shown improvements in indel calling sensitivity and 
specificity. Despite The Genome Analysis Toolkit (GATK) and The Sequence Alignment/Map 
format (SAM)-tools’s superior sensitivity over the TS, proper computational indel calling analysis 
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is able to maximize the sensitivity and specificity at the single base level, which will enable 
future application of this technology in clinical genetic testing.  
 
15.6.3. Comprehensive cancer panel screen in familial breast cancer 
Variable penetrance of breast cancer as demonstrated by Kotze et al. (2005) in a relatively large 
South African family with the founder BRCA1 mutation E881X supports the view that other 
genetic and/or environmental factors may modify breast cancer risk not only in the general 
population, but also in familial cases (King et al. 2003). High penetrance breast cancer 
susceptibility genes account for up to 50% of familial breast cancer risk (Miki et al. 1994; Zhong 
et al. 2013). RAD50 has been documented as an intermediate-risk gene for breast cancer 
susceptibility allele, attributable to its critical role in the aberrant repair of DNA double strand 
breaks (Damiola et al. 2014).  
The RAD50 variant (rs139372231) is a C>T base change detected at nucleotide position 1153 
that results in an amino acid change from Arginine to Cysteine at position 385. The RAD50 
protein forms a complex with the MRE11 and NBN proteins and binds to strands of damaged 
DNA, holding broken ends together during the repair process. The RAD50/MRE11A/NBN 
protein complex work together to mend damaged strands of DNA, thereby preventing the 
accumulation of DNA damage that may trigger uncontrollable cellular division. This complex 
therefore aids maintenance of genetic information stability (Heikkinen et al. 2006). In addition, 
the RAD50/MRE11A/NBN complex interacts with the protein encoded by the ataxia 
telangiectasia mutated ATM gene, which plays an essential role in recognizing broken strands 
of DNA and coordinating their repair (Deshpande et al. 2014). Kinoshita et al. (2015) suggested 
that MRE11 is important in maintaining the structural arrangement of RAD50 in this protein 
complex.  Mutations in the RAD50 gene lead to the production of an abnormally small, non-
functional or missing RAD50 protein which results in the inability to respond effectively to DNA 
damage (Bartkova et al. 2008). Dai et al. (2014) demonstrated that RAD50 and inositol 
polyphosphate 4-phosphatase B (INPP4B) expression levels have a synergistic influence on 
breast cancer survival, possibly through their effects on treatment response. INPP4B has been 
identified as a tumour suppressor mutated in various epithelial cancers by inhibiting PI3K/Akt 
signaling. However recently, tumour-promoting features of INPP4B in leukemia and breast 
cancer have been uncovered. Due to the combined effect reported between INPP4B and 
various DNA repair genes including RAD50 (Ip et al. 2015; Kofuji et al. 2015; Dai et al. 2015), 
we have investigated and excluded co-inheritance of deleterious mutations in the family. 
RAD50 rs139372231 was scored as being benign by PolyPhen-2 and PROVEAN. In contrast, 
this variant was predicted to have a potentially damaging effect by the SIFT algorithm. RAD50 
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rs139372231 detected in our exome-sequenced family has previously only been found in 
African, South Asian and European (Non-Finnish) populations (http://exac.broadinstitute.org/). 
Other, more common RAD50 gene variants have however been detected in Swedish, 
Norwegian, Finnish and Icelandic populations (Heikkinen et al. 2006; Heikkinen et al. 2003). To 
date, a splicing mutation in the RAD50 gene (IVS3-1G>A) leading to a translational frameshift 
as well as a deletion Finnish founder mutation (RAD50 687delT) not present in the other Nordic 
cohorts was identified by Heikkinen et al. (2003). In this study, the authors concluded that their 
findings support an effect for RAD50 and NBS1 haploinsufficiency on genomic integrity and 
susceptibility to breast as well as ovarian cancer. Tommiska et al. (2006) screened 435 
European and 46 Finnish familial breast cancer cases and concluded that RAD50 mutations are 
rare in familial breast cancer and contribute a negligible amount to overall genetic risk for 
cancer. The authors contended that RAD50 only provides a very minor contribution to familial 
breast cancer predisposition in UK and Finland. Dai et al. (2015) found that RAD50 and INPP4B 
expression levels have a synergistic influence on breast cancer survival, possibly through their 
effects on treatment response. Abuzeid et al. (2009) suggested that the use of targeted RAD50 
disruption could be a novel chemo-sensitizing approach for cancer therapy in the context of 
chemo-resistance. This strategy could be applicable to several types of cancers that 
demonstrate chemo-resistance and may exert a positively influence on breast cancer treatment 
leading to improved therapeutic outcomes. Heterozygosity for RAD50 rs13937223 identified in 
the index patient and her mother was verified by IGV and TaqMan genotyping of their DNA 
samples. Although this variant was detected in one of 456 unrelated individuals screened, and 
shown to be absent in a cousin of the index patient’ mother, it may express a deleterious effect 
against a background of risk conferred by variation in the MTHFR, MTR and MTRR genes 
shown to be associated with ER status (phase II of this study). Functional polymorphisms in 
these genes underlying dysfunction of the folate-methylation pathway confers risk at the 
population level (Choi and Mason 2002; Macis et al. 2007; Maruti et al. 2009; Peerbooms et al. 
2011; Wu et al. 2013; Weiwei et al. 2014; Kakkoura et al. 2015). 
The difference in tumour subtypes between the index case and her mother - albeit the same 
MTHFR rs1801133 genotype associated with the luminal B subtype (Naushad et al. 2011) - 
prompted the search for gene variants which may be responsible for their discrepant HER2 
statuses. Two HER2 variants previously studied in relation to breast (rs1136201) (AbdRaboh et 
al. 2013) and endometrial cancer risk (rs1810132) (Tong et al. 2009) were identified in the index 
patient but not in her mother, nor the unrelated breast cancer patient. Three variants in the 
MUC1 and IGF2R genes previously associated with HER2 were identified in the daughter but 
not in her mother, as was confirmed with the use of Sanger sequencing for MUC1. MUC1 is a 
heterodimeric oncoprotein that associates with HER2 at the surface of breast cancer cells (Li et 
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al. 2003; Kufe et al. 2013). This gene has been documented as a moderate penetrance gene in 
the development of breast cancer (Siroy et al. 2013; Raina et al. 2014). Raina et al. (2014) 
suggested that, in carcinoma cells with sustained activation of the epithelial-mesenchymal 
transition, the MUC1-C protein is positioned to interact with the HER2 complex and promote 
activation of the HER2 pathway in HER2-overexpressing breast cancer cells, thereby promoting 
their growth and clonogenic survival. Rakha et al. (2005) assessed the prognostic value of 
several mucins in 1447 cases of invasive breast carcinoma. They concluded that most breast 
cancers express MUC1, MUC3 and MUC4 and that MUC1 and MUC3 in particular are potential 
prognostic indicators, with MUC1 having the strongest relationship with patient outcome. Kufe 
and Kharbanda (2014) have shown that MUC1 peptide therapy can be used successfully in 
conjunction with an anti-HER2 agent such as trastuzumab to render resistant cells sensitive to 
treatment. Kufe and Kharbanda (2014) have shown that MUCl peptide therapy can be used 
successfully in conjunction with anti-HER2 trastuzamab to render resistant cells sensitive to 
treatment. Moreover, Mountzios et al. (2014) evaluated the prognostic significance of 
components of the insulin-like growth factor (IGFR) pathway across different breast cancer 
subtypes and found that aberrant expression of important components of the IGF1R-
alpha/IGF2R complex are associated with better clinical outcomes in patients with hormone-
receptor positive, HER2-negative, node-positive early-onset breast cancer. They concluded that 
their results support the important interplay between the IGFR pathway and hormone receptors 
and suggest their potential role as molecular targets for therapeutic intervention in hormone-
receptor positive disease.  
The genetic heterogeneity detected in the family is compatible with a disturbance in the folate 
pathway which has been documented as one of the three most important mechanisms in the 
pathogenesis of cancer (Wishart 2015). The presence of RAD50 rs139372231 in combination 
with MTHFR rs1801133 as a BRCA-modifier gene (Pepe et al. 2007) as well as other risk-
contributing SNPs is consistent with an intermediate risk profile as reflected by the family 
history. According to several authors (Antoniou et al. 2008; Pharoah et al. 2008, Ricks-Santi et 
al. 2013), the overall importance of polymorphisms remains high due to their effect which 
appears to be multiplicative, such that individuals possessing several polymorphisms may have 
a significantly increased risk of breast cancer. Gene-gene interaction between RAD50 
rs139372231 and other gene variants implicated in a dysfunctional folate pathway such as 
MTHFR rs1801133, methionine synthase MTR (rs1805087) and methionine synthase reductase 
(MTRR) (rs1081394) may, as Bodmer and Tomlinson (2010) suggested, be sufficient in 
accounting for the breast cancer in the index case and her mother. Extended mutation 
screening of the mother’s cousin diagnosed with breast cancer at the age of 53 years, excluded 
the presence of RAD50 rs139372231, although she was heterozygous for MTHFR 677 C>T,  
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MTR 2756 A>G and MTRR 66 A>G. In the unrelated TNBC patient without a family history of 
cancer, neither the RAD50 R385C nor MTHFR rs1801133 were identified. 
 
5.6.4. Analysis of low penetrance variants implicated in DNA mismatch repair 
Cancer development may involve three types of gene families: tumour suppressor genes such 
as BRCA1/2, proto-oncogenes including HER2 routinely assessed in all breast cancer patients, 
and stability genes responsible for DNA repair. When stability genes such as MTHFR are 
affected by functional polymorphisms, mutations may occur at significantly higher rates in other 
genes involved in a wide spectrum of diseases. MTHFR, MTR and MTRR are involved in the 
folate pathway essential for DNA repair and methylation. Functional variants in the MTHFR 
gene resulting in reduced enzyme activity have been shown to cause alterations in 
chromosomal recombination and abnormal chromosome segregation (Friso et al. 2002). It has 
been found in many studies that common SNPs in the MTHFR gene are involved in 
chromosomal nondisjunction and linked to an increasing risk of trisomy 21  (Hobbs et al. 2000), 
as well as other chromosomal aneuploidy (Hassold et al. 2001, Oliveira et al. 2008). The 
OncoScan™ microarray for analysis of copy number and somatic mutations in cancer could be 
used to confirm the diagnosis of malignant melanoma, stratify the risk of recurrence and direct 
pharmacologic interventions (Chandler et al. 2012). Sangrajrang et al. (2010) reported an 
association between MTR and MTRR and breast cancer risk in a study performed in 1067 
individuals. Variation in these genes may therefore disrupt folate homeostasis and confer 
significant risk of breast cancer, attributable to impaired DNA repair associated with the 
epigenetic process of DNA methylation (Macis et al. 2007; Weiwei et al. 2014). To avoid the 
accumulation of DNA damage induced by environmental stimulants (e.g. alcohol, smoking, 
chemical agents and high dietary fat intake), cells have developed precise and effective DNA 
repair systems (Zhang et al. 2011). Base excision repair (BER) is the major DNA repair pathway 
(Wilson et al. 2011) which recognizes and repairs base modifications and single strand breaks 
(SSB) (Maynard et al. 2009). BER involves four steps including (1) base lesion recognition, 
excision, and cleavage of an aberrant site; (2) terminal-processing of SSB ends to generate 3’ 
hydroxyl (OH)/5’ phosphate group ends; (3) gap-filling after lesion excision; and finally (4) nick 
sealing by DNA ligases (Hegde et al. 2012).  
APEX1 is one of three key enzymes responsible for the incision of the apurinic/apyrimidinic sites 
and the generation of 3’-OH termini (Tell et al. 2010). APEX1 is a multi-functional enzyme that 
exhibits DNA repair activity and plays a role in the reductive activation of many transcription 
factors which are involved in various cellular processes such as cell survival, growth signalling 
and inflammatory pathways (Gaiddon et al. 1999; Bapat et a. 2008; Tell et al. 2010). According 
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to dbSNP in NCBI, APEX1 rs1130409 results in a T>G change and an amino acid change from 
Asp to Glu at position 148. However, studies of the prevalence of this variant in different 
populations indicate that the minor allele in Caucasian is in fact the T-allele and not the G-allele 
as in other population groups. Exome sequence-alignment to the ethnically concordant MARS 
correctly unmasked this variant in the Caucasian family where both mother and daughter are 
homozygous for the T-allele, whereas it was missed by the ethnically ignorant hg19. Although a 
very commonly occurring polymorphism (MAF=0.36), and despite the fact function prediction 
using bioinformatics tools was negative, the deleterious effect of the APEX1 variant has been 
proven by an in vitro study performed by Hu et al. (2001). In addition, APEX1 has been 
documented as an emerging therapeutic target across the disease spectrum. APEX1/redox 
effector factor-1 (Ref-1) repair and redox functions are activated as a part of the DNA repair 
response to maintain cellular genomic integrity as well as regulate various transcription factors 
in cell-survival pathways. Natural plant products and phytochemicals (including soy isoflavones, 
curcumin, resveratrol, tea polyphenols and decursin) potentially modulate the expression and 
the repair/redox activities of APE1/Ref-1, thus representing a possible therapeutic intervention 
against various human diseases associated with reactive oxygen/nitrogen species (ROS/RNS)-
mediated oxidative stress, including cancer, cardiovascular and neurodegenerative disorders 
(Thakur et al. 2014). Pharmacogenetic studies have traditionally focused on genes involved in 
processes such as drug metabolism however attention is increasingly shifting to the effects of 
genetic variations in drug targets and associated pathway components on drug responses 
(Krejsa et al. 2006). 
 
5.6.5. Verification of gene variants identified using WES 
APEX1 rs1130409 was identified in the family using the MARS but not hg19, representing a 
locus of conflicting assignment of the major/minor allele using the two different reference 
genomes. In the dbSNP database, APEX1 rs1130409 is documented as a T>G change while 
studies performed in various population groups document that the T-allele is in fact the minor 
allele in Caucasians. Based on this finding it is clear that the major/minor allele status is 
population-dependent, emphasising the importance of using an ethnically concordant reference 
genome in WES. Interestingly, MTRR rs1081394 was detected using hg19 but not with the 
MARS in all three breast cancer patients studied. Differences in detection of this SNP possibly 
occurred due to differences in allocation of the minor/risk allele according to the MAF as 
previously determined in world populations. This discrepancy warranted verification by Sanger 
sequencing/ Taqman genotyping, which then confirmed the results obtained using hg19.  
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Subsequent to the identification of a large number of false-positives and false-negatives caused 
by incorrectly designated minor alleles by hg19 vs MARS, a list of potentially causative variants 
identified by WES filtered on a MAF of less than 1% and subsequently possible low-penetrance 
pharmacogenetics targets were prioritized for verification in the Pathology Research Facility 
(PRF) laboratory using Sanger sequencing. Except for MTRR rs1081394 due to the different 
allele assignment in hg19 vs MARS, sequencing results of all of the gene variants investigated 
in this study corresponded to WES genotype calls using the MARS. This high level of 
correspondence increased our confidence in using the MARS as a standard reference genome 
when applying WES in uncharacterized patients.  
The assessment of the aforementioned non-deterministic risk modifier variants across the 
diagnostic spectrum as part of a multi-gene assay has led to extended analysis in genetically 
uncharacterised patients using the PSGT approach (Kotze et al. 2015). Homozygosity for the 
MTHFR rs1801133 variant in both mother and daughter with early-onset breast cancer raised 
the question of whether or not this genotype is sufficient to confer significant disease risk in a 
synergistic/additive manner together with other intermediary risk alleles. The involvement of 
MTHFR rs1801133 in the development of breast cancer and associated comorbidities including 
depression (Delport et al. 2014), CVD and treatment-related side effects is in keeping with the 
role of MTHFR as a target for both prevention and treatment across the diagnostic boundaries. 
Although genetic variants identified by the EPA, of which some were excluded prior to WES, do 
not confer significant individual risk for breast cancer, cumulative data supported by WES 
suggests that co-inheritance of multiple low-penetrance mutations (in genes such as MTHFR, 
MTR, MTRR, APEX1) and rare variants (eg. in RAD50 gene) may explain the majority of BRCA 
mutation-unrelated familial disease (Antoniou and Easton 2006; Gracia-Aznarez et al. 2013).   
In this exploratory study, we built upon our prior experience with prospective molecular profiling 
(Grant et al. 2013, 2015). This experience has taught us that any new method or technology, 
however unlimited the potential in its respective capacity, is subject to flaws that can only be 
rectified through on-going discovery and frequently the process of trial and error. Since NGS is 
an emerging technology, there were expected and unforeseen challenges encountered during 
the course of the study. Foreseen challenges included the discordance expected between the 
use of two different reference genomes hg19 and the MARS, resulting in the detection of an 
unprecedented amount of false-positives and false-negatives. An unforeseen challenge realized 
through the course of the study was the flawed processing of variant call files which can only be 
detected with thorough evaluation of resulting variants against SNP/mutation databases, prior to 
the commencement of Sanger sequencing and genotyping for verification. Even if there are no 
technical or logical delays in NGS, the interpretation and application of this information in clinical 
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practice as confirmed in this study, is fraught with uncertainty. Not all gene variants identified by 
WES will have a deleterious effect on protein function, so the mere identification of variants - 
even when validated by Sanger sequencing - does not ascertain or guarantee clinical 
usefulness in relation to risk prediction or disease management.  
There are considerable challenges associated with the discovery and testing of rare 
predisposition alleles, many of which are illustrated by the issues associated with variants of 
unknown significance in the Mendelian cancer predisposition genes including BRCA1 and 
BRCA2. Bodmer and Tomlinson (2010) reckoned that whether or not rare variants end up filling 
the heritability gap, it is imperative to look for them alongside common variants. This study has 
demonstrated the feasibility of WES to achieve this level of comprehensive genomic testing. 
The detection of RAD50 rs139372231 in two affected members of the index family while the 
niece / cousin with ILC tested negative, and detection in only one control (out of a total of 457 
individuals screened) confirms that it is a rare variant and suggests a possible role in 
combination with other functional variants in the development of breast cancer in the studied 
family.  
Several novel variants were detected in genes described above, highlighting the genetic 
differences in South African Caucasian women and emphasising the fact that complete analysis 
of the genes, rather than looking for a few known variants, may be required to identify these 
high risk women. At loci where the major alleles of variants with potential high impact are absent 
from hg19, potential causative variants may be missed. Our findings highlight the fact that the 
presence of minor alleles relating to disease-susceptibility in hg19 should be taken into account 
during data interpretation for assessment of personal disease risk, since it is dependent on the 
identification and functional annotation of genetic variants that may be discordant or erroneous. 
In this study, the need for improvement of hg19 used as an intermediate bioinformatics step for 
data translation between the laboratory and clinic was addressed by the use of a MARS, which 
effectively reduced the number of false variants identified.  
Given that ~85% of disease-associated variants reside within exons, the remainder of variants 
in non-exonic (intronic, UTR, intergenic, etc.) regions may be missed by WES. WES however 
has the potential to accelerate the discovery of new susceptibility genes which may provide a 
means to identify novel therapeutic targets to optimize patient care based partly on the 
assessment of genetic risk factors. Nevertheless, this era of vast data generation and 
identification of novel genes, while opening new roads in cancer susceptibility, still needs to be 
treated with caution, as the gaps in knowledge highlighted in this study have indisputable 
implications for data translation in the clinical setting. Genetic counselling for novel or 
unexpected findings may present a challenge that needs to be addressed using a 
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multidisciplinary approach which incorporates all relevant information in relation to current and 
future risk in each individual. Our findings support previous WES results indicating that the 
majority of genetically uncharacterised breast cancer may be caused by a combination of low-
penetrance mutations exerting their effect against a high-risk clinical background. WES applied 
beyond the limited scope of single-gene testing has the potential to detect both known and 
novel mutations across diagnostic boundaries to facilitate prevention of cumulative risk 
underlying the development of breast cancer and associated comorbidities.  
The genomic database utilized in this study proved to be a valuable resource for validation of 
variants detected by WES as well as the interpretation of those of uncertain clinical significance. 
Its on-going development provides an important resource for health outcomes studies and 
allows for follow-up and careful monitoring of patients over time. Ultimately, it is envisioned that 
the patient database enabling extensive local research will continue to inform clinical decision 
making and optimize delivery and implementation of a comprehensive and truly individualized 
genomics-based healthcare service for breast cancer patients based on disease patterns 
relevant to the South African population. 
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This study contributed to the development of a pathology-supported genetic testing (PSGT) 
framework for whole exome sequencing (WES) beyond the limitations of single-gene BRCA 
testing in South African breast cancer patients. The cardiovascular disease (CVD) multi-gene 
assay that combines well-characterised clinically actionable single nucleotide polymorphisms 
(SNPs) in key overlapping disease pathways for multifactorial diseases in a way similar to 
founder mutations for single high-penetrance genes such as BRCA1/2, was used as part of a 
newly developed exome pre-screen algorithm (EPA) to identify genetically uncharacterised 
patients or non-responders to treatment as eligible for WES (Figure 6.1). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. The PSGT platform used to develop an exome pre-screen algorithm (EPA) for 
selection of genetically uncharacterised patients for WES. 1) Diagnostic BRCA testing is offered 
as a routine service according to standard referral guidelines (aged <40 years, bilateral breast 
cancer, additional ovarian cancer, one 1st degree relative with breast or ovarian cancer, > 2nd 
1 2 
3 
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degree affected relatives and male breast cancer in a relative) or  2) the chronic disease risk 
screen is offered to patients receiving hormone therapy, are at high risk for tumour recurrence 
(family history, BRCA1/2 positive), or are required to take potentially competing antidepressants 
or  3) combined diagnostic and pharmacogenetics testing to explain the presence of 
comorbidities or predict drug response/recurrence risk. Where extended mutation analysis of 
the entire BRCA1 and 2 genes as well as the CYP2D6 gene were unable to explain breast 
cancer or the occurrence of drug side effects/failure, WES is performed to identify potential 
novel causative genes/mutations.   
 
The lack of a clear road map to follow in navigating and interpreting vast amounts of genomic 
information generated by WES impedes the rapid translation of genomic discoveries into 
practical benefits for patients and their at-risk family members. PSGT is positioned to bridge the 
gap between massive amounts of genomic information generated by advanced technologies in 
order to achieve a high degree of concordance between genotype and phenotype. This study 
was performed in three phases, starting with single-gene CYP2D6 genotyping extended to a 
multi-gene panel for identification of cardio-metabolic risk factors as part of a screening step to 
identify genetically uncharacterized breast cancer patients eligible for WES. 
By combining diagnostic and pharmacogenetic testing of breast cancer patients using the PSGT 
approach, the occurrence of breast cancer recurrence and associated co-morbidities including 
depression, cognitive impairment and deep vein thrombosis could at least in part be explained 
by genotype. The age at diagnosis/onset of breast cancer was significantly lower in ER-negative 
than ER-positive patients after adjustment for ethnicity (p=0.022), while the presence of the 
relatively common multi-functional E4 allele of the APOE polymorphism was shown to reduce 
the mean age of disease onset by an average of 10 years regardless of ethnicity, alcohol 
consumption, current smoking or family history of cancer/BRCA mutation status (p=0.003). The 
APOE allelic effect was 9% (95% CI: 4 to 15). BMI was found to be significantly higher in ER-
positive compared to ER-negative breast cancer patients after adjustment for age, ethnicity, and 
family history of cancer/BRCA mutation status (p=0.035). In addition, BMI showed a positive 
allelic association with the relatively common low penetrance MTHFR 1298 A>C mutation 
(p=0.01). Presence of the risk-associated C-allele, previously linked to sporadic breast cancer, 
was associated with an 8% (95% CI: 3 to 14) increase in BMI. The finding of a significant 
positive association between BMI and the fat score (p=0.032) in the implementation data set as 
assessed by the medical and lifestyle questionnaire completed for this subgroup, highlights the 
fact that dietary adjustments guided partly from the genetic background may not only prevent 
obesity, but also a substantial proportion of breast cancer in the general population.   
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Based on the above findings, CYP2D6 pharmacogenetic testing, as well as APOE and MTHFR 
genotyping performed as part of an extended CVD multi-gene assay, were incorporated into the 
EPA used in this study to select genetically uncharacterized South African patients for extended 
NGS. As part of this PSGT approach, each individual was asked to complete a medical and 
lifestyle questionnaire required to interpret the genetic results in a clinical context. After 
evaluation of the EPA in each individual considered for extended genetic testing, three patients 
were selected for WES performed as part of this study: 1) two ER-positive breast cancer 
patients from the same family without mutations in the BRCA1/2 genes (familial breast cancer) 
and 2) one triple-negative breast cancer patient (TNBC) not previously screened for BRCA 
mutations due to absence of a family history of cancer (sporadic breast cancer). In accordance 
with the EPA, CYP2D6 allele 4, the APOE E4 allele and MTHFR 1298 A>C were excluded as 
possible contributory factors to disease development or medication side effects prior to WES 
performed in these patients.  Due to the significantly higher BMI observed in the ER-positive 
compared with ER-negative South African breast cancer patients studied, obesity and other 
lifestyle risk factors were also identified as important criteria evaluated as part of the EPA. In the 
patient with TNBC diagnosed with this severe disease subtype at the relatively young age of 43 
years, the BMI was within the normal range (20.4 kg/m2). In the family with inherited breast 
cancer, both the index patient (BMI of 27.5 kg/m2) and her mother (BMI 27.8 kg/m2) were 
overweight. Both breast cancer patients from the same family were homozygous for the MTHFR 
677 C>T mutation assessed as part of the EPA, while the TNBC patient tested negative for this 
low-penetrance mutation. Previous studies reported better progression-free survival in breast 
cancer patients with MTHFR 677 C>T found to be linked to the luminal-type breast cancer. This 
is in accordance with results obtained from a 70-gene microarray profile (MammaPrint) 
performed in 2007 on both tumours of the mother presenting with bilateral breast cancer. This 
patient has remained disease-free over the past 8 years despite termination of tamoxifen after 
one year of treatment due to severe side effects. WES was considered important in this family 
due to the fact that homozygosity for MTHFR 677 C>T in both the mother and daughter may not 
be sufficient to cause breast cancer in the family. Notably, human epidermal growth factor 
receptor-2 (HER2) status was negative in the mother, while her daughter’s tumour was HER2-
positive. 
The next step involved variant calling using both hg19 and the MARS following WES performed 
in DNA samples of the three patients and three population-matched controls, which revealed 
>20% discrepancy in the number of gene variants identified in the same samples. After 
exclusion of a large number of false-positives caused by minor alleles in hg19, a list of 
potentially causative variants identified by WES filtered on a minor allele frequency (MAF) of 
less than 1% were prioritized for verification in the Pathology Research Facility (PRF) laboratory 
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using Sanger sequencing. In the family with ER-positive breast cancer WES identified a rare 
missense mutation R385 in a DNA mismatch repair gene, RAD50 (rs139372231), in both the 
index patient and her mother. The RAD50 R385C missense mutation was predicted to be 
damaging by only one of the three bioinformatics prediction tools used. To help determine the 
potential clinical relevance of this rare variant in the South African population, an additional 160 
breast cancer patients and 301 female controls (101 individuals above the age of 65 years and 
200 individuals selected from the genomics database resource) were screened for RAD50 
R385C. This resulted in the identification of RAD50 R385C in one relatively young control 
individual, aged 36 years, with no family history of cancer. In an attempt to clarify the clinical 
relevance of RAD50 R385C in the index patient with familial breast cancer and her mother, a 
blood sample was obtained for mutation screening in an affected first-degree cousin as the only 
remaining affected member in this BRCA-negative family. This patient diagnosed with invasive 
lobular carcinoma (ILC) at the age of 42 years tested negative for RAD50 R385C. Notably, the 
index patient was diagnosed with invasive ductal carcinoma (IDC) at the age of 29 years, while 
her 57-year old mother had IDC in the left breast and invasive lobular carcinoma (ILC) in the 
right breast. 
Further screening for gene variants that may explain clinical heterogeneity within the index 
family revealed a rare missense mutation Q67E in the Mucin 1 gene (MUC1, chr1: 155160668), 
predicted to be damaging by all three bioinformatics tools applied. This missense mutation was 
confirmed by Sanger sequencing in the HER2-positive index case with early-onset breast 
cancer (<30 years), while absent in her HER2-negative mother with postmenopausal breast 
cancer and the cousin. Neither the RAD50 nor the MUC1 missense mutations were identified in 
the exomes of the TNBC patient and the three control individuals. This TNBC patient was 
furthermore evaluated for potentially causative mutations in the BRCA1 and BRCA2 genes 
based on tumour pathology, as TNBC is frequently associated with mutations in these high-
penetrance genes irrespective of family history. Although a high impact protein truncating 
mutation was not identified in this patient, two functional BRCA1 polymorphisms (rs16941, 
E1038G and rs1799966, S1613C) considered potential contributory factors to the disease 
profile were identified in the TNBC patient. This finding, together with confirmation of at least 10 
non-pathogenic BRCA1/2 polymorphic variants previously identified in the index case, 
confirmed that WES performed in this study on the Proton NGS apparatus generates sufficient 
coverage of the BRCA1 and BRCA2 genes to replace single gene-by-gene sequencing, 
provided that any potentially causative mutations identified are verified by Sanger sequencing 
and family screening where possible.  
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Failure to identify the rare RAD50 and MUC1 mutations identified in the index case with IDC 
also in her mother with bilateral breast cancer (only RAD50 identified) and the affected cousin 
with ILC, may reflect the clinical variability in the family. Although further studies are warranted 
to screen for causative mutations in the cousin using WES, it is noteworthy that this patient 
tested positive for one copy of the MTHFR 677 C>T mutation. Since this mutation causing 
dysfunction of the methylation pathway was detected in both mother and daughter prior to WES, 
the likelihood that MTHFR 677 C>T contributes to the disease profile in this family cannot be 
excluded. This multi-functional SNP has previously been linked to ER-positive breast cancer, 
the only clinical feature shared by all three patients with familial breast cancer, while absent in 
the TNBC patient. Extended analysis of SNPs in the folate pathway revealed the presence of 
additional functional variants in the MTR and MTRR genes in the family. Assessment of allelic 
combinations of MTHFR 677 C>T, MTHFR 1298 A>C, MTR 2756 A>G and MTRR 66 A>G 
revealed that the TAGG combination is significantly associated with ER-positive breast cancer 
(p=0.034), after adjustment for age, ethnicity and BMI. Wishart (2015) contended that many of 
the vast number of cancer genes/mutations in humans affect one-carbon metabolism as one of 
the three major metabolic pathways involved in the pathogenesis of cancer. Differences in 
detection of the MTRR SNP were also noted when the results obtained with variant calling using 
hg19 were compared with the MARS, possibly due to differences in allocation of the minor/risk 
allele according to the MAF as previously determined in world populations. Discrepancies 
between hg19 and the MARS were also noted for the D148E SNP in the DNA mismatch repair 
gene, APEX1 (rs1130409). The APEX1 T-allele confirmed in this study to be the minor allele in 
Caucasians, while it is the major allele in most other world populations studied worldwide, was 
correctly identified by the MARS but has been missed by hg19. However, the gene effect does 
not depend on the frequency of a specific allele in a population, as evidenced by the fact that 
the APEX1 G-allele has clinical relevance in patients receiving radiotherapy. 
 
6.1. Ethical considerations 
The advent of new genomic technologies has changed the way researchers approach both 
basic and translational research. Various questions have arisen due to the vast amounts of 
information generated by approaches such as exome sequencing, including how to manage, 
interpret and prioritise this information. Other questions relate to whether or not participating 
individuals should be allowed access to their sequencing information or whether it should be 
shared with insurance companies. While the best-defined risk is most insurable, it is impossible 
to cover risk that cannot be assessed. Appropriate risk classification is essential to maintain a 
viable voluntary insurance industry since all insurers make decisions based on available genetic 
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information, including family history and prior diagnostic tests performed in the applicant and 
his/her family. A common misconception is that genetic testing for breast cancer may result in 
exclusion from life insurance, however, mounting evidence is accelerating change in this regard 
and proving testing to be more beneficial (Kotze et al. 2004). 
The use of NGS technologies can lead to unexpected findings and complicate clinical utility and 
patient benefit. This area of genomics still remains a challenge and research is more frequently 
addressing these questions (Biesecker 2010). The most critical issue regarding 
commercialization of personalized medicine is the protection of patients. One of the major 
issues is the fear and potential consequences for patients who are predisposed after genetic 
testing or found to be non-responsive towards certain treatments. This includes the 
psychological effects on patients due to genetic testing results. The implications for certain 
ethnic groups and presence of a common susceptibility allele due to a founder effect also has to 
be considered (Van der Merwe and van Rensburg 2009; Reeves et al. 2004). As part of the 
PSGT strategy, the chronic disease screen including a lifestyle intervention plan is purposed to 
address these issues by providing genetic counseling as a standard of care (Kotze et al. 2005; 
Kotze et al. 2004).  
In the 36-year old breast cancer-free participant of the chronic disease risk screen in whom the 
RAD50 R385C mutation was identified, the study consent form guided decisions surrounding 
the management of WES results. The consent form states that the genetic results obtained (e.g. 
if additional WES was performed) will be made known to the individual only if results indicate 
that the study participant 1) has a particular disorder or family history relevant to the test results, 
2) have a condition or predisposition to developing a condition that is treatable or avoidable e.g. 
by a lifestyle modification, or 3) may need genetic counselling. This control individual had no 
family history of cancer and did not receive genetic counselling. This was due to the fact that we 
could not ascertain the clinical relevance of the RAD50 R385C mutation with the use of various 
bioinformatics prediction tools that indicated contradictory results.     
 
6.2. Conclusion 
A multidisciplinary approach to chronic disease risk management captures the essence of 
personalized medicine as it could assist clinicians in the development and timely implementation 
of individual lifestyle-based intervention strategies aimed at decreasing cumulative cardio-
metabolic risk in patients with or at risk for breast cancer. In this study we demonstrated the 
potential value of the CVD multi-gene assay positioned alongside the assessment of relevant 
non-genetic data such as BMI, to guide clinical and therapeutic decision making across 
diagnostic boundaries. In addition to its added value in the context of chronic disease risk 
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screening, the clinical application of our PSGT approach could also assist clinicians in the 
identification of patients set to derive optimal benefit from extended genetic testing including 
BRCA screening and ultimately WES in genetically uncharacterised patients or those 
experiencing drug side effects or failure. A genomic solution is provided to facilitate the lowering 
of cumulative risk and at the same time identify the need for further analysis beyond the 
limitations of the CVD multi-gene assay. 
The genomic database utilized in this study proved to be a valuable resource for validation of 
variants detected by WES as well as the interpretation of those of uncertain clinical significance. 
Its on-going development provides an important resource for health outcomes studies and 
allows for follow-up and careful monitoring of patients over time. Ultimately, it is envisioned that 
the patient database which enabled extensive local research to date will continue to inform 
clinical decision making and optimize delivery of a comprehensive and truly individualized 
genomics-based healthcare service for breast cancer patients based on disease patterns 
relevant to the South African population. 
WES has the potential to accelerate the discovery of new susceptibility genes which may 
provide a means to identify novel therapeutic targets to optimize patient care based partly on 
the assessment of genetic risk factors. Nevertheless, this era of vast data generation and 
identification of novel genes, while opening new roads in cancer susceptibility, still needs to be 
treated with caution, as the gaps in knowledge highlighted in this study have indisputable 
implications for data translation in the clinical setting. Genetic counselling for novel or 
unexpected findings may present a challenge that needs to be addressed using a 
multidisciplinary approach which incorporates all relevant information in relation to current and 
future risk in patients as well as their family members. Inclusion of MARS in the workflow 
effectively reduced the number of false variants identified by hg19 used as an intermediate 
bioinformatics step for data translation between the laboratory and clinic.  Our findings support 
previous WES results indicating that the majority of genetically uncharacterised breast cancer 
may be caused by a combination of low-penetrance mutations exerting their effect against a 
high-risk backdrop. WES applied beyond the limited scope of single-gene testing has the 
potential to detect both known and novel mutations across diagnostic boundaries to facilitate 
prevention of cumulative risk underlying the development of breast cancer and associated 
comorbidities. 
This study led to the development of a EPA for WES that involves 1) IHC to determine ER 
status and family history of cancer, 2) use of a clinical and lifestyle questionnaire to determine 
risk factors for CVD and other treatment-related co-morbidities, 3) selection of a gene panel 
incorporating high-penetrance founder mutations in the BRCA1 and 2 genes as well as low-
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intermediate risk alleles implicated in cancer development, recurrence risk and treatment 
response across the diagnostic spectrum. The genomics database developed as part of this 
study proved to be a valuable resource for interpretation of variants of uncertain clinical 
significance. Inclusion of MARS in the workflow effectively reduced the number of false variants 
when using hg19 as an intermediate bioinformatics step for data translation between the 
laboratory and clinic.  At loci where the major alleles of disease associated variants are absent 
from hg19, potential causative variants and functional polymorphisms may be missed. Our 
findings support previous WES results indicating that the majority of genetically uncharacterised 
familial breast cancer may be caused by a combination of low-moderate penetrance mutations 
exerting their effect in a high-risk environment such as a high BMI and suboptimal diet. WES 
enables identification of genetic risk factors of relevance to both cancer development and 
tailored therapeutic intervention in a single test. 
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APPENDIX I 
Appendix I describes the DNA extraction protocol used to extact DNA from whole blood, 
followed by the procedure for quantification of extracted DNA using the NanoDrop® ND-1000 
spectrophotometer.   
 
DNA extraction Protocol 
The QIAGEN QIAamp® DNA Blood Maxi Kit DNA extraction protocol (spin protocol) for whole 
blood: 
1. The DNA extraction procedure started with dispensing 500 µl QIAGEN Protease stock 
solution into the bottom of a 50 ml centrifuge tube. This solution contains the enzyme 
(protease) responsible for lysing or breaking up the cells, expelling their cellular 
components and releasing their DNA into the solution.  
2. 5 ml of blood sample was added to the stock solution and very briefly mixed (to create 
homogenous solution for adequate lysis), using a vortex machine.  
3. 6 ml buffer AL was added to the tube and mixed by inverting the tube 15 times, followed 
by vigorous shaking (using a vortex machine) for approximately 1 minute.  
4. The homogenized solution was incubated at 70°C in a dry block for 15 minutes. After 
incubation, 5ml ethanol (96% -100%) was added to the sample and mixed (to ensure 
binding of the lysate to the membrane) by inverting the tube 10 times followed by vigorous 
shaking.  
5. The solution was carefully transfered onto the QIAamp® Maxi column (membrane) inside 
a 50 ml centrifuge tube and was centrifuged at 3000 rpm for 3 minutes.  
6. The QIAamp® Maxi column was transferred to a clean 50 ml centrifuge tube and the 
filtrate discarded to prevent the nozzle of the QIAamp® Maxi column from being 
submerged in the filtrate (reduces the washing efficacy). 
7. 5 ml Buffer AW1 was added to the QIAamp® Maxi column and centrifuged at 5000 rpm 
for 1 minute. This step was repeated for buffer AW2 but centrifuged for 15 minutes.  
8. The QIAamp® Maxi column was placed into a clean 50 ml centrifuge tube and the 
collection tube containing the filtrate was discarded.  
9. 600 µl distilled water equilibrated to room temperature (15-25°C) was added directly onto 
the membrane of the QIAamp® Maxi column.  
10. This was incubated at room temperature for 5 minutes, followed by centrifugation at 5000 
rpm for 2 minutes.  
11. The same volume of distilled water was added and this step repeated, but centrifuged for 
5 minutes. The eluted solution now contained the newly extracted DNA.  
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Spectrophotometry 
Subsequent to switching on the instrument and selecting the Nucleic Acid analysis option, the 
instrument pedestal was cleaned and Nuclease Free Water added onto the pedestal to initialize 
the instrument. RNase Free water (2 µl) was placed on the pedestal to calibrate the instrument 
before taking any measurements. Upon completion of the blanking process, all the samples 
were measured and stored. The pedestal was cleaned between each measurement with 70% 
ethanol followed by double distilled water. The ratio absorbance reading at 230 nm, 260 nm and 
280 nm was used to assess the purity of the DNA. Purity values for all samples were within the 
accepted range (260/280 absorbance ratio: 1.6-1.9; 260/230 absorbance ratio : >1.9) indicating 
the absence of contaminants such as proteins, salts or phenols in the sample.  
 
Validation of prioritized variants by the Pathology Research Facility research team 
Whole exome sequencing identified potential causative gene variations and functional 
polymorphisms in the breast cancer patients selected for extended mutation analysis using the 
newly developed exome prescreen algorithm (EPA). Conventional polymerase chain reaction 
(PCR) was performed followed by direct DNA sequencing of the resulting PCR fragments and/or 
and/or real-time PCR for validation of WES results. Results obtained for the APEX1 and MYH9 
variants are provided as examples of common and rare variants with no clinical relevance in the 
patients studied. Confirmation of the RAD50 and MUC1 variants provide examples of rare 
missense mutations identified in the index patient with familial breast cancer.  
Identification of wild type, heterozygous and homozygous genotypes for the APEX1 and MYH9 
variants are listed in Table 8.2, followed by high-throughput genotyping using ABI™ TaqMan® 
SNP technology with standard reaction mixes and cycling parameters (described in the subjects 
and methods Tables 5.4 and 5.5). 
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8.1. Conventional PCR and Sanger sequencing results 
The specific amplicons obtained for the APEX1 and MYH9 variants using conventional primers 
visualized with ethidium Bromide in a 2 % agarose gel is presented in figure 8.1.  
 
 
 
 
 
Figure 8.1: A 2% (w/v) agarose gel visualized with 0.0001% (v/v) ethidium bromide (EtBr). 
Following PCR amplification using APEX1 D148E and MYH9 G236G primer sets, lanes 1-3 
contain amplicons of 898bp and lanes 4-6 contain  547bp. Lane 7 contains a 100bp ladder. 
 
Figure 8.2 depicts the Sanger sequencing results of APEX1 D148E and MYH9 G236G, 
performed by the Central Analytical Facility (CAF) of Stellenbosch University. The sequencing 
results of each genotype in relation to the risk-associated allele when not detected (wild type), 
heterozygous or homozygous are presented in electropherograms for the exome-sequenced 
index and unrelated breast cancer patients in figures 8.2 (APEX1-wild type), 8.3 (APEX1-
heterozygous), 8.4 (APEX1-homozygous), 8.5 (MYH9- wild type) and 8.6 (MYH9- 
heterozygous). Figures 8.7 to 8.9 relates to the sequences of the index patient (MUC1-
heterozygous), her mother (MUC1-wild type) and the unrelated breast cancer patient (MUC1-
wild type), respectively. The index patient’s mother’s sequencing results are omitted since she 
possesses the same APEX1 and MYH9 genotypes as her daughter. No homozygous genotype 
was detected for the rare MYH9 variant. Although forward (sense) and reverse (anti-sense) 
sequencing were carried out for each genotype to demonstrate the analytical validity, only the 
forward sequencing results supported by the reverse sequences are shown here.  
 
 
 
 1    2    3    4    5     6    7 
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Figure 8.2. Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product (index breast cancer patient) obtained with the APEX1 D148E primer set. The 
nucleotide position of the SNP is indicated by the highlighted region and corresponds to a 
genotype of TT, representing a wild type genotype.  
 
Figure 8.3. Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product (non-exome sequenced breast cancer patient) obtained with the APEX1 D148E primer 
set. The nucleotide position of the SNP is indicated by the highlighted region and corresponds 
to a genotype of GT, representing a heterozygous genotype.  
Figure 8.4. Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product (unrelated breast cancer patient) obtained with the APEX1 D148E primer set. The 
nucleotide position of the SNP is indicated by the highlighted region and corresponds to a 
genotype of GG, representing a homozygous mutant genotype.  
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Figure 8.5. Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product (index patient) obtained with the MYH9 G236G primer set. The nucleotide position of 
the variant is indicated by the highlighted region and corresponds to a genotype of CT, 
representing a heterozygous genotype.  
 
Figure 8.6. Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product obtained with the MYH9 G236G primer set. The nucleotide position of the variant is 
indicated by the highlighted region and corresponds to a genotype of CC, representing a wild 
type genotype detected in the exome-sequenced unrelated breast cancer patient and extended 
breast cancer patient sample. 
 
 
 
 
Figure 8.7. Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product obtained with the MUC1 Q67E primer set. The nucleotide position of the variant is 
indicated by the highlighted region and corresponds to a genotype of CG, representing a 
heterozygous genotype detected in the exome-sequenced index breast cancer patient.  
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Figure 8.8. Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product obtained with the MUC1 Q67E primer set. The nucleotide position of the variant is 
indicated by the highlighted region and corresponds to a genotype of CC, representing a wild 
type genotype detected in the index patient’s mother with breast cancer. 
 
 
 
 
 
Figure 8.9. Electropherogram illustrating the forward sequencing reaction of an amplified PCR 
product obtained with the MUC1 Q67E primer set. The nucleotide position of the variant is 
indicated by the highlighted region and corresponds to a genotype of CC, representing a wild 
type genotype detected in the unrelated breast cancer patient. 
 
The above mentioned samples with known genotypes verified by Sanger sequening were 
subsequently used as positive controls to screen the extended patient and control groups using 
real-time PCR methodology. 
  
8.2. Real-time PCR results 
The SNP assays included in the CVD multi-gene test (subjects and methods Table 4.7) were 
successfully performed on the Corbett Rotor-Gene™ 6000 series multiplexing system and the 
WES-identified variants on the Roche LightCycler® 480 II real-time(RT)-PCR machine, by the 
Pathology Research Facility (PRF). Real-time PCR experiments yielded clear amplification as 
well as precise genotype calling of samples. This result was further demonstrated by the verified 
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exome-sequenced samples as well as internal controls (K1-K3) included in each real-time PCR 
experiment and loaded on each plate. The non-template controls (NTC’s) revealed clear 
clustering per plate with no indication of fluorescence and therefore amplification. This 
confirmed and depicted the absence of contamination during the experimental procedure. 
Samples with dubious genotyping results were repeated whereas failed samples that displayed 
little or no fluorescence, attributed to poor DNA quality (degredation or fragmentation of the 
DNA), were excluded from subsequent analyses. 
Due to the bulk of genotyping results generated from this study only one sample batch of each 
assay is illustrated in this section to demonstrate the results obtained with the use of the Corbett 
Rotor-Gene or Roche LightCycler machines. Verification and analytical validation of gene 
variants identified by WES concluded the final phase of this study. 
The allelic discrimination analysis for the RAD50 (1153 C>T, rs139372231) assay is presented 
in Figure 8.10 with the legend and genotypes illustrated by Table 8.1. The lines without 
intermitted circles represent the (C) allele, which is detected by FAM™-labelled probes, while the 
lines with the intermitted circles signifies the homozygote (T) allele detected by the VIC®-
labelled probes. Amplification of both alleles simultaneously indicative of significant 
fluorescence of both dyes represents the heterozygous (C/T) genotype. A threshold level (0.25) 
was established as a discriminatory parameter during analysis to indicate the presence of allele 
specific fluorescence above the threshold setting. 
 
 
 
 
 
 
 
 
Figure 8.10. Allelic discrimination analysis of RAD50 (1153 C>T, rs139372231) using the ABI™ 
TaqMan® (C_171053490_10) genotyping assay. (Normalized fluorescence vs. number of 
cycles) performed on the Corbett Rotor-Gene™ 6000. 
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Table 8.1. Legend for figure 8.6, specifying genotypes of the samples based on Allelic 
discrimination data and Scatterplot analysis on the Corbett Rotor-Gene™ 6000. 
No. Colour Name Genotype Cycling A.Green Cycling A.Yellow 
1 
 
Index patient Heterozygous Reaction Reaction 
2 
 
Mother Heterozygous Reaction Reaction 
3 
 
Unrelated patient          Wild Type No Reaction Reaction 
4 
 
Sample 1 Wild Type No Reaction Reaction 
5 
 
Sample 2 Wild Type No Reaction Reaction 
6 
 
Sample 3 Wild Type No Reaction Reaction 
7 
 
Sample 4 Wild Type No Reaction Reaction 
8 
 
Sample 5 Wild Type No Reaction Reaction 
9 
 
Sample 6 Wild Type No Reaction Reaction 
10 
 
Sample 7 Wild Type No Reaction Reaction 
11 
 
Sample 8 Wild Type No Reaction Reaction 
12 
 
Sample 9 Wild Type No Reaction Reaction 
13 
 
Sample 10 Wild Type No Reaction Reaction 
14 
 
Sample 11 Wild Type No Reaction Reaction 
15 
 
Sample 12  Wild Type No Reaction Reaction 
16 
 
Sample 13 Wild Type No Reaction Reaction 
17 
 
Sample 14 Wild Type No Reaction Reaction 
18 
 
Sample 15 Wild Type No Reaction Reaction 
19 
 
Sample 16 Wild Type No Reaction Reaction 
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Table 8.1. Legend for figure 8.6, specifying genotypes of the samples based on Allelic 
discrimination data and Scatterplot analysis on the Corbett Rotor-Gene™ 6000. 
No. Colour Name Genotype Cycling A.Green Cycling A.Yellow 
20 
 
Sample 17 Wild Type No Reaction Reaction 
21 
 
Sample 18 Wild Type No Reaction Reaction 
22 
 
Sample 19 Wild Type No Reaction Reaction 
23 
 
Sample 20 Wild Type No Reaction Reaction 
24 
 
Sample 21 Wild Type No Reaction Reaction 
25 
 
Sample 22 Wild Type No Reaction Reaction 
26 
 
Sample 23 Wild Type No Reaction Reaction 
27 
 
Sample 24 Wild Type No Reaction Reaction 
28 
 
Sample 25  Wild Type No Reaction Reaction 
29 
 
Sample 26 Wild Type No Reaction Reaction 
30 
 
Sample 27 Wild Type No Reaction Reaction 
31 
 
Sample 28  Wild Type No Reaction Reaction 
32 
 
Sample29 Wild Type No Reaction Reaction 
33 
 
Sample 30 Wild Type No Reaction Reaction 
34 
 
K1  Wild Type No Reaction Reaction 
35 
 
K2 Wild Type No Reaction Reaction 
36 
 
NTC1 Wild Type No Reaction Reaction 
37 
 
NTC2 Wild Type No Reaction Reaction 
38 
 
NTC3 Wild Type No Reaction Reaction 
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Generated by the Roche LightCycler® 480 II software, the allele-specific PCR (ASPCR) 
amplification curve for the MUC1 Q67E assay is presented in Figure 8.11. The purple curve 
represents the ancestral allele while the blue curve represents the variant allele. In Figure 8.11, 
both curves showed amplification in the index patient’s sample. The curves that display early 
amplification (i.e low cycle number) represent the ancestral or wild type allele, while the variant 
allele amplifies during later cycles (i.e high cycle number). Amongst the exome-sequenced 
individuals, only the index patient was confirmed to be heterozygous for MUC1 Q67E. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.11. ASPCR amplification curve of MUC1 (Q67E) depicting fluorescence vs. number of 
cycles, performed on the Roche LightCycler® 480 II.  
 
In addition to endpoint genotyping allelic discrimination of APEX1 D148E on the Roche 
LightCycler® 480 II, scatterplot analysis was also performed to further validate the genotyping 
results. Scatterplot analysis was applied using two channels simultaneously. Genotype 
acquisition is based on specific regions found on the scatterplot as well as relative expression of 
amplification of the green (FAM™ = Y: G-allele) and yellow (VIC® = X: T-allele) channels 
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respectively. Upon normalization, the different fold increases of each channel and log 
transformation accentuated the differences in expression of each individual sample. 
The scatterplot analysis and allelic discrimination plot for the APEX1 D148E assay is presented 
in Figures 8.12 and 8.13, respectively, with the legend and genotypes depicted in Table 8.2. 
Genotype determinations were based on the dual VIC® and FAM™ Minor Groove Binding (MGB) 
probes. Table 8.3 shows the comparison of genotype distribution allele frequencies for APEX1 
rs1130409 between breast cancer patients and controls who participated in the chronic disease 
screen. 
 
Figure 8.12.  Genotypes grouped by scatterplot analysis (FAM™ fluorescence vs. VIC® 
fluorescence) of the ABI™ TaqMan® (C_8921503_10) APEX1 D148E assay. [Allele Y (G- FAM 
labelled) vs Allele X (T- VIC labelled)]. Upper left cluster = Homozygous GG, middle cluster = 
Heterozygous GT, bottom left cluster = Homozygous TT. The legend is presented in Table 8.2. 
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Figure 8.13. Allelic discrimination analysis (fluorescence vs. number of cycles) of APEX1 
D148E using the ABI™ TaqMan® (C_7514879_10) genotyping assay. 
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Table 8.2. Legend for Figures 8.8 and 8.9, specifying genotypes of the samples                   
based on Endpoint analysis data and Scatterplot analysis. 
Table 8.3. Genotype distribution comparisons of APEX1 rs1130409 between breast 
cancer patients and controls who participated in the chronic disease screen. 
Genotypes 
Coloured 
breast cancer 
patients 
Caucasian 
breast cancer 
patients 
Coloureds 
vs 
Cauasians 
Caucasian 
Controls 
Caucasian 
Pts vs 
Controls 
APEX1 T>G n=82 n=81  n=147  
TT 23 (28%) 26 (32%) 
0.35 
32 (22%) 
0.23 GT 42 (51%) 33 (41%) 78 (53%) 
GG 17 (21%) 22 (27%) 37 (25%) 
T 88 (54%) 85 (52%) 
0.89 
142 (48%) 
1.0 
G 76 (46%) 77 (48%) 152 (52%) 
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Table 8.4. List of variants identified in three whole exome-sequenced breast cancer patients for verification and validation using Sanger 
Sequencing and Taqman genotyping. 
Gene 
ID 
dbSNP ID# 
Nulceotide   
Change 
Primer 
ID 
Sequence 
Length 
(bp) 
GC  
Content 
(%) 
PrimerBLAST 
Tm (°C) 
Amplicon 
(bp) 
TaqMan Assay 
ID 
APEX1 rs1130409 
g.6865T>G 
c.444T>G 
APEX1-
FWD 
TGCTGCTTGACTCGAACTCC 20 55.00 60.32 
898 C___8921503_10 
APEX1-
REV 
TGCAGGTAACAGAGAGTGGG 20 55.00 59.02 
MYH9 rs754650591 
g.71200C>T 
c.708C>T 
MYH9-
FWD 
GTGTGGGATCAGCTTGTCTC 20 55.00 58.27 
547 N/A 
MYH9-
REV 
TAGACGGCTTTCAACAGCTC 20 50.00 57.92 
RAD50 rs139372231 
g.36865C>T 
c.1153C>T 
RAD50-
FWD 
ATCCACATGCTCAGGGGTAC 20 55.00 59.16 
528 C_171053490_10 
RAD50-
REV 
GCCAAAATGGAGTCCAACC 19 52.60 56.78 
MUC1 
 
N/A 
 
Q67E 
MUC1-
FWD 
ATTCCCAGCCACCACTCTGA 20 55 60.84 
493 N/A 
MUC1- 
REV 
CCCAACCTTAAGTGCACCAGT 21 52.38 60.48 
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